BENZYLPHENYL HYDROXYISOXAZOLINE COMPOUND AND ANALOGUE, COMPOSITION COMPRISING SAID COMPOUND, USES THEREOF AND METHOD FOR CONTROLLING PHYTOPATHOGENIC FUNGI

Abstract

benzylphenyl hydroxy-isoxazolines and analogues as novel antifungal agents. The present invention relates to novel hydroxy-isoxazoline derivatives, their use as fungicides and compositions comprising the same. formula (i)

Description

"BENZYLPHENYL HYDROXYISOXAZOLINE COMPOUND AND ANALOGUE, COMPOSITION COMPRISING SAID COMPOUND, USE THEREOF AND METHOD FOR CONTROLLING PHYTOPATHOGENIC FUNGI" Field of Technique

[001] The present invention relates to the use of hydroxy-isoxazolines and derivatives thereof as fungicides. It also relates to new derivatives of hydroxy-isoxazolines, their use as fungicides and compositions comprising them. Fundamentals

[002] Isoxazole derivatives are known to be useful as crop protection agents to combat or prevent infestations of microorganisms. For example, document WO2015 / 129773 discloses isoxazole derivatives that can be used as fungicides. Document WO2006 / 031631 discloses substituted isoxazoles that can be used for the control of microbial pests, particularly fungal pests, in plants.

[003] On the other hand, hydroxy-isoxazole derivatives are much less common and rarely used for the control of microbial pests. For example, documents WO99 / 05130 and WO2018 / 006561 disclose hydroxy-isoxazole derivatives that can be used for the treatment of many human diseases. More recently, hydroxy-isoxazoles have been shown to be useful for controlling phytopathogenic fungi (WO2018 / 202487).

[004] Numerous fungicidal agents have been developed to date. However, the need remains for the development of new fungicidal compounds in order to meet the constantly increasing environmental and economic demands placed on modern crop protection agents and compositions. This includes, for example, improvements in spectrum of action, safety profile, selectivity, application rate, residue formation and ability to Petition 870250039092, dated 05 / 14 / 2025, page 9 / 383 2 / 178 favorable preparation. It may also be desirable to have new compounds to prevent the emergence of fungicide resistance.

[005] The present invention provides novel fungicidal compounds that have advantages over known compounds and compositions in at least some of these respects. SUMMARY

[006] The present invention relates to compounds of formula (I): (I) wherein X, Y, R1, R2, L, m, and A are as reported in the present invention, as well as their salts, N-oxides, solvates, stereoisomers, and any mixtures of stereoisomers.

[007] The present invention relates to a composition comprising at least one compound of formula (I) as defined in the present invention and at least one suitable agricultural auxiliary.

[008] The present invention also relates to the use of a compound of formula (I) as defined in the present invention or a composition as defined in the present invention to control phytopathogenic fungi.

[009] The present invention relates to a method for controlling phytopathogenic fungi comprising the step of applying at least one compound of formula (I) as defined in the present invention or a composition as defined in the present invention to plants, plant parts, seeds, fruits or the soil in which the plants grow. DEFINITIONS Petition 870250039092, dated 05 / 14 / 2025, p. 10 / 383 3 / 178

[010] The term “halogen” as used in the present invention refers to fluorine, chlorine, bromine or iodine atoms.

[011] The term “oxo” as used in the present invention refers to an oxygen atom that is bonded to a carbon atom or a sulfur atom by means of a double bond.

[012] The term “C1-C8-alkyl” as used in the present invention refers to a saturated, branched or straight hydrocarbon chain having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms. Examples of C1-C8 alkyl groups include, but are not limited to, methyl, ethyl, propyl (n-propyl), 1-methylethyl (isopropyl), butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl. 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl.Specifically, the aforementioned hydrocarbon chain has 1, 2, 3, or 4 carbon atoms (“C1-C4-alkyl”), for example, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, or tert-butyl.

[013] The term “C2-C8-alkenyl” as used in the present invention refers to an unsaturated, branched or straight hydrocarbon chain having 2, 3, 4, 5, 6, 7 or 8 carbon atoms and comprising at least one double bond. Examples of C2-C8-alkenyl include, but are not limited to, ethenyl (or “vinyl”) group, prop-2en-1-yl (or “allyl”), prop-1-en-1-yl, but-3-enyl, but-2-enyl, but-1-enyl, pent-4-enyl, pent-3-enyl, pent-2-enyl, pent-1-enyl, hex-5-enyl, hex-4-enyl, hex-3-enyl, hex-2enyl, hex-1-enyl, prop-1-en-2-yl (or “isopropenyl”), 2-methylprop-2-enyl, 1-methylprop2-enyl, 2-methylprop-1-enyl, 1-methylprop-1-enyl, 3-methylbut-3-enyl, 2-methylbut-3-enyl, 1-methylbut-3-enyl, 3-methylbut-2-enyl, 2-methylbut-2-enyl, 1-methylbut-2-enyl, 3-methylbut1-enyl, 2-methylbut-1-enyl, 1-methylbut-1-enyl, 1,1-dimethylprop-2-enyl, 1-ethylprop-1Petition 870250039092, of 05 / 14 / 2025, p. 11 / 383 4 / 178 enyl, 1-propylvinyl, 1-isopropylvinyl, 4-methylpent-4-enyl, 3-methylpent-4-enyl, 2-methylpent-4-enyl, 1-methylpent-4-enyl, 4-methylpent-3-enyl, 3-methylpent-3-enyl, 2-methylpent-3-enyl, 1-methylpent-3-enyl, 4-methylpent-2-enyl, 3-methylpent-2-enyl, 2-methylpent-2-enyl, 1-methylpent-2-enyl, 4-methylpent-1-enyl, 3-methylpent-1-enyl, 2methylpent-1-enyl, 1-methylpent-1-enyl, 3-ethylbut-3-enyl, 2-ethylbut-3-enyl, 1-ethylbut-3-enyl, 3-ethylbut-2-enyl, 2-ethylbut-2-enyl, 1-ethylbut-2-enyl, 3-ethylbut-1-enyl, 2-ethylbut-1-enyl, 1-ethylbut-1-enyl, 2-propylprop-2-enyl, 1-propylprop-2-enyl, 2-isopropylprop-2-enyl, 1-isopropylprop-2-enyl, 2-propylprop-1-enyl, 1-propylprop-1-enyl, 2isopropylprop-1-enyl, 1-isopropylprop-1-enyl, 3,3-dimethylprop-1-enyl, 1-(1,1dimethylethyl)ethenyl, but-1,3-dienyl, penta-1,4-dienyl, hexa-1,5-dienyl or methylhexadienyl.

[014] The term “C2-C8-alkynyl” as used in the present invention refers to a branched or straight hydrocarbon chain having 2, 3, 4, 5, 6, 7 or 8 carbon atoms and comprising at least one triple bond.Examples of C2-C8alkynyl include, but are not limited to, ethynyl, prop-1-ynyl, prop-2-ynyl (or “propargyl”), but-1-ynyl, but-2-ynyl, but-3-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, 1-methylprop-2ynyl, 2-methylbut-3-ynyl, 1-methylbut-2-ynyl, 3-methylbut-1-ynyl, 1ethylprop-2-ynyl, 3-methylpent-4-ynyl, 2-methylpent-4-ynyl, 1-methylpent-3-ynyl, 4-methylpent-2-ynyl, 1-methyl- pent-2-ynyl, 4methylpent-1-ynyl, 3-methylpent-1-ynyl, 2-ethylbut-3-ynyl, 1-ethylbut-3-ynyl, 1-ethylbut-2-ynyl, 1-propylprop-2-ynyl, 1-isopropylprop-2-ynyl, 2,2-dimethylbut-3-ynyl, 1,1-dimethylbut-3-ynyl, 1,1-dimethylbut-2-ynyl or 3,3-dimethylbut-1-ynyl.

[015] The term “C1-C8-halogenalkyl” as used in the present invention refers to a C1-C8-alkyl group as defined above in which one or more hydrogen atoms are replaced with one or more halogen atoms which may be the same or different. Typically, C1-C8-halogenalkyl comprises up to 9 atoms. Petition 870250039092, dated 05 / 14 / 2025, page 12 / 383 5 / 178 halogen, which may be the same or different.

[016] The term “C2-C8-halogenalkenyl” as used in the present invention refers to a C2-C8-alkenyl group as defined above in which one or more hydrogen atoms are replaced with one or more halogen atoms which may be the same or different. Typically, C1-C8-halogenalkenyl comprises up to 9 halogen atoms which may be the same or different.

[017] The term “C2-C8-halogenalkynyl” as used in the present invention refers to a C2-C8-alkynyl group as defined above in which one or more hydrogen atoms are replaced with one or more halogen atoms which may be the same or different. Typically, C1-C8-halogenalkynyl comprises up to 9 halogen atoms which may be the same or different.

[018] The term “C1-C8-alkoxy” as used in the present invention refers to a group of the formula (C1-C8-alkyl)-O-, wherein the term “C1-C8-alkyl” is as defined in the present invention. Examples of C1-C8 alkoxy compounds include, but are not limited to, methoxy, ethoxy, n-propoxy, 1-methylethoxy, n-butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1-dimethylethoxy, n-pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, n-hexyloxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy. 3,3-dimethylbutoxy, 1-ethylbutoxy, 2ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy and 1-ethyl-2methylpropoxy.

[019] The term “C1-C8-halogenalkoxy” as used in the present invention refers to a C1-C8-alkoxy group as defined above in which one or more hydrogen atoms are replaced with one or more halogen atoms which may be the same or different. Examples of C1-C8-halogenalkoxy include, but are not limited to, chloromethoxy, bromomethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoromethoxy, dichlorofluoromethoxy, chloro-difluoro Petition 870250039092, dated 05 / 14 / 2025, page 13 / 383 6 / 178 methoxy, 1-chloroethoxy, 1-bromoethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy and 1,1,1-trifluoroprop-2-oxy.

[020] The term “C1-C8-alkylsulfanyl” as used in the present invention refers to a saturated, linear or branched group of the formula (C1-C8-alkyl)-S-, wherein the term “C1-C8-alkyl” is as defined in the present invention. Examples of C1-C8 alkylsulfanyl include, but are not limited to, methylsulfanyl, ethylsulfanyl, propylsulfanyl, isopropylsulfanyl, butylsulfanyl, sec-butylsulfanyl, isobutylsulfanyl, tert-butylsulfanyl, pentylsulfanyl, isopentylsulfanyl, hexylsulfanyl.

[021] The term “C1-C8-halogenalkylsulfanyl” as used in the present invention refers to a C1-C8-alkylsulfanyl as defined above in which one or more hydrogen atoms are replaced with one or more halogen atoms which may be the same or different.

[022] The term “C1-C8-alkylsulfinyl” as used in the present invention refers to a saturated, linear or branched group of the formula (C1-C8-alkyl)-S(=O)-, wherein the term “C1-C8-alkyl” is as defined in the present invention. Examples of C1C8-alkylsulfinyl include, but are not limited to, saturated, straight-chain or branched alkylsulfinyl radicals having 1 to 8, preferably 1 to 6, and more preferably 1 to 4 carbon atoms, for example (but not limited to) methylsulfinyl, ethylsulfinyl, propylsulfinyl, 1-methyl-ethyl-sulfinyl, butylsulfinyl, 1-methyl-propyl-sulfinyl, 2-methylpropylsulfinyl, 1,1-dimethyl-ethyl-sulfinyl, pentylsulfinyl, 1-methylbutylsulfinyl, 2-methylbutylsulfinyl, 3-methylbutylsulfinyl, 2,2-dimethylpropylsulfinyl, 1-ethylpropylsulfinyl, 1,1-dimethyl-propylsulfinyl, 1,2-dimethylpropylsulfinyl, hexylsulfinyl, 1-methylpentylsulfinyl, 2methyl-pentylsulfinyl, 3-methylpentylsulfinyl, 4-methylpentylsulfinyl, 1,1-dimethylbutylsulfinyl, 1,2-dimethyl-butylsulfinyl,1,3-dimethylbutylsulfinyl, 2,2-dimethylbutylsulfinyl, 2,3dimethylbutylsulfinyl, 3,3-dimethylbutylsulfinyl, 1-ethylbutylsulfinyl, 2-ethyl-butylsulfinyl, 1,1,2trimethylpropylsulfinyl, 1,2,2-trimethylpropylsulfinyl, 1-ethyl-1-methyl-propyl-sulfinyl and 1-ethyl-2, Petition 870250039092, dated 05 / 14 / 2025, page 14 / 383 7 / 178 methylpropylsulfinyl.

[023] The term “C1-C8-halogenalkylsulfinyl” as used in the present invention refers to a C1-C8-alkylsulfinyl as defined above in which one or more hydrogen atoms are replaced with one or more halogen atoms which may be the same or different.

[024] The term “C1-C8-alkylsulfonyl” as used in the present invention refers to a saturated, linear or branched group of the formula (C1-C8-alkyl)-S(=O)2-, wherein the term “C1-C8-alkyl” is as defined in the present invention.Examples of C1-C8 alkylsulfonyl compounds include, but are not limited to, methylsulfonyl, ethylsulfonyl, propylsulfonyl, 1-methylethylsulfonyl, butylsulfonyl, 1-methylpropylsulfonyl, 2-methylpropylsulfonyl, 1,1-dimethylethylsulfonyl, pentylsulfonyl, 1-methylbutylsulfonyl, 2-methylbutylsulfonyl, 3-methylbutylsulfonyl, 2,2-dimethylpropylsulfonyl, 1-ethylpropylsulfonyl, 1,1-dimethylpropylsulfonyl, 1,2-dimethylpropylsulfonyl, hexylsulfonyl, 1-methylpentylsulfonyl, 2-methylpentylsulfonyl, 3-methylpentylsulfonyl, 4-methylpentylsulfonyl, 1,1-dimethylbutylsulfonyl, 1,2-dimethylbutylsulfonyl. 1,3-dimethylbutylsulfonyl, 2,2dimethylbutylsulfonyl, 2,3-dimethyl-butylsulfonyl, 3,3-dimethylbutylsulfonyl, 1-ethyl-butylsulfonyl, 2-ethylbutylsulfonyl, 1,1,2-trimethyl-propylsulfonyl, 1,2,2-trimethylpropylsulfonyl, 1-ethyl-1-methyl-propylsulfonyl and 1-ethyl-2-methylpropylsulfonyl.

[025] The term “C1-C8-halogenalkylsulfonyl” as used in the present invention refers to a C1-C8-alkylsulfonyl as defined above in which one or more hydrogen atoms are replaced with one or more halogen atoms which may be the same or different.

[026] The term “C1-C8-alkylcarbonyl” as used in the present invention refers to a saturated, linear or branched group of the formula (C1-C8-alkyl)-C(=O)-, wherein the term “C1-C8-alkyl” is as defined in the present invention.

[027] The term “C1-C8-halogen alkyl carbonyl” as used in the present invention refers to a C1-C8-alkyl carbonyl as defined above in which one or Petition 870250039092, dated 05 / 14 / 2025, p. 15 / 383 8 / 178 more hydrogen atoms are replaced with one or more halogen atoms, which may be the same or different.

[028] The term “C1-C8-alkoxycarbonyl” as used in the present invention refers to a saturated, linear or branched group of the formula (C1-C8-alkoxy)-C(=O)-, wherein the term “C1-C8-alkoxy” is as defined in the present invention.

[029] The term “C1-C8-haloalkoxycarbonyl” as used in the present invention refers to a C1-C8-alkoxycarbonyl as defined above in which one or more hydrogen atoms are replaced with one or more halogen atoms which may be the same or different.

[030] The term “non-aromatic C3-C12-carbocycle” as used in the present invention refers to a non-aromatic hydrocarbon ring system, saturated or partially unsaturated, in which all ring members, ranging from 3 to 12, are carbon atoms. The ring system may be monocyclic or polycyclic (fused, spiral or bridged).Non-aromatic C3-C12-carbocycles include, but are not limited to, C3-C12-cycloalkyl (mono- or bicyclic), C3-C12-cycloalkenyl (mono- or bicyclic), bicyclic systems comprising an aryl (e.g., phenyl) fused to a monocyclic C3-C7-cycloalkyl (e.g., tetrahydronaphthalenyl, indanyl), bicyclic systems comprising an aryl (e.g., phenyl) fused to a monocyclic C3-C8-cycloalkenyl (e.g., indenyl, dihydronaphthalenyl), and tricyclic systems comprising a cyclopropyl connected via a carbon atom to a bicyclic system comprising an aryl (e.g., phenyl) fused to a monocyclic C3-C7-cycloalkyl or a monocyclic C3-C8-cycloalkenyl. The non-aromatic C3-C12 carbocycle can be linked to the precursor molecular moiety through any carbon atom.

[031] The term “C3-C12-cycloalkyl” as used in the present invention refers to a saturated, monovalent, mono- or bicyclic hydrocarbon ring containing 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. “C3-C7-cycloalkyl” as Petition 870250039092, dated 05 / 14 / 2025, p. 16 / 383 9 / 178 used in the present invention designates C3-C7 monocyclic cycloalkyls which include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, cycloheptyl. Examples of C6-C12 bicyclic cycloalkyls include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, bicyclo[4.2.0]octyl, octahydropentanelyl and bicyclo[4.2.1]nonane.

[032] The term “C3-C12-cycloalkenyl” as used in the present invention refers to an unsaturated, monovalent, mono- or bicyclic hydrocarbon ring containing 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. Examples of monocyclic C3-C8 cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloeptenyl and cyclooctenyl groups. Examples of bicyclic C6-C12 cycloalkenyl groups include, but are not limited to, bicyclo[2.2.1]hept-2-enyl or bicyclo[2.2.2]oct-2-enyl.

[033] The term “C6-C14-aromatic carbocycle” or “aryl” as used in the present invention refers to an aromatic hydrocarbon ring system in which all ring members, ranging from 6 to 14, preferably from 6 to 10, are carbon atoms. The ring system may be monocyclic or fused polycyclic (e.g., bicyclic or tricyclic). Examples of aryl include, but are not limited to, phenyl, azulenyl, naphthyl, and fluorenyl. The aryl may be linked to the precursor molecular moiety through any carbon atom. It is also understood that when said aryl group is substituted with one or more substituents, said substituent(s) may be in any positions on said aryl ring(s). Specifically, if aryl is a phenyl group, the substituent(s) in question may occupy one or both ortho positions, one or both meta positions, or the para position, or any combination of these positions.

[034] The term “non-aromatic heterocycle of 3 to 10 members” or “heterocyclyl” as used in the present invention refers to a saturated or partially unsaturated non-aromatic ring system comprising 1 to 4, or 1 to 3 Petition 870250039092, dated 05 / 14 / 2025, page 17 / 383 10 / 178 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. If the ring system contains more than one oxygen atom, they are not directly adjacent. Non-aromatic heterocycles include, but are not limited to, 3- to 7-membered monocyclic non-aromatic heterocycles and 6- to 10-membered polycyclic (e.g., bicyclic or tricyclic) non-aromatic heterocycles. The non-aromatic 3- to 10-membered heterocycle can be connected to the precursor molecular portion through any carbon atom or nitrogen atom contained within the heterocycle.

[035] The term “non-aromatic monocyclic heterocycle of 3 to 7 members” as used in the present invention refers to a monocyclic ring system of 3, 4, 5, 6 or 7 members containing 1, 2 or 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur where the ring system is saturated or unsaturated but non-aromatic. For example, the heterocycle may comprise one to three nitrogen atoms, or one or two oxygen atoms, or one or two sulfur atoms, or one to three nitrogen atoms and one oxygen atom, or one to three nitrogen atoms and one sulfur atom, or one sulfur atom and one oxygen atom.Examples of saturated non-aromatic heterocycles include, but are not limited to, 3-membered rings such as oxaraniyl, aziridinyl; 4-membered rings such as azetidinyl, oxetanyl, thietanyl; 5-membered rings such as tetrahydrofuranyl, 1,3-dioxolanyl, tetrahydrothienyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, triazolidinyl, isoxazolidinyl, oxazolidinyl, oxadiazolidinyl, thiazolidinyl, isothiazolidinyl, thiadiazolidinyl; 6-membered rings such as piperidinyl, hexahydropyridazinyl, hexahydropyrimidinyl, piperazinyl, triazinanyl, hexahydrotriazinyl, tetrahydropyranyl, dioxanyl, tetrahydrothiopyranyl, ditianyl, morpholinyl. 1,2-oxazinanyl, oxatianyl, thiomorpholinyl or 7-membered rings such as oxepanyl, azepanyl, 1,4-diazepanyl and 1,4-oxazepanyl. Examples of unsaturated non-aromatic heterocycles include, but are not limited to, 5-membered rings. Petition 870250039092, dated 05 / 14 / 2025, page 18 / 383 11 / 178 members such as dihydrofuranyl, 1,3-dioxolyl, dihydrothienyl, pyrrolinyl, dihydroimidazolyl, dihydropyrazolyl, isoxazolinyl, dihydro-oxazolyl, dihydrothiazolyl or 6-membered ring such as pyranyl, thiopyranyl, thiazinyl and thiadiazinyl.

[036] When an amino group or the amino portion of any other amino-containing group is replaced by two substituents which may be the same or different, the two substituents together with the nitrogen atom to which they are attached may form a heterocyclyl group, preferably a 5- to 7-membered monocyclic heterocyclyl group, which may be substituted or may include other heteroatoms, for example a morpholino group or a piperidinyl group.

[037] The term “non-aromatic polycyclic heterocycle of 6 to 10 members” as used in the present invention refers to a polycyclic ring system of 6, 7, 8, 9, 10 members (e.g., bicyclic or tricyclic) containing 1, 2 or 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur where the ring system is saturated or unsaturated but not aromatic. Non-aromatic bicyclic heterocycles may consist of a monocyclic heteroaryl as defined in the present invention fused to a monocyclic C3-C7-cycloalkyl, a monocyclic C3-C8-cycloalkenyl or a monocyclic non-aromatic heterocycle, or may consist of a monocyclic non-aromatic heterocycle fused to an aryl (e.g., phenyl), a monocyclic C3-C7-cycloalkyl, a monocyclic C3-C8-cycloalkenyl or a monocyclic non-aromatic heterocycle.When two monocyclic heterocycles (aromatic or non-aromatic) comprising nitrogen atoms are fused, the nitrogen atom may be in the bridging area (e.g., 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, 5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridinyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl). Non-aromatic tricyclic heterocycles may consist of a monocyclic cycloalkyl group connected through a common atom to a non-aromatic bicyclic heterocycle.

[038] The term “5 to 14 membered aromatic heterocycle” or “heteroaryl” Petition 870250039092, dated 05 / 14 / 2025, page 19 / 383 12 / 178 as used in the present invention refers to an aromatic ring system comprising 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. Aromatic heterocycles include 5- or 6-membered monocyclic aromatic heterocycles and 6- to 14-membered polycyclic (e.g., bicyclic or tricyclic) aromatic heterocycles. The 5- to 14-membered aromatic heterocycle can be connected to the precursor molecular portion through any carbon atom or nitrogen atom contained within the heterocycle.

[039] The term “5- or 6-membered aromatic monocyclic heterocycle” or “monocyclic heteroaryl” as used in the present invention refers to a 5- or 6-membered monocyclic ring system containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. Examples of 5-membered monocyclic heteroaryls include, but are not limited to, furyl (furanyl), thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, oxatriazolyl, isothiazolyl, thiazolyl, thiadiazolyl, and thiatriazolyl. Examples of 6-membered monocyclic heteroaryls include, but are not limited to, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and tetrazinyl.

[040] The term “6- to 14-membered polycyclic aromatic heterocycle” or “polycyclic heteroaryl” as used in the present invention refers to a 6, 7, 8, 9, 10, 11, 12, 13 or 14-membered polycyclic (e.g., bicyclic or tricyclic) ring system containing 1, 2 or 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur. Bicyclic aromatic heterocycles may consist of a monocyclic heteroaryl as defined in the present invention fused to an aryl (e.g., phenyl) or a monocyclic heteroaryl. Examples of bicyclic aromatic heterocycles include, but are not limited to, 9-membered rings such as indolyl, indolizinyl, isoindolyl, Petition 870250039092, dated 05 / 14 / 2025, page 20 / 383 13 / 178 benzimadozolyl, imidazopyridinyl, indazolyl, benzotriazolyl, purinyl, benzofuranyl, benzothiophenyl, benzothiazolyl, benzoxazolyl and benzisoxazolyl or 10-membered ring such as quinolinyl, isoquinolinyl, cinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, naphthyridinyl, pteridinal and benzodioxinyl. In 9- or 10-membered aromatic bicyclic heterocycles comprising two fused 5- or 6-membered monocyclic aromatic heterocycles, the nitrogen atom may be in the bridgehead (e.g., imidazo[1,2-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, imidazo[1,2a]pyridinyl, imidazo[2,1-b]oxazolyl, furo[2,3-d]isoxazolyl). Examples of tricyclic aromatic heterocycles include, but are not limited to, carbazolyl, acridinyl, and phenazinyl.

[041] The terms “non-aromatic C3-C12-carbocyclyloxy”, “C3-C7-cycloalkyloxy”, “aromatic C6-C14-carbocyclyloxy”, “5 to 10 membered aromatic heterocyclyloxy”, “5 to 10 membered non-aromatic heterocyclyloxy” as used in the present invention designate a group of formula -OR wherein R is respectively a non-aromatic C3-C12-carbocyclyl, a C3-C7-cycloalkyl, an aromatic Ce-Cu-carbocyclyl, a 5 to 14 membered aromatic heterocyclyl or a 5 to 14 membered non-aromatic heterocyclyl group as defined in the present invention.

[042] As used in the present invention, when a group is said to be “substituted”, the group may be substituted with one or more substituents. The expression “one or more substituents” refers to multiple substituents ranging from one to the maximum number of possible substituents based on the number of available binding sites, provided that the conditions of stability and chemical viability are met.

[043] The term “leaving group” as used in the present invention should be understood to mean a group that is displaced from a compound in a substitution or elimination reaction, for example a halogen atom, a trifluoromethanesulfonate (“triflate”), alkoxy, methanesulfonate (“mesylate”), ptoluenesulfonate (“tosylate”) group, etc. Petition 870250039092, dated 05 / 14 / 2025, page 21 / 383 14 / 178 DETAILED DESCRIPTION

[044] The present invention provides compounds of formula (I): in which X is hydrogen, fluorine, or chlorine; And it is selected from the group consisting of hydrogen, C1-C8-alkyl, C1-C8-halogenalkyl, C2-C8-alkenyl, C2-C8-halogenalkenyl, C2-C8-alkynyl, C2C8-halogenalkynyl, C1-C8-alkoxy-C1-C8-alkyl, tri-C1-C8-alkylsilane, di-C1-C8-alkyl(aryl)silane, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C8-alkyl, C1-C8-alkylcarbonyl-C1-C8-alkyl, C1-C8-alkylcarbonyloxy-C1-C8-alkyl, aryl, aryl-C1-C8alkyl, heteroaryl, heteroaryl-C1-C8-alkyl, di-C1-C8-alkylphosphate and C(=O)Z com Z sendo seleccionado a partir do grupo consistindo em hidrogênio, amino, C1-C8-alkyla, C1-C8-halogenoalkyla, C1-C8-alcóxi, C1-C8-halogenoalcóxi, C2-C8-alkenila, C2-C8halogenoalkenila, C2-C8-alkynila, C2-C8-halogenoalkynila, C1-C8-alkylsulfanila, C1C8-halogenoalkylsulfanila, C1-C8-alkylamino, di-C1-C8-alkylamino, C3-C7cicloalkyla, aryla, heterociclila, heteroaryla, arylóxi, heterociclilóxi e heteroarylóxi,wherein the acyclic radicals Y and Z can be replaced respectively with one or more substituents Yaou Zae wherein the cyclic radicals Y and Z can be replaced respectively with one or more substituents Ybou Zb;, m is 0, 1, or 2; R1 and R2 are selected independently from the group consisting of hydrogen, halogen, cyano, hydroxyl, sulfanyl, amino, formyl, C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-halogenalkoxy, C2-C8-alkenyl, C2-C8 Petition 870250039092, dated 05 / 14 / 2025, p. 22 / 383 15 / 178 halogenalkenyl, C2-C8-alkynyl, C2-C8-halogenalkynyl, C1-C8-alkylsulfanyl, C1-C8-halogenalkylsulfanyl, C1-C8-alkylsulfinyl, C1-C8-halogenalkylsulfonyl, C1-C8-halogenalkylsulfonyl, C1-C8-alkylamino, di-C1-C8-alkylamino, C1-C8-alkylcarbonyl, C1-C8-halogenalkylcarbonyl, C1-C8-alkoxycarbonyl, C3-C7-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the acyclic radicals R1, R2 may be substituted with one or more substituents Rb, or wherein the cyclic radicals R1, R2 may be substituted with one or more substituents Rb, or R1-R2 can form, together with the carbon atom to which they are attached, a C3-C7-cycloalkyl or a heterocyclyl ring wherein said C3-C7-cycloalkyl and heterocyclyl ring can be substituted with one or more Rb substituents, or R1, R2 can form, together with the carbon atom to which they are attached, a C=CH2, C=O, C=N-OH or C=N-ORc group with Rc being selected from the group consisting of C1-C8-alkyl, aryl and aryl-C1-C8-alkyl, when n is 0 or L is CR3R4, wherein the acyclic radicals Rc can be substituted with one or more substituents Rb and wherein the cyclic radicals Rc can be substituted with one or more substituents Rb; n is 0 or 1; L is CR3R4, O, S, S=O, S(=O)2, S(=O)(=NH), S(=N-CN) or NR5, wherein R3 and R4 are independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, sulfanyl, amino, formyl, C1-C8 alkyl, C1-C8 haloalkyl, C1-C8 alkoxy, C1-C8 haloalkoxy, C2-C8 alkenyl, C2-C8 haloalkenyl, C2-C8 alkynyl, C2-C8 haloalkynyl, C1-C8 alkylsulfanyl, C1-C8 haloalkylsulfanyl, C1-C8 haloalkylsulfanyl, C1-C8 haloalkylsulfanyl, C1-C8 alkylsulfinyl, C1-C8 haloalkylsulfinyl, C1-C8 haloalkylsulfinyl, C1-C8 haloalkylsulfanyl, C1-C8 haloalkylsulfanyl, C1-C8 haloalkylsulfanyl, C1-C8 haloalkylsulfanyl, C1-C8 haloalkylsulfanyl, C1-C8 haloalkylsulfanyl, C1-C8 haloalkylsulfanyl, C1-C8 alkylsulfinyl, C1-C8 haloalkylsulfanyl, C1-C8 haloalkylsulfanyl, C1-C8 alkylamino, C1-C8 haloalkylsulfanyl, C1-C8 haloalkylsulfanyl, C1-C8 haloalkylsulfon ... di-C1-C8-alkylamino, C1-C8-alkylcarbonyl, C1-C8 Petition 870250039092, dated 05 / 14 / 2025, page 23 / 383 16 / 178 halogen alkyl carbonyl, C1-C5 alkoxy carbonyl, C3-C7 cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the acyclic radicals R3 and R4 may be substituted with one or more Rb substituents, or wherein the cyclic radicals R3 and R4 may be substituted with one or more Rb substituents, or wherein R3 and R4 may form, together with the carbon atom to which they are attached, a C3-C7 cycloalkyl or heterocyclyl, wherein said C3-C7 cycloalkyl and heterocyclyl may be substituted with one or more Rb substituents, or wherein when L is CR3R4, R1 and R3 may form, together with the carbon atoms to which they are attached, a C3-C7 cycloalkyl ring, wherein said C3-C7 cycloalkyl ring may be substituted with one or more Rb substituents, wherein R5 is selected from the group consisting of hydrogen atom, Ci-Cs-alkyl, Ci-Cs-haloalkyl, C2-Cs-alkenyl, C2-Cs-haloalkenyl, C3Cs-alkynyl, C3-Cs-haloalkyl, C3-C7-cycloalkyl,C3-C7-cycloalkyl-C1-Csalkyl, C1-Cs-alkylcarbonyl, C1-Cs-haloalkylcarbonyl, C3-C7cycloalkylcarbonyl, C1-Cs-alkoxycarbonyl, C1-Cs-haloalkoxycarbonyl, C1-Csalkylsulfonyl, C1-Cs-haloalkylsulfonyl, arylsulfonyl, aryl, heterocyclyl, heteroaryl, aryl-Ci-Cs-alkyl, heterocyclyl-Ci-Cs-alkyl, heteroaryl-Ci-Cs-alkyl, aryloxy-Ci-Cs-alkyl, heterocyclyloxy-Ci-Cs-alkyl, heteroaryloxy-Ci-Cs-alkyl, arylsulfanyl-Ci-Cs-alkyl, heterocyclylsulfanyl-Ci-Cs-alkyl, heteroarylsulfanyl-Ci-Csalkyl, arylcarbonyl, heterocyclylcarbonyl and heteroarylcarbonyl, in which the acyclic radicals R5 can be substituted with one or more substituents Rb; and in which the cyclic radicals R5 can be substituted with one or more substituents Rb. A is a C3-C7-cycloalkyl, aryl, heterocyclyl or heteroaryl ring, wherein said C3-C7-cycloalkyl, aryl, heterocyclyl or heteroaryl may be substituted, one or more times, in the same or different ways, with R6, wherein R6 is selected from the group consisting of halogen, cyano, hydroxyl, sulfanyl, amino, nitro, C1-C5-alkyl, C1-C5-halogenalkyl, C1-C5-alkoxy, C1-C5-alkoxy, Petition 870250039092, dated 14 / 05 / 2025, p. 24 / 383 17 / 178 C8-halogenoalkóxi, C2-C8-alquenila, C2-C8-halogenoalquenila, C2-C8-alquinila, C2-C8halogenoalquinila, Ci-C8-alquilsulfanila, Ci-C8-halogenoalquil-sulfanila, C1-C8alquilsulfinila, Ci-C8-halogenoalquilsulfanila, Ci-C8-alquilsulfonila, C1-C8halogenoalquil-sulfonila, C1-C8-alquilamino, di-C1-C8-alquilamino, C3-C7-cycloalquila, aryla, heterociclila, heteroarila, arylóxi, heterociclilóxi, heteroarylóxi, aryl-C1-C8-alquila, heterocyclyl-C1-C8-alquila, heteroaryl-C1-C8-alkyl, tri-C1-C8-alkylsilane, -C(=O)R7, C(=O)OR7, -C(=O)N(R7)(R8), -C(=S)R7, -C(=S)OR7, -C(=S)N(R7)(R8), -C(=NR8)R7, C(=NR8)OR7, -C(=NR8)N(R7)(R8), -NR8C(=O)R7, -NR8C(=S)R7, -NR8C(=O)OR7, NR8C(=O)N(R7)(R8), -NR8C(=S)N(R7)(R8), -NR8C(=NR8)R7, -OC(=O)R7, OC(=O)N(R7)(R8), -OC(=S)N(R7)(R8), -NR8S(=O)2R7, -S(=O)2R7, -S(=O)2N(R7)(R8) and P(=O)(OR7)2, where R7 is selected from the group consisting of hydrogeny, C1-C8alquila, C1-C8-haloalquila, C2-C8-alquenyla, C2-C8-halogenoalquinyla, C2-C8-alquinyla, C2-C8-halogenoalquinyla,C3-C7-cycloalkyl, aryl, heteroaryl, aryl-C1-C8-alkyl and heteroaryl-C1-C8-alkyl, wherein R8 is selected from the group consisting of hydrogen, hydroxy, amino, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, C2C8-alkenyl, C2-C8-haloalkenyl, C2-C8-alkynyl, C2-C8-haloalkynyl, C1C8-alkylamino, di-C1-C8-alkylamino, C3-C7-cycloalkyl, aryl, heteroaryl, aryl-C1-C8alkyl, heteroaryl-C1-C8-alkyl, aryloxy, heteroaryloxy, arylamino and heteroarylamino, or two geminal substituents R6 can form, together with the carbon atom to which they are attached, a C3-C7-cycloalkyl or a heterocyclyl, wherein said C3-C7-cycloalkyl and the heterocyclyl ring may be substituted with one or more Rb substituents, or two geminal R6 substituents, may form, if structurally feasible, together with the carbon atom to which they are attached, a C=O group; in which the acyclic radicals R6, R7 and R8 can be replaced with one or Petition 870250039092, dated 05 / 14 / 2025, p. 25 / 383 18 / 178 more Rae substituents where the cyclic radicals R6, R7 and R8 can be substituted with one or more Rb substituents; Ra, Ya and Za are independently selected from the group consisting of nitro, hydroxyl, cyano, carboxyl, amino, sulfanyl, pentafluoro^6-sulfanyl, formyl, carbamoyl, carbamate, C3-C7-cycloalkyl, C3-C7-halogenocycloalkyl, C1-C8alkylamino, di-C1-C8-alkylamino, C1-C8-alkoxy, C1-C8-halogenoalkoxy, C1-C8-alkylsulfanyl, C1-C8-halogenoalkylsulfanyl, C1-C8-alkylcarbonyl, C1-C8halogenoalkylcarbonyl, C1-C8-alkylcarbamoyl, di-C1-C8-alkylcarbamoyl, C1-C8alkoxycarbonyl, C1-C8-halogenoalkoxycarbonyl, C1-C8-alkylcarbonyloxy, C1-C8 halogenalkylcarbonyloxy, C1-C8 alkylcarbonylamino, C1-C8 halogenalkylcarbonylamino, C1-C8 alkylsulfinyl, C1-C8 halogenalkylsulfinyl, C1C8 alkylsulfonyl, C1-C8 halogenalkylsulfonyl, C1-C8 alkylsulfonylamino, C1-C8 halogenalkylsulfonylamino, sulfamoyl, C1-C8 alkylsulfamoyl and di-C1-C8 alkylsulfamoyl, Rb, Yb and Zb are independently selected from the group consisting of halogen atom, nitro, hydroxyl, cyano, carboxyl, amino, sulfanyl, pentafluoroλ6-sulfanyl, formyl, carbamoyl, carbamate, C1-C8-alkyl, C3-C7-cycloalkyl, C1-C8halogenoalkyl, C3-C7-halogenocycloalkyl, C2-C8-alkenyl, C2-C8-alkynyla, C1-C8alkylamino, di-C1-C8-alkylamino, C1-C8-alkoxy, C1-C8-halogenalkoxy, C1-C8alkylsulfanyl, C1-C8-halogenoalkylsulfanyl, C1-C8-alkylcarbonyl, C1-C8halogenoalkylcarbonyl, C1-C8-alkylcarbamoyl, di-C1-C8-alkylcarbamoyl, C1-C8-alkoxycarbonyl, C1-C8-halogenalkoxycarbonyl, C1-C8-alkylcarbonyloxy, C1-C8-halogenalkylcarbonyloxy, C1-C8-alkylcarbonylamino, C1-C8-alkylsulfanyl, C1-C8-halogenalkylsulfanyl, C1-C8-alkylsulfinyl, C1-C8-halogenalkylsulfinyl, C1-C8-alkylsulfonyl, C1-C8-halogenalkylsulfonyl, C1-C8-alkylsulfonylamino, C1-C8-halogenalkylsulfonylamino, sulfamoyl, C1-C8-alkylsulfamoyl and di-C1-C8-alkylsulfamoyl; Petition 870250039092, dated 05 / 14 / 2025, p. 26 / 383 19 / 178 provided that the compound of formula (I) is not: (a) 3-{4-[(4-fluorophenoxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5ol [2358785-16-5], and (b) 3-{4-[1-(cyclopropylamino)ethyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2oxazol-5-ol [2358785-04-1].

[045] Compounds (a) and (b) are disclosed in document WO2019 / 122393.

[046] The invention encompasses pure stereoisomers of the compound of formula (I) and any mixture of these isomers.

[047] Not covered by the present invention are compounds resulting from combinations that are contrary to natural laws and which a person skilled in the art would therefore exclude based on their expert knowledge. For example, ring structures having three or more adjacent oxygen atoms are excluded.

[048] Depending on the nature of the substituents, the compound of formula (I) may be present in the form of different stereoisomers. These stereoisomers are, for example, enantiomers, diastereomers, atropisomers or geometric isomers. Consequently, the invention encompasses both pure stereoisomers and any mixture of these isomers. Where a compound may be present in two or more tautomeric forms in equilibrium, reference to the compound by means of a tautomeric description shall be considered as including all tautomeric forms.

[049] Any of the compounds of the present invention may also exist in one or more geometric isomer forms depending on the number of double bonds in the compound. Geometric isomers by nature of substituents on a double bond or a ring may be present in cis (= Z-) or trans (= E-) form. The invention thus relates equally to all geometric isomers and to all possible mixtures, in all proportions.

[050] The compounds of formula (I) may be suitably in their form Petition 870250039092, dated 05 / 14 / 2025, p. 27 / 383 20 / 178 free, salt form, N-oxide form or solvate form (e.g., hydrate).

[051] Depending on the nature of the substituents, the compound of formula (I) may be present in the form of the free compound and / or a salt thereof, such as an agrochemically active salt.

[052] Agrochemically active salts include acid addition salts of inorganic and organic acids as well as salts of common bases. Examples of inorganic acids are hydrohalic acids, such as hydrogen fluoride, hydrogen chloride, hydrogen bromide and hydrogen iodide, sulfuric acid, phosphoric acid and nitric acid, and acid salts, such as sodium bisulfate and potassium bisulfate. Useful organic acids include, for example, formic acid, carbonic acid, and alkanoic acids such as acetic acid, trifluoroacetic acid, trichloroacetic acid, and propionic acid, as well as glycolic acid, thiocyanic acid, lactic acid, succinic acid, citric acid, benzoic acid, cinnamic acid, oxalic acid, saturated or mono- or di-unsaturated fatty acids having 6 to 20 carbon atoms, alkylsulfuric monoesters, alkylsulfonic acids (sulfonic acids having straight or branched alkyl radicals having 1 to 20 carbon atoms).Arylsulfonic acids or aryldisulfonic acids (aromatic radicals, such as phenyl and naphthyl, bearing one or two sulfonic acid groups), alkylphosphonic acids (phosphonic acids having straight-chain or branched alkyl radicals having 1 to 20 carbon atoms), arylphosphonic acids or aryldiphosphonic acids (aromatic radicals, such as phenyl and naphthyl, bearing one or two phosphonic acid radicals), where the alkyl and aryl radicals may bear other substituents, for example p-toluenesulfonic acid, salicylic acid, p-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, etc.

[053] Solvates of the compounds of the invention or their salts are stoichiometric compositions of the compounds with solvents.

[054] The compounds of the invention can exist in multiple crystalline forms. Petition 870250039092, dated 05 / 14 / 2025, page 28 / 383 21 / 178 and / or amorphous. Crystalline forms include non-solvated crystalline forms, solvates, and hydrates.

[055] The compounds of formula (I) are referred to in this invention as “active ingredient(s)”.

[056] In some forms, in formula (I) above, X is fluorine.

[057] In some embodiments, in formula (I) above, Y is selected from the group consisting of hydrogen, C1-C8-alkyl, tri-C1-C8-alkylsilane and C(=O)Z with Z as described herein above or below.

[058] In some embodiments, in formula (I) above, Z is selected from the group consisting of C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-halogenalkoxy, C1-C8-alkylamino, di-C1-C8-alkylamino, aryloxy and heteroaryloxy.

[059] In some embodiments, in formula (I) above, Y is selected from the group consisting of hydrogen, C1-C8-alkyl, tri-C1-C8-alkylsilane and C(=O)Z; wherein Z is selected from the group consisting of C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-halogenalkoxy, C1-C8-alkylamino, di-C1-C8-alkylamino, aryloxy and heteroaryloxy.

[060] In some embodiments, in formula (I) above, Z is C1-C8-alkyl (preferably C1-C4-alkyl, for example, methyl or ethyl), C1-C8-alkoxy (preferably C1-C4-alkoxy, for example, methoxy, ethoxy or tert-butoxy) or phenyloxy.

[061] In some embodiments, in formula (I) above, Y is hydrogen, tert-butyl(dimethyl)silane or acetyl.

[062] In some forms, in formula (I) above, m is 0 or 1.

[063] In some forms, in formula (I) above, m is 0.

[064] In some forms, in formula (I) above, n is 0.

[065] In some forms, in formula (I) above, n is 1.

[066] In some embodiments, in formula (I) above, L is selected from the group consisting of CR3R4, O, S, S(=O), S(=O)2, S(=O)(=NH) and NR5 with R3, R4 Petition 870250039092, dated 05 / 14 / 2025, p. 29 / 383 22 / 178 and R5 as described above or below.

[067] In some embodiments, in formula (I) above, L is NR5 with R5 being selected from the group consisting of hydrogen atom, C1-C8-alkyl, C3C7-cycloalkyl-C1-C8-alkyl, C1-C8-alkylcarbonyl, C1-C8-alkoxycarbonyl, C1-C8-alkylsulfonyl, C1-C8-halogenalkylsulfonyl, arylsulfonyl and aryl-C1-C8-alkyl.

[068] In some embodiments, in formula (I) above, L is NR5 with R5 being selected from the group consisting of hydrogen atom, C1-C4-alkyl (e.g., methyl), C3-C7-cycloalkyl-C1-C8-alkyl (e.g., cyclopropylmethyl), C1-C4-alkylcarbonyl (e.g., acyl), C1-C4-alkoxycarbonyl (e.g., methoxycarbonyl or ethoxycarbonyl), C1-C4-alkylsulfonyl (e.g., mesyl), C1-C4-halogenalkylsulfonyl (e.g., triphyll), arylsulfonyl (e.g., phenylsulfonyl or tosyl) and aryl-C1-C4-alkyl (e.g., benzyl).

[069] In some embodiments, in formula (I) above, L is NR5 with R5 being hydrogen.

[070] In some embodiments, in formula (I) above, L is selected from the group consisting of CR3R4, O, S, S(=O), S(=O)2, S(=O)(=NH), S(=N-CN) and NR5, wherein R3 and R4 are independently hydrogen and C1-C8-alkyl and wherein R5 is selected from the group consisting of hydrogen atom, C1-C8-alkyl, C3C7-cycloalkyl-C1-C8-alkyl, C1-C8-alkylcarbonyl, C1-C8-alkoxycarbonyl, C1-C8-alkylsulfonyl, C1-C8-halogenalkylsulfonyl, arylsulfonyl and aryl-C1-C8-alkyl.

[071] In some embodiments, in formula (I) above, n is 0 or 1 and L is CR3R4, O, S, S=O, S(=O)2, S(=O)(=NH) or S(=N-CN), preferably CH2, O, S, S=O, S(=O)2, S(=O)(=NH) or S(=N-CN). In some of these embodiments, n is 0.

[072] In some forms, in formula (I) above, n is 1 and L is NR5, preferably NH.

[073] In some embodiments, in formula (I) above, R3 and R4 are independently selected from the group consisting of hydrogen and C1 Petition 870250039092, dated 05 / 14 / 2025, page 30 / 383 23 / 178 C8-alkyl.

[074] In some embodiments, in formula (I) above, R3 and R4 are hydrogen.

[075] In some embodiments, in formula (I) above, L is CH2, O, S, S(=O) or NH.

[076] In some embodiments, in formula (I) above, A is a C3-C7 cycloalkyl, aryl or heteroaryl ring. A may be substituted as described herein above or below.

[077] In some embodiments, in formula (I) above, A is C3-C7-cycloalkyl, preferably cyclopentyl or cyclohexyl. A may be substituted as described herein above or below.

[078] In some embodiments, in formula (I) above, A is phenyl. A may be substituted as described here above or below.

[079] In some embodiments, in formula (I) above, A is a heteroaryl ring, preferably selected from the group consisting of imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine, pyrazine, indole, benzothiazine and phenothiazine. A may be substituted as described herein above or below.

[080] In some embodiments, in formula (I) above, A is a 5- or 6-membered heteroaryl ring, preferably selected from the group consisting of imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine and pyrazine. A may be substituted as described herein above or below.

[081] In some embodiments, in formula (I) above, A is a heterocyclyl ring, such as tetrahydro-2H-pyran, 1,2-dihydropyridine, 2,3-dihydro-4H-1,4-benzothiazine, 4,5,6,7-tetrahydropyrazolo-[1,5-a]-pyridine or 1,2,3,4-tetrahydrocarbazole. A may be substituted as described above or below.

[082] In some embodiments, in formula (I) above, A is cyclopentyl, cyclohexyl, phenyl, imidazole, pyrazole, 1,2-oxazolepyrrole, thiophene, thiazole, pyridine, pyrimidine, pyrazine, tetrahydro-2H-pyran or 1,2-dihydropyridine. A may be substituted as Petition 870250039092, dated 05 / 14 / 2025, p. 31 / 383 24 / 178 described above or below.

[083] In some embodiments, in formula (I) above, A is selected from the group consisting of 5- or 6-membered heteroaryl, phenyl and C3-C7-cycloalkyl, preferably selected from the group consisting of imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine, pyrazine, phenyl, cyclohexyl and cyclopentyl. A may be substituted as described herein above or below.

[084] In some embodiments, in formula (I) above, A is selected from the group consisting of imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine, pyrazine, indole, benzothiazine, phenothiazine, tetrahydropyran, 1,2-dihydropyridine, 2,3-dihydro-4H-1,4-benzothiazine, 4,5,6,7-tetrahydropyrazolo-[1,5-a]pyridine or 1,2,3,4-tetrahydrocarbazole, phenyl, cyclohexyl and cyclopentyl. A may be substituted as described herein above or below.

[085] In some embodiments, in formula (I) above, A is replaced with R6 which is selected from the group consisting of halogen, C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-halogenalkoxy, C3-C7-cycloalkyl, aryl, heterocyclyl, -C(=O)OR7 and -C(=O)N(R7)(R8) with R7 and R8 as described herein above or below.

[086] In some embodiments, in formula (I) above, A is replaced with R6 which is selected from the group consisting of halogen (e.g., Cl or F), C1-C4-alkyl (e.g., methyl), C1-C4-alkoxy (e.g., methoxy), C3-C7-cycloalkyl (e.g., cyclopropyl), aryl (e.g., phenyl, 4-chlorophenyl), C(=O)OR7 (e.g., methoxycarbonyl or ethoxycarbonyl) and -C(=O)N(R7)(R8) (e.g., phenylaminocarbonyl).

[087] In some embodiments, in formula (I) above, R6 is selected from the group consisting of halogen, cyano, C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-alkylamino, C3-C7-cycloalkyl, aryl, aryl-C1-C8-alkyl, heterocyclyl-C1-C8-alkyl, heteroaryl-C1-C8-alkyl, -C(=O)R7, -C(=O)OR7 and -C(=O)N(R7)(R8) with Petition 870250039092, dated 05 / 14 / 2025, p. 32 / 383 25 / 178 R7 and R8, as described above or below; or two geminal R6 substituents, may form, if structurally feasible, together with the carbon atom to which they are attached, a C=O group.

[088] In some embodiments, in formula (I) above, R6 is selected from the group consisting of halogen (e.g., Cl or F), cyano, C1-C4-alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, isobutyl), C1-C4-halogenalkyl (e.g., trifluoromethyl, difluoromethyl or trifluoroethyl), C1-C4-alkoxy (e.g., methoxy), C1-C4-alkylamino (e.g., dimethylamino), C3-C7-cycloalkyl (e.g., cyclopropyl, cyclopentyl), aryl (e.g., phenyl, 4-chlorophenyl), aryl-C1-C4-alkyl (e.g., benzyl, 2-fluorobenzyl), heteroaryl-C1-C4-alkyl (e.g., thienylmethyl), -C(=O)R7, -C(=O)OR7e -C(=O)N(R7)(R8), wherein R7 is selected from the group consisting of hydrogen, C1-C8-alkyl, aryl and C3-C7-cycloalkyl and R8 is selected from the group consisting of hydrogen and C1-C8-alkyl; Two geminal R6 substituents can form, if structurally feasible, a C=O group together with the carbon atom to which they are attached.

[089] In some embodiments, in formula (I) above, R6 is selected from the group consisting of Cl, F, cyano, methyl, ethyl, n-propyl, isopropyl, isobutyl, trifluoromethyl, difluoromethyl, trifluoroethyl, methoxy, dimethylamino, cyclopropyl, cyclopentyl, phenyl, 4-chlorophenyl, benzyl, 2-fluorobenzyl, thienylmethyl, -C(=O)R7, C(=O)OR7 and -C(=O)N(R7)(R8), wherein R7 is selected from the group consisting of hydrogen, methyl, ethyl, phenyl, 4-chlorophenyl and cyclopropyl and R8 is selected from the group consisting of hydrogen and methyl; Two geminal R6 substituents can form, if structurally feasible, a C=O group together with the carbon atom to which they are attached.

[090] In some embodiments, in formula (I) above, R7 is selected from the group consisting of hydrogen, C1-C8-alkyl, aryl and C3-C7-cycloalkyl. R7 may be substituted as described in the present invention. Petition 870250039092, dated 05 / 14 / 2025, page 33 / 383 26 / 178

[091] In some embodiments, in formula (I) above, R7 is selected from the group consisting of hydrogen, methyl, ethyl, phenyl, 4-chlorophenyl and cyclopropyl.

[092] In some embodiments, in formula (I) above, R8 is selected from the group consisting of hydrogen and C1-C8-alkyl.

[093] In some embodiments, in formula (I) above, R8 is selected from the group consisting of hydrogen and methyl.

[094] In some embodiments, in formula (I) above, R1 and R2 are independently selected from the group consisting of hydrogen, hydroxy, C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-halogenalkoxy, C1-C8-alkylcarbonyl, C1-C8-alkoxycarbonyl, C3-C7-cycloalkyl, C3-C7-halogencycloalkyl, aryl, heterocyclyl and heteroaryl, or R1 and R2 may form, together with the carbon atom to which they are attached, a C3-C7-cycloalkyl ring, or R1 and R2 may form, together with the carbon atom to which they are attached, a C=CH2, C=O, C=N-OH or C=N-ORc group, where n is 0 or L is CR3R4Rce as described in the present invention.

[095] In some embodiments, in formula (I) above, R1 and R2 are independently selected from the group consisting of hydrogen, hydroxy, C1-C8-alkyl, C1-C8-alkoxy and C1-C8-alkoxycarbonyl, or R1 and R2 may form, together with the carbon atom to which they are attached, a C3-C7-cycloalkyl ring, or R1 and R2 may form, together with the carbon atom to which they are attached, a C=CH2, C=O or C=N-OH group, when n is 0 or L is CR3R4.

[096] In some embodiments, in formula (I) above, R1 and R2 are independently selected from the hydrogen, hydroxy, methyl, methoxy and acetoxy group, or R1 and R2 may form, together with the carbon atom to which they are attached, a cyclopropyl ring.

[097] In some embodiments, in formula (I) above, R1 and R2 are independently selected from the group consisting of hydrogen, hydroxy, Petition 870250039092, dated 05 / 14 / 2025, page 34 / 383 27 / 178 Methyl, methoxy, and acetoxy groups, or R1 and R2, can form, together with the carbon atom to which they are attached, a C=CH2, C=O, or C=N-OH group, when n is 0 or L is CR3R4.

[098] In some embodiments, compounds are excluded, wherein in formula (I) above n is 0, A is an N-linked heterocyclyl ring and R1 and R2 are selected from the group consisting of hydrogen, halogen, cyano, C1-C4 alkyl, C1-C4 halogen alkyl, C2-C4 alkenyl, C2-C4 alkynyl and C1-C4 alkoxy; and compounds are excluded, wherein in formula (I) above n is 0, A is an N-linked heterocyclyl ring and R1 and R2 form, together with the carbon atom to which they are attached, a C3-C7 cycloalkyl or a saturated 3- to 6-membered heterocyclyl ring containing 1 to 3 heteroatoms which may be the same or different and selected from the group consisting of O, S and N.

[099] In some embodiments, compounds are excluded, wherein in formula (I) above, n is 0, A is a non-aromatic heterocyclyl ring bonded to N and at least one group adjacent to said nitrogen bonded to the CR1R2 moiety is a C(=O), C(=S), S(=O)p, NR'-C(=O), NR'-C(=S) or an NR'-S(O)p group, where p is 0, 1 or 2 and where R' is hydrogen or a substituent bonded to C.

[0100] The definitions specified above of X, Y, Z, L, m, n, A, R1, R2, R3, R4, R5, R6, R7 and R8 can be combined in various ways to provide subclasses of compounds according to the invention.

[0101] Non-limiting examples of compound subclasses include the subclasses described in the present invention below.

[0102] In some embodiments (referred to in the present invention as embodiment Ia), the present invention relates to the compound of formula (I): Petition 870250039092, dated 05 / 14 / 2025, p. 35 / 383 28 / 178 (I) in which X stands for fluorine; Y is selected from the group consisting of hydrogen, C1-C8-alkyl, triC1-C8-alkylsilane and C(=O)Z with Z as described in the present invention, wherein the acyclic radicals Y and Z may be respectively substituted with one or more Ya or Za substituents as described in the present invention and wherein the cyclic radicals Z may be respectively substituted with one or more Y or Zb substituents as described in the present invention; m is 0 or 1; R1, R2 are independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, sulfanyl, amino, formyl, C1-C8-alkyl, C1-C8haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, C2-C8-alkenyl, C2-C8haloalkenyl, C2-C8-alkynyl, C2-C8-haloalkynyl, C1-C8-alkylsulfanyl, C1C8-haloalkylsulfanyl, C1-C8-alkylsulfinyl, C1-C8-haloalkylsulfinyl, C1-C8alkylsulfonyl, C1-C8-haloalkylsulfonyl, C1-C8-alkylamino, di-C1-C8-alkylamino, C1-C8-alkylcarbonyl, C1-C8-haloalkylcarbonyl, C1-C8-alkoxycarbonyl, C3-C7-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the acyclic radicals R1, R2 may be substituted with one or more Ra substituents as described in the present invention and wherein the cyclic radicals R1, R2 may be substituted with one or more Rb substituents as described in the present invention, or R1, R2 can form, together with the carbon atom to which they are attached, a C3-C7-cycloalkyl or heterocyclyl ring wherein said C3-C7-cycloalkyl and heterocyclyl ring can be substituted with one or more Rb substituents as described in the present invention, or R1 and R2, together with the carbon atom to which they are attached, can form Petition 870250039092, dated 05 / 14 / 2025, p. 36 / 383 29 / 178 a C=CH2, C=O, C=N-OH or C=N-ORc group with Rc being selected from the group consisting of C1-C8-alkyl, aryl and aryl-C1-C8-alkyl, when n is 0 or when L is CR3R4, wherein the acyclic radicals Rc may be substituted with one or more substituents Rb as described in this invention and wherein the cyclic radicals Rc may be substituted with one or more substituents Rb as described in this invention; n is 0 or 1; L is CR3R4, O, S, S=O, S(=O)2, S(=O)(=NH) or NR5, wherein R3, R4 and R5 are as described in the present invention, wherein when L is CR3R4, R1 and R3 may form, together with the carbon atoms to which they are attached, a C3-C7-cycloalkyl ring, wherein said C3-C7-cycloalkyl ring may be substituted with one or more Rb substituents as described in the present invention. A is a C3-C7-cycloalkyl, aryl, heterocyclyl or heteroaryl ring, wherein said C3-C7-cycloalkyl, aryl, heterocyclyl or heteroaryl may be substituted, one or more times, in the same way or differently, with R6, R6 being as described in the present invention; provided that the compound of formula (I) is not: (a) 3-{4-[(4-fluorophenoxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5ol [2358785-16-5], and (b) 3-{4-[1-(cyclopropylamino)ethyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol [2358785-04-1].

[0103] In some embodiments (referred to in the present invention as embodiment Ib), the present invention refers to the compound of formula (I): Petition 870250039092, dated 05 / 14 / 2025, pp. 37 / 383 30 / 178 (I) in which X stands for fluorine; Y is selected from the group consisting of hydrogen, C1-C8-alkyl, triC1-C8-alkylsilane and C(=O)Z with Z as described in the present invention, wherein the acyclic radicals Y and Z may be respectively substituted with one or more Ya or Za substituents as described in the present invention and wherein the cyclic radicals Z may be respectively substituted with one or more Y or Zb substituents as described in the present invention; m is 0 or 1; R1, R2 are independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, sulfanyl, amino, formyl, C1-C8-alkyl, C1-C8haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, C2-C8-alkenyl, C2-C8haloalkenyl, C2-C8-alkynyl, C2-C8-haloalkynyl, C1-C8-alkylsulfanyl, C1C8-haloalkylsulfanyl, C1-C8-alkylsulfinyl, C1-C8-haloalkylsulfinyl, C1-C8alkylsulfonyl, C1-C8-haloalkylsulfonyl, C1-C8-alkylamino, di-C1-C8-alkylamino, C1-C8-alkylcarbonyl, C1-C8-haloalkylcarbonyl, C1-C8-alkoxycarbonyl, C3-C7-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the acyclic radicals R1, R2 may be substituted with one or more Ra substituents as described in the present invention and wherein the cyclic radicals R1, R2 may be substituted with one or more Rb substituents as described in the present invention, or R1-R2 can form, together with the carbon atom to which they are attached, Petition 870250039092, dated 05 / 14 / 2025, pp. 38 / 383 31 / 178 a C3-C7-cycloalkyl or a heterocyclyl ring wherein said C3-C7-cycloalkyl and heterocyclyl ring may be substituted with one or more Rb substituents as described in this invention, or R1, R2 can form, together with the carbon atom to which they are attached, a C=CH2, C=O, C=N-OH or C=N-ORc group with Rc being selected from the group consisting of C1-C8-alkyl, aryl and aryl-C1-C8-alkyl, when n is 0, or when L is CR3R4, wherein the acyclic radicals Rc can be substituted with one or more substituents Rb as described in the present invention and wherein the cyclic radicals Rc can be substituted with one or more substituents Rb as described in the present invention; n is 0 or 1; L is CR3R4, O, S, S=O, S(=O)2, S(=O)(=NH) or NR5, wherein R3, R4 and R5 are as described in the present invention, wherein when L is CR3R4, R1 and R3 may form, together with the carbon atoms to which they are attached, a C3-C7-cycloalkyl ring, wherein said C3-C7-cycloalkyl ring may be substituted with one or more Rb substituents as described in the present invention. A is a 5- or 6-membered C3-C7-cycloalkyl, phenyl or heteroaryl ring, wherein said 5- or 6-membered C3-C7-cycloalkyl, phenyl or heteroaryl ring may be substituted, one or more times, in the same way or differently, with R6, R6 being as described in the present invention; provided that the compound of formula (I) is not: (a) 3-{4-[(4-fluorophenoxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5ol [2358785-16-5], and (b) 3-{4-[1-(cyclopropylamino)ethyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol [2358785-04-1]. Petition 870250039092, dated 05 / 14 / 2025, pp. 39 / 383 32 / 178

[0104] In some embodiments (referred to in the present invention as embodiment Ic), the present invention relates to the compound of formula (I): in which X stands for fluorine; Y is selected from the group consisting of hydrogen, C1-C8-alkyl, triC1-C8-alkylsilane and C(=O)Z with Z as described in the present invention, wherein the acyclic radicals Y and Z can be substituted respectively with one or more Ya or Za substituents and wherein the cyclic radicals Z can be substituted respectively with one or more Y or Zb substituents; m is 0 or 1; R1 and R2 are independently selected from the group consisting of hydrogen, hydroxy, C1-C8-alkyl, C1-C8-alkoxy and C1-C8-alkoxycarbonyl, or R1 and R2 form, together with the carbon atom to which they are attached, a C3-C7 cycloalkyl ring, or R1 and R2 form, together with the carbon atom to which they are attached, a C=CH2, C=O or C=N-OH group, when n is 0, or when L is CR3R4; preferably R1 and R2 are independently selected from the hydrogen, hydroxy, methyl, methoxy and acetoxy group, or R1 and R2 form, together with the carbon atom to which they are attached, a cyclopropyl ring; n is 0 or 1; L is CR3R4, O, S, S=O, S(=O)2, S(=O)(=NH) or NR5, wherein R3, R4 and R5 are as described in the present invention, wherein when L is CR3R4, R1 and R3 may form, together with the atoms of Petition 870250039092, dated 05 / 14 / 2025, p. 40 / 383 33 / 178 carbon to which they are attached, a C3-C7-cycloalkyl ring, wherein said C3-C7-cycloalkyl ring may be substituted with one or more Rb substituents, A is a 5- or 6-membered C3-C7-cycloalkyl, phenyl or heteroaryl ring, wherein said 5- or 6-membered C3-C7-cycloalkyl, phenyl or heteroaryl ring may be substituted, one or more times, in the same way or differently, with R6, R6 being as described in the present invention; provided that the compound of formula (I) is not: (a) 3-{4-[(4-fluorophenoxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5ol [2358785-16-5], and (b) 3-{4-[1-(cyclopropylamino)ethyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol [2358785-04-1].

[0105] In some embodiments, according to embodiments Ia, Ib and Ic, Y is selected from the group consisting of hydrogen, C1-C8-alkyl, tri-C1C8-alkylsilane and C(=O)Z with Z being selected from the group consisting of C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-halogenalkoxy, C1-C8-alkylamino, di-C1-C8-alkylamino, aryloxy and heteroaryloxy.

[0106] In some embodiments, according to embodiments Ia, Ib and Ic, Y is selected from the group consisting of hydrogen, C1-C8-alkyl, tri-C1C8-alkylsilane and C(=O)Z; wherein Z is selected from the group consisting of C1C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-halogenalkoxy, C1-C8-alkylamino, di-C1-C8-alkylamino, aryloxy and heteroaryloxy.

[0107] In some embodiments, according to embodiments Ia, Ib and Ic, Y is hydrogen, tert-butyl(dimethyl)silane or acetyl.

[0108] In some modalities, according to modalities Ia, Ib and Ic, m is 0.

[0109] In some modalities, according to modalities Ia, Ib and Ic, n is 0. Petition 870250039092, dated 05 / 14 / 2025, p. 41 / 383 34 / 178

[0110] In some modalities, according to modalities Ia, Ib and Ic, n is 1.

[0111] In some embodiments, according to embodiments Ia, Ib and Ic, n is 1 and L is selected from the group consisting of CR3R4, preferably CH2, O, S, S(=O), S(=O)2 and S(=O)(=NH).

[0112] In some embodiments, according to embodiments Ia, Ib and Ic, L is CR3R4, O, S, S=O, S(=O)2 or S(=O)(=NH), preferably CH2, O, S, S=O, S(=O)2 or S(=O)(=NH). In some of these embodiments, n is 0.

[0113] In some forms, in formula (I) above, n is 1 and L is NR5, preferably NH.

[0114] In some modalities, according to modalities Ia, Ib and Ic, L is selected from the group consisting of CR3R4, O, S, S(=O), S(=O)2, S(=O)(=NH) and NR5 with: R3e R4sendo seletivo qualquer qualquer de grupo constando de hidro e C1-C8-alkyl, R5 being selected from the group consisting of hydrogen atom, C1-C8-alkyl, C3-C7-cycloalkyl-C1-C8-alkyl, C1-C8-alkylcarbonyl, C1-C8alkoxycarbonyl, C1-C8-alkylsulfonyl, C1-C8-haloalkylsulfonyl, arylsulfonyl and arylC1-C8-alkyl.

[0115] In some forms, according to forms Ia, Ib and Ic, L is CH2, O, S, S(=O) or NH.

[0116] In some embodiments, according to embodiments Ia, Ib and Ic, A is a heteroaryl ring, preferably selected from the group consisting of imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine, pyrazine, indole, benzothiazine and phenothiazine. A may be substituted as described above or below.

[0117] In some modalities, according to modalities Ia, Ib and I Petition 870250039092, dated 05 / 14 / 2025, p. 42 / 383 35 / 178 c, A is a 5- or 6-membered heteroaryl ring, preferably selected from the group consisting of imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine, and pyrazine. A may be substituted as described above or below.

[0118] In some embodiments, according to embodiments Ia, Ib and Ic, A is a heterocyclyl ring, such as tetrahydro-2H-pyran, 1,2-dihydropyridine, 2,3-dihydro-4H-1,4-benzothiazine, 4,5,6,7-tetrahydropyrazolo-[1,5-a]-pyridine or 1,2,3,4-tetrahydrocarbazole. A may be substituted as described above or below.

[0119] In some embodiments, according to embodiments Ia, Ib and Ic, A is selected from the group consisting of imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine, pyrazine, indole, benzothiazine, phenothiazine, tetrahydropyran, 1,2-dihydropyridine, 2,3-dihydro-4H-1,4-benzothiazine, 4,5,6,7-tetrahydropyrazolo-[1,5-a]-pyridine or 1,2,3,4-tetrahydrocarbazole, phenyl, cyclohexyl and cyclopentyl. A may be substituted as described above or below.

[0120] In some embodiments, according to embodiments Ia, Ib and Ic, A is selected from the group consisting of 5 or 6 heteroaryl, phenyl and C3-C7-cycloalkyl members, preferably selected from the group consisting of imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine, pyrazine, phenyl, cyclohexyl and cyclopentyl. A may be substituted as described above or below.

[0121] In some embodiments, according to embodiments Ia, Ib and Ic, A is replaced with R6 which is selected from the group consisting of halogen, C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-halogenalkoxy, C3-C7-cycloalkyl, aryl, heterocyclyl, -C(=O)OR7 and -C(=O)N(R7)(R8) with R7 and R8 as described above or below.

[0122] In some embodiments, according to embodiments Ia, Ib and Ic, A is replaced with R6 which is selected from the group consisting of halogen (e.g., Cl or F), C1-C4-alkyl (e.g., methyl), C1-C4-alkoxy (e.g., methoxy), C3-C7-cycloalkyl (e.g., cyclopropyl), aryl (e.g., phenyl, 4 Petition 870250039092, dated 05 / 14 / 2025, p. 43 / 383 36 / 178 chlorophenyl), -C(=O)OR7 (for example, methoxycarbonyl or ethoxycarbonyl) and C(=O)N(R7)(R8) (for example, phenylaminocarbonyl).

[0123] In some embodiments, according to embodiments Ia, Ib and Ic, R6 is selected from the group consisting of halogen, cyano, C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-alkylamino, C3-C7-cycloalkyl, aryl, arylC1-C8-alkyl, heterocyclyl-C1-C8-alkyl, heteroaryl-C1-C8-alkyl, -C(=O)R7, C(=O)OR7 and -C(=O)N(R7)(R8) with R7 and R8 as described above or below; or two geminal R6 substituents may form, if structurally feasible, together with the carbon atom to which they are attached, a C=O group.

[0124] In some embodiments, according to embodiments Ia, Ib and Ic, R6 is selected from the group consisting of halogen (e.g., Cl or F), cyano, C1-C4-alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, isobutyl), C1-C4-halogenalkyl (e.g., trifluoromethyl, difluoromethyl or trifluoroethyl), C1-C4-alkoxy (e.g., methoxy), C1-C4-alkylamino (e.g., dimethylamino), C3-C7-cycloalkyl (e.g., cyclopropyl, cyclopentyl), aryl (e.g., phenyl, 4-chlorophenyl), aryl-C1-C4-alkyl (e.g., benzyl, 2-fluorobenzyl), heteroaryl-C1-C4-alkyl (e.g., thienylmethyl), -C(=O)R7, -C(=O)OR7e -C(=O)N(R7)(R8), wherein R7 is selected from the group consisting of hydrogen, C1-C8-alkyl, aryl and C3C7-cycloalkyl and R8 is selected from the group consisting of hydrogen and C1C8-alkyl; Two geminal R6 substituents can form, if structurally feasible, a C=O group together with the carbon atom to which they are attached.

[0125] In some embodiments, according to embodiments Ia, Ib and Ic, R6 is selected from the group consisting of Cl, F, cyano, methyl, ethyl, n-propyl, isopropyl, isobutyl, trifluoromethyl, difluoromethyl, trifluoroethyl, methoxy, dimethylamino, cyclopropyl, cyclopentyl, phenyl, 4-chlorophenyl, benzyl, 2-fluorobenzyl, thienylmethyl, C(=O)R7, -C(=O)OR7 and -C(=O)N(R7)(R8), wherein R7 is selected from the group Petition 870250039092, dated 05 / 14 / 2025, page 44 / 383 37 / 178 consisting of hydrogen, methyl, ethyl, phenyl, 4-chlorophenyl and cyclopropyl and R8 is selected from the group consisting of hydrogen and methyl; Two geminal R6 substituents can form, if structurally feasible, a C=O group together with the carbon atom to which they are attached.

[0126] In some embodiments, according to embodiments Ia, Ib and Ic, A is imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine, pyrazine, indole, benzothiazine, phenothiazine, tetrahydropyran, 1,2-dihydropyridine, 2,3-dihydro-4H1,4-benzothiazine, 4,5,6,7-tetrahydropyrazolo-[1,5-a]-pyridine or 1,2,3,4-tetrahydrocarbazole, phenyl, cyclohexyl and cyclopentyl. A may be replaced with R6 as described in the present invention.

[0127] In some of these embodiments, R6 may be selected from the group consisting of halogen, C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-halogenalkoxy, C3-C7-cycloalkyl, aryl, heterocyclyl, -C(=O)OR7 and C(=O)N(R7)(R8) with R7 and R8 as described above or below; or two geminal R6 substituents may form, if structurally feasible, together with the carbon atom to which they are attached, a C=O group.

[0128] In some other embodiments, R6 is selected from the group consisting of halogen (e.g., Cl or F), C1-C4-alkyl (e.g., methyl), C1-C4-alkoxy (e.g., methoxy), C3-C7-cycloalkyl (e.g., cyclopropyl), aryl (e.g., phenyl, 4-chlorophenyl), -C(=O)OR7 (e.g., methoxycarbonyl or ethoxycarbonyl) and -C(=O)N(R7)(R8) (e.g., phenylaminocarbonyl); or two geminal R6 substituents may form, if structurally feasible, together with the carbon atom to which they are attached, a C=O group.

[0129] In some embodiments, R7 is selected from the group consisting of hydrogen, C1-C8-alkyl and aryl. R7 may be substituted as described in the present invention. Petition 870250039092, dated 05 / 14 / 2025, p. 45 / 383 38 / 178

[0130] In some embodiments, R7 is selected from the group consisting of hydrogen, methyl, ethyl, phenyl and 4-chlorophenyl.

[0131] In some embodiments, R8 is selected from the group consisting of hydrogen and C1-C8-alkyl.

[0132] In some embodiments, R8 is selected from the group consisting of hydrogen and methyl.

[0133] In some modalities, according to modalities Ia, Ib and Ic, A is selected from the group consisting of 5- or 6-membered heteroaryl, phenyl and C3-C7-cycloalkyl, preferably selected from the group consisting of imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine, pyrazine, phenyl, cyclohexyl and cyclopentyl, and A may be substituted with one or more R6 independently selected from the group consisting of halogen, cyano, C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-alkylamino, C3-C7-cycloalkyl, aryl, heteroaryl, aryl-C1-C8-alkyl, heterocyclyl-C1-C8-alkyl, heteroaryl-C1-C8-alkyl, -C(=O)R7, -C(=O)OR7 and -C(=O)N(R7)(R8). wherein preferably R7 is selected from the group consisting of hydrogen, methyl, ethyl, phenyl, 4-chlorophenyl and cyclopropyl and R8 is selected from the group consisting of hydrogen and methyl; or two geminal R6 substituents may form, if structurally possible, together with the carbon atom to which they are attached, a C=O group.

[0134] In some modalities, according to modalities Ia, Ib and Ic, A is selected from the group consisting of 5- or 6-membered heteroaryl, phenyl, and C3-C7-cycloalkyl groups, preferably selected from the group consisting of imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine, pyrazine, phenyl, cyclohexyl, and cyclopentyl groups, and A may be substituted with one or more R6 groups. Petition 870250039092, dated 05 / 14 / 2025, p. 46 / 383 39 / 178 independently selected from the group consisting of halogen, cyano, C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-alkylamino, C3-C7-cycloalkyl, aryl, heteroaryl, aryl-C1-C8-alkyl, heterocyclyl-C1-C8-alkyl, heteroaryl-C1-C8-alkyl, -C(=O)R7, -C(=O)OR7 and -C(=O)N(R7)(R8), wherein preferably R7 is selected from the group consisting of hydrogen, methyl, ethyl, phenyl, 4-chlorophenyl and cyclopropyl and R8 is selected from the group consisting of hydrogen and methyl.

[0135] In some embodiments, according to embodiments Ia and Ib, R1 and R2 are selected independently from the group consisting of hydrogen, hydroxy, C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-halogenalkoxy, C1-C8-alkylcarbonyl, C1-C8-alkoxycarbonyl, C3-C7-cycloalkyl, C3C7-halogencycloalkyl, aryl, heterocyclyl and heteroaryl, or R1 and R2 may form, together with the carbon atom to which they are attached, a C3-C7-cycloalkyl ring, or R1 and R2 may form, together with the carbon atom to which they are attached, a C=CH2, C=O, C=N-OH or C=N-ORc group, when n is 0 or L is CR3R4Rce as described in the present invention.

[0136] In some embodiments, according to embodiments Ia and Ib, R1 and R2 are independently selected from the group consisting of hydrogen, hydroxyl, C1-C8-alkyl, C1-C8-alkoxy and C1-C8-alkoxycarbonyl, or R1 and R2 may form, together with the carbon atom to which they are attached, a C3-C7-cycloalkyl ring, or R1 and R2 may form, together with the carbon atom to which they are attached, a C=CH2, C=O or C=N-OH group, when n is 0 or L is CR3R4

[0137] In some embodiments, according to embodiments Ia, Ib and Ic, R1 and R2 are independently selected from the hydrogen, hydroxy, methyl, methoxy and acetoxy group, or R1 and R2 can form, together with the carbon atom to which they are attached, a cyclopropyl ring.

[0138] In some modalities, according to modalities Ia, Ib and I Petition 870250039092, dated 05 / 14 / 2025, p. 47 / 383 40 / 178 c, R1 and R2 are independently selected from the hydrogen, hydroxyl, methyl, methoxy and acetoxy group, or R1 and R2 can form, together with the carbon atom to which they are attached, a C=CH2, C=O or C=N-OH group, when n is 0 or L is CR3R4.

[0139] In some embodiments (referred to in the present invention as embodiment Id), the present invention relates to the compound of formula (I): (I) in which X stands for fluorine; Y is selected from the group consisting of hydrogen, C1-C8-alkyl, triC1-C8-alkylsilane and C(=O)Z with Z being selected from the group consisting of C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-halogenalkoxy, C1-C8-alkylamino, di-C1-C8-alkylamino, aryloxy and heteroaryloxy, preferably Y is hydrogen, tert-butyl(dimethyl)silane or acetyl; m is 0; R1 and R2 are selected independently from the group consisting of hydrogen, hydroxyl, C1-C8-alkyl, C1-C8-alkoxy and C1-C8-alkoxycarbonyl, or R1 and R2, together with the carbon atom to which they are attached, form a C3-C7-cycloalkyl ring, or when n is 0 or L is CH2, R1 and R2 can form, together with the carbon atom to which they are attached, a C=CH2, C=O or C=N-OH group; n is 0 or 1; L is selected from the group consisting of CR3R4, O, S, S(=O), S(=O)2, S(=O)(=NH), S(=N-CN) and NR5, where R3 and R4 are independently hydrogen and Petition 870250039092, dated 05 / 14 / 2025, p. 48 / 383 41 / 178 C1-C8-alkyl and wherein R5 is selected from the group consisting of hydrogen atom, C1-C8-alkyl, C3-C7-cycloalkyl-C1-C8-alkyl, C1-C8-alkylcarbonyl, C1-C8-alkoxycarbonyl, C1-C8-alkylsulfonyl, C1-C8-halogenalkylsulfonyl, arylsulfonyl and arylC1-C8-alkyl; preferably L is CH2, O, S, S=O, S(=O)2, S(=O)(=NH), S(=N-CN) or NH; A is a 5- or 6-membered C3-C7-cycloalkyl, phenyl or heteroaryl ring, preferably selected from the group consisting of phenyl, cyclopentyl, cyclohexyl, imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine and pyrazine, wherein A may be substituted with one or more R6 substituents; R6 are selected independently from the group consisting of halogen, cyano, C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-alkylamino, C3-C7-cycloalkyl, aryl, heteroaryl, aryl-C1-C8-alkyl, heterocyclyl-C1-C8-alkyl, heteroaryl-C1-C8-alkyl, -C(=O)R7, -C(=O)OR7 and -C(=O)N(R7)(R8), wherein R7 is selected from the group consisting of hydrogen, C1-C8-alkyl, aryl and C3C7-cycloalkyl and R8 is selected from the group consisting of hydrogen and C1C8-alkyl; provided that the compound of formula (I) is not: (a) 3-{4-[(4-fluorophenoxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5ol [2358785-16-5], and (b) 3-{4-[1-(cyclopropylamino)ethyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2oxazol-5-ol [2358785-04-1].

[0140] In some preferred embodiments according to embodiment (Id), R6 is selected from the group consisting of halogen (e.g., Cl or F), cyano, C1-C4-alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, isobutyl), C1-C4-halogenalkyl (e.g., trifluoromethyl, difluoromethyl or trifluoroethyl), C1-C4-alkoxy (e.g., methoxy), C1-C4-alkylamino (e.g., dimethylamino), C3-C7 Petition 870250039092, dated 05 / 14 / 2025, page 49 / 383 42 / 178 cycloalkyl (e.g., cyclopropyl, cyclopentyl), aryl (e.g., phenyl, 4-chlorophenyl), aryl-C1-C4-alkyl (e.g., benzyl, 2-fluorobenzyl), heteroaryl-C1-C4-alkyl (e.g., thienylmethyl), -C(=O)R7, -C(=O)OR7 and -C(=O)N(R7)(R8), wherein R7 is selected from the group consisting of hydrogen, C1-C8-alkyl, aryl and C3C7-cycloalkyl and R8 is selected from the group consisting of hydrogen and C1C8-alkyl.In some of these embodiments, R6 is more preferably selected from the group consisting of Cl, F, cyano, methyl, ethyl, n-propyl, isopropyl, isobutyl, trifluoromethyl, difluoromethyl, trifluoroethyl, methoxy), dimethylamino, cyclopropyl, cyclopentyl, phenyl, 4-chlorophenyl, benzyl, 2-fluorobenzyl, thienylmethyl, C(=O)R7, -C(=O)OR7 and -C(=O)N(R7)(R8), wherein R7 is selected from the group consisting of hydrogen, methyl, ethyl, phenyl, 4-chlorophenyl and cyclopropyl and R8 is selected from the group consisting of hydrogen and methyl.

[0141] In some embodiments according to embodiment (Id), R1 and R2 are independently selected from the group consisting of hydrogen, hydroxy, C1-C8-alkyl, C1-C8-alkoxy and C1-C8-alkoxycarbonyl, or R1 and R2 form, together with the carbon atom to which they are attached, a C3-C7-cycloalkyl ring, or when n is 0 or L is CH2, R1 and R2 may form, together with the carbon atom to which they are attached, a C=O or C=N-OH group.

[0142] In some embodiments according to embodiment (Id), R1 and R2 are independently selected from the group consisting of hydrogen, hydroxy, C1-C8-alkyl, C1-C8-alkoxy and C1-C8-alkoxycarbonyl, or R1 and R2 form, together with the carbon atom to which they are attached, a C3-C7-cycloalkyl ring, or when n is 0 and A is attached to C, or when L is CH2, R1 and R2 may form, together with the carbon atom to which they are attached, a C=O or C=N-OH group.

[0143] In some modalities according to the modality (Id), n is 0.

[0144] In some forms depending on the form (Id), n is 0 or n is 1 and L is CH2. Petition 870250039092, dated 05 / 14 / 2025, p. 50 / 383 43 / 178

[0145] In some embodiments according to the embodiment (Id), n is 0 or 1 and L is CH2, O, S, S=O, S(=O)2, S(=O)(=NH) or S(=N-CN). In some of these embodiments, n is 1.

[0146] In some modalities according to the modality (Id), n is 1 and L is NR5, preferably NH.

[0147] In some modalities according to the modality (Id), A is selected from the group consisting of imidazole, pyrazole, 1,2-oxazole, pyrrole, pyridine, pyrimidine, pyrazine, phenyl, cyclohexyl, and cyclopentyl.

[0148] In some embodiments (referred to in the present invention as embodiment Ie), the present invention relates to the compound of formula (I): (I) in which X stands for fluorine; Y is hydrogen, tert-butyl(dimethyl)silane, or acetyl; m is 0; R1 and R2 are selected independently of the hydrogen, hydroxyl, methyl, methoxy, and acetoxy groups; or when n is 0 or when L is CH2, R1 and R2 can form, together with the carbon atom to which they are attached, a C=CH2, C=O or C=N-OH group, n is 0 or 1; L is CH2, O, S, S=O, S(=O)2, S(=O)(=NH), S(=N-CN) or NH, A is a 5- or 6-membered C3-C7-cycloalkyl, phenyl or heteroaryl ring, preferably selected from the group consisting of imidazole, pyrazole, 1,2Petition 870250039092, dated 14 / 05 / 2025, page 51 / 383 44 / 178 oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine, pyrazine, phenyl, cyclohexyl and cyclopentyl, where A may be replaced with one or more R6 substituents; R6 are independently selected from the group consisting of halogen, cyano, C1-C8-alkyl, C1-C8-halogenalkyl, C1-C8-alkoxy, C1-C8-alkylamino, C3-C7-cycloalkyl, aryl, heteroaryl, aryl-C1-C8-alkyl, heteroaryl-C1-C8-alkyl, -C(=O)R7, -C(=O)OR7 and -C(=O)N(R7)(R8), wherein preferably R7 is selected from the group consisting of hydrogen, methyl, ethyl, phenyl, 4-chlorophenyl and cyclopropyl and R8 is selected from the group consisting of hydrogen and methyl; provided that the compound of formula (I) is not: (a) 3-{4-[(4-fluorophenoxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5ol [2358785-16-5].

[0149] In some preferred embodiments according to embodiment (Ie), R6 is selected from the group consisting of halogen (e.g., Cl or F), cyano, C1-C4-alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, isobutyl), C1-C4-halogenalkyl (e.g., trifluoromethyl, difluoromethyl or trifluoroethyl), C1-C4-alkoxy (e.g., methoxy), C1-C4-alkylamino (e.g., dimethylamino), C3-C7-cycloalkyl (e.g., cyclopropyl, cyclopentyl), aryl (e.g., phenyl, 4-chlorophenyl), aryl-C1-C4-alkyl (e.g., benzyl, 2-fluorobenzyl), heteroaryl-C1-C4-alkyl (e.g., thienylmethyl), -C(=O)R7, -C(=O)OR7e -C(=O)N(R7)(R8), wherein R7 is selected from the group consisting of hydrogen, C1-C8-alkyl, aryl and C3C7-cycloalkyl and R8 is selected from the group consisting of hydrogen and C1C8-alkyl.In some of these embodiments, R6 is more preferably selected from the group consisting of Cl, F, cyano, methyl, ethyl, n-propyl, isopropyl, isobutyl, trifluoromethyl, difluoromethyl, trifluoroethyl, methoxy), dimethylamino, cyclopropyl, cyclopentyl, phenyl, 4-chlorophenyl, benzyl, 2-fluorobenzyl, thienylmethyl, C(=O)R7, -C(=O)OR7 and -C(=O)N(R7)(R8), wherein R7 is selected from the group. Petition 870250039092, dated 05 / 14 / 2025, page 52 / 383 45 / 178 consisting of hydrogen, methyl, ethyl, phenyl, 4-chlorophenyl and cyclopropyl and R8 is selected from the group consisting of hydrogen and methyl.

[0150] In some embodiments according to embodiment (Ie), R1, R2 are independently selected from the hydrogen, hydroxy, methyl, methoxy and acetoxy group; or when n is 0 or when L is CH2, R1 and R2 can form, together with the carbon atom to which they are attached, a C=O or C=N-OH group.

[0151] In some embodiments according to embodiment (Ie), R1, R2 are selected independently of the hydrogen, hydroxy, methyl, methoxy and acetoxy group; or when n is 0 and A is bonded to C, or when L is CH2, R1 and R2 can form, together with the carbon atom to which they are bonded, a C=O or C=N-OH group.

[0152] In some modalities according to the modality (Ie), n is 0.

[0153] In some forms depending on the form (Ie), n is 0 or n is 1 and L is CH2.

[0154] In some embodiments according to the embodiment (Ie), n is 0 or 1 and L is CH2, O, S, S=O, S(=O)2, S(=O)(=NH) or S(=N-CN). In some of these embodiments n is 1.

[0155] In some modalities according to the modality (Id), n is 1 and L is NR5, preferably NH.

[0156] The present invention also relates to any compounds of formula (I) disclosed in Table 1: - 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(trifluoromethyl)-4,5-di-hydro-1,2-oxazol-5ol, - 3-[4-(1H-pyrazol-1-ylmethyl)phenyl]-5-(trifluoromethyl)-4,5-di-hydro-1,2-oxazol-5-ol, - 3-[4-(1H-pyrazol-4-ylmethyl)phenyl]-5-(trifluoromethyl)-4,5-di-hydro-1,2-oxazol-5-ol, - 3-[4-(1,2-oxazol-4-ylmethyl)phenyl]-5-(trifluoromethyl)-4,5-di-hydro-1,2-oxazol-5-ol, - 3-[4-(cyclopentylmethyl)phenyl]-5-(trifluoromethyl)-4,5-di-hydro-1,2-oxazol-5-ol, Petição 870250039092, at 14 / 05 / 2025, pág. 53 / 383 46 / 178 - 3-(4-benzylphenyl)-5-(trifluoromethyl)-4,5-di-hydro-1,2-oxazol-5-ol, - 3-[4-(pyridin-2-ylmethyl)phenyl]-5-(trifluoromethyl)-4,5-di-hydro-1,2-oxazol-5-ol, - 3-[4-(pyrimidin-2-ylmethyl)phenyl]-5-(trifluoromethyl)-4,5-di-hydro-1,2-oxazol-5-ol, - 3-[4-(pyrazine-2-ylmethyl)phenyl]-5-(trifluoromethyl)-4,5-di-hydro-1,2-oxazol-5-ol, - 3-[4-(pyrimidin-5-ylmethyl)phenyl]-5-(trifluoromethyl)-4,5-di-hydro-1,2-oxazol-5-ol, - 3-{4-[(1-methyl-1H-pyrrol-2-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(1-methyl-1H-pyrazol-5-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(4-methyl-1H-pyrazol-1-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(3-methyl-1,2-oxazol-5-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-[4-(2-thienylmethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-[4-(cyclohexylmethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-[4-(1,3-thiazol-5-ylmethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[cyclopentyl(hydroxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-[4-(1-phenylvinyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, -{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3yl]phenyl}(phenyl)methanone, - 3-[4-(4-methylbenzyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-[4-(1-phenylethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[hydroxy(phenyl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]benzyl}pyridin2(1H)-one, - 3-[4-(4-fluorobenzyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, Petition 870250039092, de 14 / 05 / 2025, p. 54 / 383 47 / 178 - 3-{4-[(1-ethyl-1H-pyrazol-5-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(3-fluoropyridin-4-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(2-fluoropyridin-3-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(2-fluoropyridin-4-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(6-fluoropyridin-3-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[cyclohexyl(hydroxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[hydroxy(tetrahydro-2H-pyran-4-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(2-chloro-1H-imidazol-1-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2oxazol-5-ol, - 5-{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]benzyl}nicotinonitrile, - 3-{4-[(hydroxyimino)(phenyl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-[4-(2-methoxybenzyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[hydroxy(2-methylphenyl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(5-cyclopropyl-1 H-pyrazol-1 -yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-di-hydro1,2-oxazol-5-ol, Petition 870250039092, dated 05 / 14 / 2025, p. 55 / 383 48 / 178 - 3-{4-[(3-cyclopropyl-1 H-pyrazol-1 -yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-di-hydro 1,2-oxazole-5-ol, - 3-{4-[(1-cyclopropyl-1 H-pyrazol-5-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-di-hydro1,2-oxazol-5-ol, - 3-{4-[(4-methoxypyridine-3-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-di-hydro-1,2- oxazol-5-ol, - 3-{4-[(6-methoxypyridine-2-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-di-hydro-1,2- oxazol-5-ol, - 3-{4-[(2-methoxypyridine-3-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-di-hydro-1,2- oxazol-5-ol, - 3-{4-[(2-methoxypyridine-4-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-di-hydro-1,2- oxazol-5-ol, - 3-{4-[(3-methoxypyridine-4-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-di-hydro-1,2- oxazol-5-ol, - 3-{4-[(6-methoxypyridin-3-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-(4-{[2-(methylamino)pyrimidin-5-yl]methyl}phenyl)-5-(trifluoromethyl)-4,5-dihydro1,2-oxazol-5-ol, - 5-{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]benzyl}thiophene-2carbonitrile, -(4-fluorophenyl){4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3yl]phenyl}methanone, - 3-{4-[(1-propyl-1H-pyrazol-5-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - ácido 1-{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]benzyl}-1 Hpyrazole-4-carboxylic acid, - 3-{4-[(4-fluorophenyl)(hydroxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2 Petition 870250039092, de 14 / 05 / 2025, p. 56 / 383 49 / 178 oxazol-5-ol, - 5-{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]benzyl}thiophene-2carbaldehyde, - 3-[4-(4-chlorobenzyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2oxazol-5-ol, - 3-[4-(2,4-difluorobenzyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(2,3-difluoropyridin-4-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(2,6-difluoropyridin-3-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(2,6-difluoropyridin-4-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(2-chloro-1-methyl-1H-imidazol-5-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(4-isopropylpyrimidin-5-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-[4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-ylmethyl)phenyl]-5-(trifluoromethyl)4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(1-isobutyl-1H-pyrazol-5-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2oxazol-5-ol, - 1-(5-{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]benzyl}-2-thienyl)ethanone, -(4-chlorophenyl){4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3yl]phenyl}methanone, -(3,5-difluorophenyl){4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3yl]phenyl}methanone, Petition 870250039092, de 14 / 05 / 2025, p. 57 / 383 50 / 178 - 3-{4-[(4-chlorophenyl)(hydroxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2oxazol-5-ol, - 3-{4-[(3,5-difluorophenyl)(hydroxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2oxazol-5-ol, - 3-{4-[(1-methyl-1H-indol-3-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(1-cyclopentyl-1H-pyrazol-4-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro1,2-oxazol-5-ol, - 1 -{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]benzyl}-1 H-pyrazole-4-carboxylate ethyl, - 3-{4-[(1-phenyl-1H-pyrazol-5-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-[4-(2,6-dichlorobenzyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(2,3-dichloropyridin-4-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(2,5-dichloropyridin-4-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 5-(trifluoromethyl)-3-(4-{[2-(trifluoromethyl)pyrimidin-5-yl]methyl}phenyl)-4,5-dihydro1,2-oxazol-5-ol, - 3-(4-{[1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]methyl}phenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - N-cyclopropyl-1-{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]benzyl}-1H-pyrazole-4-carboxamide, - 3-[4-(2,3-dihydro-4H-1,4-benzothiazin-4-ylmethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(4-fluorophenyl)(hydroxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-yl acetate, Petition 870250039092, de 14 / 05 / 2025, p. 58 / 383 51 / 178 - (4-{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]benzyl}-1 Hpyrazol-1-yl)acetato de ethyl, - 3-{4-[(1-benzyl-1H-pyrrol-3-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(1-benzyl-1H-pyrazol-5-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(5-methyl-3-phenyl-1,2-oxazol-4-yl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro1,2-oxazol-5-ol, - 3-{4-[(3,5-dichlorophenyl)(hydroxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2oxazol-5-ol, - 3-(4-{[1-(2-thienylmethyl)-1H-pyrazol-4-yl]methyl}phenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-[4-(1,2,3,4-tetrahydro-9H-carbazol-9-ylmethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-(4-{[1-(2-fluorobenzyl)-1H-pyrazol-3-yl]methyl}phenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[acetoxy(phenyl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2oxazol-5-yl acetate, - 3-(4-{[4-(4-chlorophenyl)-1H-pyrazol-1-yl]methyl}phenyl)-5-(trifluoromethyl)-4,5-dihydro1,2-oxazol-5-ol, - 1 -{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]benzyl}-N-phenyl- H-pyrazole-4-carboxamide, - 2-{4-[5-{[tert-butyl(dimethyl)silyl]oxy}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3yl]benzyl}pyrazine, - 3-[4-(10H-phenothiazin-10-ylmethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 5-{[tert-butyl(dimethyl)silyl]oxy}-3-{4-[(2-chloro-1H-imidazol-1-yl)methyl]phenyl}-5- Petition 870250039092, de 14 / 05 / 2025, p. 59 / 383 52 / 178 (trifluoromethyl)-4,5-dihydro-1,2-oxazole, - 3-{4-[(2-chloro-5,5-dioxido-10H-phenothiazin-10-yl)methyl]phenyl}-5-(trifluoromethyl)4,5-dihydro-1,2-oxazol-5-ol, - 1-{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]phenyl}-2-phenylethanone, - 3-[4-(1-hydroxy-2-phenylethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(phenylsulfanyl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(4-fluoroanilino)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-[4-(N-hydroxy-2-phenylethanimidoyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2oxazol-5-ol, - 3-{4-[(phenylsulfinyl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(4-chloroanilino)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(3-chloroanilino)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(2-chloroanilino)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[(S-phenylsulfonimidoyl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 2-(2,4-difluorophenyl)-1-{4-[5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]phenyl}-ethanone, - 3-{4-[(phenylsulfonyl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 3-{4-[2-(2,4-difluorophenyl)-1-hydroxyethyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2oxazol-5-ol, - 3-{4-[2-(2,4-difluorophenyl)-N-hydroxyethanimidoyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol, - 5-{[tert-butyl(dimethyl)silyl]oxy}-3-{4-[(phenylsulfanyl)methyl]phenyl}-5-(trifluoromethyl)- 4,5-dihydro-1,2-oxazole, - 5-{[tert-butyl(dimethyl)silyl]oxy}-3-{4-[(phenylsulfinyl)methyl]phenyl}-5-(trifluoromethyl)- Petition 870250039092, de 14 / 05 / 2025, p. 60 / 383 53 / 178 4,5-dihydro-1,2-oxazole, - 5-{[tert-butyl(dimethyl)silyl]oxy}-3-{4-[(S-phenylsulfonimidoyl)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazole, - 5-{[tert-butyl(dimethyl)silyl]oxy}-3-{4-[(phenylsulfonyl)methyl]phenyl}-5-(trifluoromethyl)4,5-dihydro-1,2-oxazole and -[{4-[5-{[tert-butyl(dimethyl)silyl]oxy}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3yl]benzyl}(phenyl)-lambda4-sulfanilidene]cyanamide.

[0157] The compounds of formula (I) according to the present invention can be used as fungicides (i.e., to control phytopathogenic fungi, in particular, fungi that cause rust diseases, or Oomycetes in crop protection). Processes for the preparation of compounds of formula (I) and intermediates

[0158] The present invention also relates to processes for the preparation of compounds of formula (I). Unless otherwise indicated, the radicals X, Y, R1, R2, R3, R4, L and A and the integers men have the meanings given above for the compounds of formula (I). These definitions apply not only to the final products of formula (I) but also to all intermediates.

[0159] The compounds of formula (I) can be prepared by a process P1 comprising the step of reacting a compound of formula (II) with a compound Petition 870250039092, dated 05 / 14 / 2025, p. 61 / 383 54 / 178 a potassium trifluoroborate derivative; R1, R2 represent a hydrogen, C1-Cs-alkyl, C1-Cs-haloalkyl, C2-C8alkenyl, C2-Cs-haloalkenyl, C2-Cs-alkynyl, C2-C8-haloalkynyl, C3-C7cycloalkyl, C3-C7-halocycloalkyl, aryl, heterocyclyl or heteroaryl; as long as when n = 1, L is CR3R4and R3and R4represent a hydrogen, Ci-Csalkyl, Ci-Cs-haloalkyl, C2-Cs-alkenyl, C2-Cs-haloalkenyl, C2-C8alkynyl, C2-C8-haloalkynyl, C3-C7-cycloalkyl, C3-C7-halogenocycloalkyl, aryl, heterocyclyl or heteroaryl.

[0160] Process P1 can be carried out in the presence of a transition metal catalyst such as palladium and, if appropriate, in the presence of a phosphine ligand or an N-heterocyclic carbene ligand, if appropriate, in the presence of a base and, if appropriate, in the presence of a solvent according to known processes.

[0161] Boronic acid or boronic ester derivatives of formula (III) are commercially available or can be prepared by known processes.

[0162] Process P1 can be carried out in the presence of a catalyst, such as a salt or metal complex. Suitable metal derivatives for this purpose are transition metal catalysts, such as palladium. Suitable metal salts or complexes for this purpose are, for example, palladium chloride, palladium acetate, tetracis(triphenylphosphine)palladium(0), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0), bis(triphenylphosphine)palladium(II) dichloride, [1,1'-bis(diphenylphosphine)ferrocene]dichloropalladium(II), bis(cinnamyl)dichlorodipalladium(II), bis(allyl)-dichlorodipalladium(II) or [1,1'-Bis(di-tert-butylphosphine)ferrocene]dichloropalladium(II).

[0163] It is also possible to generate a palladium complex in the reaction mixture by separate addition to the reaction of a palladium salt and a ligand or salt, such as triethylphosphine, tri-tert-butylphosphine, tri-tert-butylphosphonium tetrafluoroborate, Petition 870250039092, dated 05 / 14 / 2025, p. 62 / 383 55 / 178: 2-di-tert-butylphosphine-2',4',6'-triisopropylbiphenyl, 2dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, 2-dicyclohexylphosphine-2,6'-dimethoxybiphenyl, 2dicyclohexylphosphine-2',6'-diisopropoxybiphenyl, triphenylphosphine, tris-(o-tolyl)phosphine, 3-(diphenylphosphine)benzenesulfonate sodium, tris-2-(methoxyphenyl)phosphine, 2,2'-bis(diphenylphosphine)-1,1'-binaphthyl, 1,4-bis(diphenylphosphine)butane, 1,2-bis(diphenylphosphine)ethane, 1,4-bis(dicyclohexylphosphine)butane, 1,2-bis(dicyclohexylphosphine)ethane, 2(dicyclohexylphosphine)-2'-(N,N-dimethylamino)biphenyl, 1,1'-bis(diphenylphosphine)ferrocene, (R)-(-)-1-[(S)-2-diphenylphosphine)ferrocenyl]ethyldicyclohexylphosphine, tris-(2,4-tert-butylphenyl)phosphite, di(1-adamantyl)-2-morpholinophenylphosphine or 1,3-bis(2,4,6-trimethylphenyl)imidazolium chloride.

[0164] It is also advantageous to choose the appropriate catalyst and / or ligand from commercial catalogs such as “Metal Catalysts for Organic Synthesis” from Strem Chemicals or “Phosphorous Ligands and Compounds” from Strem Chemicals.

[0165] The appropriate bases for carrying out Process P1 can be inorganic and organic bases that are usual for such reactions.Preference is given to the use of alkaline earth metal or alkali metal hydroxides, such as sodium hydroxide, calcium hydroxide, potassium hydroxide or other ammonium hydroxide derivatives; alkaline earth metal, alkali metal or ammonium fluorides such as potassium fluoride, cesium fluoride or tetrabutylammonium fluoride; alkaline earth metal or alkali metal carbonates, such as sodium carbonate, potassium carbonate, potassium bicarbonate, sodium bicarbonate or cesium carbonate; alkali metal or alkaline earth metal acetates, such as sodium acetate, lithium acetate, potassium acetate or calcium acetate; alkali metal or alkaline earth metal phosphate, such as alkali tripotassium phosphate; alkali metal alcoholates, such as potassium tert-butoxide or sodium tert-butoxide; tertiary amines, such as... Petition 870250039092, dated 05 / 14 / 2025, page 63 / 383 56 / 178 trimethylamine, triethylamine, tributylamine, N,N-dimethylaniline, N,N-dicyclohexylmethylamine, N,N-diisopropylethylamine, N-methylpiperidine, N,N-dimethylaminopyridine, diazabicyclooctane (DABCO), diazabicyclononene (DBN) or diazabicycloundecene (DBU); and also aromatic bases, such as pyridine, picolines, lutidines or colidins.

[0166] Suitable solvents for carrying out process P1 can be ordinary inert organic solvents.Preference is given to the use of optionally halogenated, aliphatic, alicyclic or aromatic hydrocarbons, such as petroleum ether, pentane, hexane, heptane, cyclohexane, methylcyclohexane, benzene, toluene, xylene or decalin; chlorobenzene, dichlorobenzene, dichloromethane, chloroform, carbon tetrachloride, dichloroethane or trichloroethane; ethers, such as diethyl ether, diisopropyl ether, methyl t-butyl ether, methyl t-amyl ether, dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, 1,2-dimethoxyethane, 1,2-diethoxyethane or anisole; nitriles, such as acetonitrile, propionitrile, n- or i-butyronitrile or benzonitrile; Amides, such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylformanilide, N-methylpyrrolidone or hexamethylphosphoric triamide; ureas, such as 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)pyrimidinone; esters, such as methyl acetate or ethyl acetate, sulfoxides, such as dimethyl sulfoxide, or sulfones, such as sulfolan; and a mixture thereof.

[0167] It may also be advantageous to carry out process P1 with a cosolvent such as water or an alcohol such as methanol, ethanol, propanol, isopropanol or tert-butanol.

[0168] Process P1 can be carried out in an inert atmosphere such as an argon or nitrogen atmosphere. When carrying out process P1, 1 mol or an excess of compound of formula (III) and 1 to 5 mol of base and 0.01 to 20 mol percent of a palladium complex can be used per mol of compound of formula (II). It is also possible to use the reaction components in other ratios. The processing is carried out by known methods.

[0169] Compounds of formula (I) where n = 0 can be prepared by Petition 870250039092, dated 05 / 14 / 2025, p. 64 / 383 57 / 178 a process P2 comprising the step of reacting a compound of formula (IV) with a compound of formula (V): Process P2: U2 represents Cl, Br, I, preferably Cl or Br; W2 represents a boron derivative such as boronic acid, a boronic ester, or a potassium trifluoroborate derivative; R1, R2 represent a hydrogen, Ci-Cs-alkyl, Ci-Cs-haloalkyl, C2-C8alkenyl, C2-Cs-haloalkenyl, C2-Cs-alkynyl, C2-C8-haloalkynyl, C3-C7cycloalkyl, Cs-Cy-halogenocycloalkyl, aryl, heterocyclyl or heteroaryl.

[0170] Process P2 can be carried out in the presence of a transition metal catalyst such as palladium and, if appropriate, in the presence of a phosphine ligand or an N-heterocyclic carbene ligand, if appropriate, in the presence of a base and, if appropriate, in the presence of a solvent according to known processes.

[0171] Halogenated derivatives of formula (V) are commercially available or can be prepared by known processes.

[0172] Suitable catalysts, bases and solvents for carrying out process P2 may be as disclosed in relation to process P1.

[0173] Process P2 can be carried out in an inert atmosphere such as an argon or nitrogen atmosphere. When carrying out process P2, 1 mol or an excess of compound of formula (V) and 1 to 5 mol of base and 0.01 to 20 mol percent of a palladium complex can be used per mol of compound of formula (IV). It is also possible to use the reaction components in other ratios. The Petition 870250039092, dated 05 / 14 / 2025, p. 65 / 383 58 / 178 processing is performed by known methods.

[0174] Compounds of formula (I) where n = 0 can be prepared by a P3 process comprising the step of reacting a compound of formula (VI) with a compound of formula (VII): Process P3: U3 represents Cl, Br, I, preferably Br or I, or a triflate group; M1 represents an alkaline earth metal such as lithium, a magnesium derivative such as a Grignard reagent, or a zinc derivative such as an organozinc reagent; R1, R2 represent a hydrogen, C1-Cs-alkyl, C1-Cs-haloalkyl, C2-C8alkenyl, C2-Cs-haloalkenyl, C2-Cs-alkynyl, C2-C8-haloalkynyl, C3-C7cycloalkyl, C3-C7-halocycloalkyl, aryl, heterocyclyl or heteroaryl.

[0175] Process P3 can be carried out in the presence of a transition metal catalyst such as palladium and, if appropriate, in the presence of a phosphine ligand or an N-heterocyclic carbene ligand, if appropriate, in the presence of a base and, if appropriate, in the presence of a solvent according to known processes.

[0176] The organometallic compounds of formula (VII) are commercially available or can be obtained from the corresponding halogenated derivative by reaction with magnesium metal, zinc metal or lithium metal, preferably under anhydrous conditions; or by halogen / metal exchange using an alkyl-lithium reagent or a Grignard reagent or a fabricated complex prepared from an alkyl-lithium reagent or a Grignard reagent, preferably under anhydrous conditions; or Petition 870250039092, dated 05 / 14 / 2025, page 66 / 383 59 / 178 by metal / metal exchange using zinc chloride in a Grignard reagent, preferably under anhydrous conditions, according to known processes.

[0177] Suitable solvents for carrying out process P3 may be ordinary inert organic solvents. Preference is given to the use of optionally halogenated, aliphatic, alicyclic or aromatic hydrocarbons, such as petroleum ether, pentane, hexane, heptane, cyclohexane, methylcyclohexane, benzene, toluene, xylene or decalin; ethers, such as diethyl ether, diisopropyl ether, methyl tert-butyl ether, methyl tert-amyl ether, dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, 1,2-dimethoxyethane, 1,2-diethoxyethane or anisole; and a mixture thereof.

[0178] The catalysts and bases suitable for carrying out process P3 can be as revealed in relation to process P1.

[0179] Process P3 can be carried out in an inert atmosphere such as an argon or nitrogen atmosphere. When carrying out process P3, 1 mol or an excess of compound of formula (VII) and 1 to 5 mol of base and 0.01 to 20 mol percent of a palladium complex can be used per mol of compound of formula (VI). It is also possible to use the reaction components in other ratios. The processing is carried out by known methods.

[0180] The compounds of formula (I) where n = 1 can be prepared by a process P4 comprising the step of reacting a compound of formula (II) with Petition 870250039092, dated 05 / 14 / 2025, p. 67 / 383 60 / 178 R1, R2 represent a hydrogen, Ci-Cs-alkyl, Ci-Cs-haloalkyl, C2-C8alkenyl, C2-Cs-haloalkenyl, C2-Cs-alkynyl, C2-Cs-haloalkynyl, C3-C7cycloalkyl, Cs-O-halogenocycloalkyl, aryl, heterocyclyl or heteroaryl.

[0181] Process P4 can be carried out, if appropriate, in the presence of a base and, if appropriate, in the presence of a solvent according to known processes.

[0182] Phenols, thiophenols and anilines and the like of formula (VIII) are commercially available or can be prepared by known processes.

[0183] Suitable bases and solvents for carrying out process P4 may be as disclosed in relation to process P1. Other suitable bases for carrying out process P4 according to the invention may be amides or organometallic derivatives. Preference is given to alkali metal hydrides, such as lithium hydride, sodium hydride or potassium hydride; alkali metal amides, such as sodium amide or potassium amide; organic amides, such as lithium diisopropylamine (LDA), lithium tetramethylpiperide, lithium hexamethyldisilazane (LiHMDS), potassium hexamethyldisilazane (KHMDS) or sodium hexamethyldisilazane (NaHMDS); organolithium derivatives, such as methyllithium, phenyllithium, n-butyllithium, sec-butyllithium, isobutyllithium or tert-butyllithium.

[0184] Process P4 can be carried out in an inert atmosphere such as an argon or nitrogen atmosphere. When carrying out process P4, 1 mol or an excess of compound of formula (VIII) and 1 to 5 mol of base can be used per mol of compound of formula (II). It is also possible to use the reaction components in other ratios. The processing is carried out by known methods.

[0185] Compounds of formula (I) where n = 1 and L is S=O or S(=O)2 can be prepared by oxidation with one or more equivalents of an oxidant according to known processes, of compounds of formula (I) where n = 1 and L is S, prepared according to process P4. Petition 870250039092, dated 05 / 14 / 2025, p. 68 / 383 61 / 178

[0186] The compounds of formula (I) where n = 1 and L is S(=O)(=NH), S(=NCN) can be prepared according to Chemical Communications, (2017), 53, 348 - 351 from compounds of formula (I) where n = 1 and L is S, prepared according to process P4.

[0187] Compounds of formula (I) in which R1 is OH and R2 is H, or R1 and R2 form a C=O group, can be prepared by a process P5 comprising the step of reacting a compound of formula (IX) with a compound of formula (X): Process P5: U4 represents H, Cl, Br, C1-Ce-alkoxy, aryloxy, di-C1-Ce-alkylamino or (NCi-Cealkoxy)-C1-C6-alkylamino group; M2 represents an alkaline earth metal such as lithium or a magnesium derivative such as a Grignard reagent; q represents a single or double bond; provided that when n = 1, L is CR3R4 and R3 and R4 represent a hydrogen, C1-Cs-alkyl, C1-Cs-halogenalkyl, C2-Cs-alkenyl, C2-Cs-halogenalkenyl, C2-C8-halogenalkenyl, C2-C8-halogenalkynyl, Cs-Cy-cycloalkyl, Cs-Cy-halogencycloalkyl, aryl, heterocyclyl or heteroaryl.

[0188] Process P5 can be carried out in the presence of a solvent according to known processes.

[0189] Organometallic derivatives of formula (X) are commercially available or can be prepared by known processes.

[0190] Suitable solvents for carrying out process P5 may include: Petition 870250039092, dated 05 / 14 / 2025, page 69 / 383 62 / 178 revealed in relation to process P3.

[0191] Process P5 can be carried out in an inert atmosphere such as an argon or nitrogen atmosphere. When carrying out process P5, 1 mol or an excess of compound of formula (X) can be used per mol of compound of formula (IX). It is also possible to use the reaction components in other ratios. The processing is carried out by known methods.

[0192] Compounds of formula (I) in which R1 and R2 form a C=O group can be prepared by oxidation with one or more equivalents of an oxidant according to known processes, of compounds of formula (I) in which R1 is OH and R2 is H, prepared according to process P5.

[0193] The compounds of formula (I) in which R1 and R2 form a C=NOH or C=N-ORc group can be prepared by reaction with NH2-OH or NH2-ORc according to known processes, from compounds of formula (I) in which R1 and R2 form a C=O group, prepared according to process P5.

[0194] Compounds of formula (I) in which R1 is halogen and R2 is H can be prepared by reacting the hydroxyl function with one or more equivalents of a halogenating agent according to known processes, from compounds of formula (I) in which R1 is OH and R2 is H, prepared according to process P5.

[0195] The compounds of formula (I) in which L is NR5 and R1 and R2 are both hydrogen, can be prepared by a process P6 comprising the step of reacting a compound of formula (IXa) with a compound of formula (VIIIa): Petition 870250039092, dated 05 / 14 / 2025, p. 70 / 383 63 / 178 C2-C8-haloalkenyl, C2-C8-alkynyl, C2-C8-haloalkynyl, Cs-Cy-cycloalkyl, C3-C7-cycloalkyl-C1-C8-alkyl, aryl, heterocyclyl, heteroaryl, aryl-Ci-Cs-alkyl, heterocyclyl-Ci-Cs-alkyl and heteroaryl-C1-Cs-alkyl;

[0196] The P6 process [reductive amination] can be carried out in accordance with “Reduction of Imines and Reduced Amination of Aldehydes and Ketones” in Science of Synthesis 4.17, Section 2.6.

[0197] Aniline dyes of formula (VIIIa) are commercially available or can be prepared by known processes.

[0198] The solvents suitable for carrying out process P6 can be as revealed in relation to process P1.

[0199] Process P6 can be carried out in an inert atmosphere such as an argon or nitrogen atmosphere. When carrying out process P6, 1 mol or an excess of compound of formula (VIIIa) and 1 to 5 mol of reducing agent can be used per mol of compound of formula (IXa). It is also possible to use the reaction components in other ratios. The processing is carried out by known methods.

[0200] Compounds of formula (I) where n = 0 and A is a heterocyclyl ring bonded to N can be prepared by a P7 process comprising the step of reacting a compound of formula (II) with a compound of formula (XI): Process P7: U1 represents Cl, Br, I, preferably Cl or Br; R1, R2 represent a hydrogen, C1-Cs-alkyl, C1-Cs-haloalkyl, C2-C8alkenyl, C2-Cs-haloalkenyl, C2-Cs-alkynyl, C2-Cs-haloalkynyl, C3-C7cycloalkyl, C3-C7-halocycloalkyl, aryl, heterocyclyl or heteroaryl; Petition 870250039092, dated 05 / 14 / 2025, p. 71 / 383 64 / 178 HN A represents an aromatic or non-aromatic heterocyclyl ring that carries a free NH group.

[0201] The P7 [nucleophilic substitution] process can be carried out, if appropriate, in the presence of a base and, if appropriate, in the presence of a solvent according to known processes.

[0202] Heterocyclyl A(XI) rings carrying a free NH group are commercially available or can be prepared by known processes.

[0203] The bases and solvents suitable for carrying out process P7 can be as revealed in relation to process P4.

[0204] Process P7 can be carried out in an inert atmosphere such as an argon or nitrogen atmosphere. When carrying out process P7, 1 mol or an excess of compound of formula (XI) and 1 to 5 mol of base can be used per mol of compound of formula (II). It is also possible to use the reaction components in other ratios. The processing is carried out by known methods.

[0205] Compounds of formula (I) in which Y is not hydrogen can be prepared by a process P8 comprising the step of reacting a compound of formula (I) in which Y is hydrogen with a compound of formula (XII): base and, if appropriate, in the presence of a solvent according to known processes. Petition 870250039092, dated 05 / 14 / 2025, page 72 / 383 65 / 178

[0207] Derivatives of formula (XII) are commercially available or can be prepared by known processes.

[0208] The bases and solvents suitable for carrying out process P8 can be as revealed in relation to process P1.

[0209] Process P8 can be carried out in an inert atmosphere such as an argon or nitrogen atmosphere. When carrying out process P8, 1 mol or an excess of compound of formula (XII) and 1 to 5 mol of base can be used per mol of compound of formula (I) where Y is hydrogen. It is also possible to use the reaction components in other ratios. The processing is carried out by known methods.

[0210] Processes P1, P2, P3, P4, P5, P6, P7 and P8 are generally carried out under atmospheric pressure. It is also possible to operate under high or low pressure.

[0211] When carrying out processes P1, P2, P3, P4, P5, P6, P7 and P8, the reaction temperatures can be varied within a relatively wide range. In general, these processes are carried out at temperatures from -78 °C to 200 °C, preferably from -78 °C to 150 °C. One way to control the temperature for the processes is to use microwave technology.

[0212] In general, the reaction mixture is concentrated under reduced pressure. The residue that remains can be released by known methods, such as chromatography or crystallization, from any impurities that may still be present.

[0213] Processing is carried out by conventional methods. Generally, the reaction mixture is treated with water and the organic phase is separated and, after drying, concentrated under reduced pressure. If appropriate, the remaining residue can be released by conventional methods, such as chromatography, crystallization or distillation, from any impurities that may still be present. Petition 870250039092, dated 05 / 14 / 2025, page 73 / 383 66 / 178

[0214] The compounds of formula (I) can be prepared according to the general preparation processes described above. However, it will be understood that, based on their general knowledge and available publications, those skilled in the art will be able to adapt the methods according to the specificities of each compound they wish to synthesize. Compositions and formulations

[0215] The present invention also relates to a composition, in particular a composition for controlling unwanted microorganisms, comprising one or more compounds of formula (I). The composition is preferably a fungicidal composition.

[0216] The composition typically comprises one or more compounds of formula (I) and one or more acceptable carriers, in particular one or more agriculturally acceptable carriers.

[0217] A carrier is a solid or liquid substance, natural or synthetic, organic or inorganic, that is generally inert. The carrier generally improves the application of compounds, for example, to plants, plant parts, or seeds. Examples of suitable solid carriers include, but are not limited to, ammonium salts, natural rock flours such as kaolin, clays, talc, chalk, quartz, attapulgite, montmorillonite, and diatomaceous earth, and synthetic rock flours such as finely divided silica, alumina, and silicates. Examples of solid carriers typically useful for preparing granules include, but are not limited to, crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite, and dolomite, synthetic granules of inorganic and organic flours, and granules of organic material such as paper, sawdust, coconut husks, corn cobs, and tobacco stalks.Examples of suitable liquid vehicles include, but are not limited to, water, organic solvents, and combinations thereof. Examples of suitable solvents include polar and non-polar organic liquids, for example, from the following classes. Petition 870250039092, dated 05 / 14 / 2025, page 74 / 383 67 / 178 of aromatic and non-aromatic hydrocarbons (such as cyclohexane, paraffins, alkylbenzenes, xylene, toluene, alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride), alcohols and polyols (which may also be optionally substituted, etherified and / or esterified, such as butanol or glycol), ketones (such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone), esters (including fats and oils) and (poly)ethers, unsubstituted and substituted amines, amides (such as dimethylformamide), lactams (such as N-alkylpyrrolidones) and lactones, sulfones and sulfoxides (such as dimethyl sulfoxide). The vehicle may also be a liquefied gaseous extender, that is, a liquid that is gaseous at standard temperature and under standard pressure, for example aerosol propellants such as halohydrocarbons, butane, propane, nitrogen and carbon dioxide.The vehicle content typically ranges from 1 to 99.99%, preferably from 5 to 99.9%, more preferably from 10 to 99.5%, and most preferably from 20 to 99% by weight of the composition.

[0218] The composition may further comprise one or more acceptable auxiliaries that are usual for formulating compositions (e.g., agrochemical compositions), such as one or more surfactants.

[0219] The surfactant may be an ionic (cationic or anionic) or non-ionic surfactant, such as ionic or non-ionic emulsifier(s), foam former(s), dispersant(s), wetting agent(s) and any mixtures thereof. Examples of suitable surfactants include, but are not limited to, polyacrylic acid salts, lignosulfonic acid salts, phenolsulfonic acid or naphthalenesulfonic acid salts, polycondensates of ethylene and / or propylene oxide with fatty alcohols, fatty acids or fatty amines (polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, for example alkylaryl polyglycol ethers), substituted phenols (preferably alkylphenols or arylphenols), sulfosuccinic ester salts, taurine derivatives (preferably alkyl taurates), Petition 870250039092, dated 05 / 14 / 2025, p. 75 / 383 68 / 178 phosphoric esters of polyethoxylated alcohols or phenols, fatty esters of polyols and derivatives of compounds containing sulfates, sulfonates, phosphates (e.g., alkyl sulfonates, alkyl sulfates, aryl sulfonates) and protein hydrolysates, residual liquors of lignosulfite and methylcellulose. A surfactant is typically used when the compound of formula (I) and / or the vehicle are insoluble in water and the application is made with water. Then, the amount of surfactants typically ranges from 5 to 40% by weight of the composition.

[0220] Other examples of auxiliaries that are commonly used in formulating agrochemical compositions include water repellents, desiccants, binders (adhesive, tackifying agent, fixing agent, such as carboxymethylcellulose, natural and synthetic polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, natural phospholipids such as cephalins and lecithins and synthetic phospholipids, polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol and tylose), thickeners, stabilizers (e.g., cold stabilizers, preservatives, antioxidants, optical stabilizers, or other agents that improve chemical and / or physical stability), colorants or pigments (such as inorganic pigments, e.g., iron oxide, titanium oxide and Prussian Blue;Organic colorants (e.g., alizarin, azo, and metallic phthalocyanine dyes), antifoaming agents (e.g., silicone and magnesium stearate antifoaming agents), preservatives (e.g., dichlorophene and benzyl alcohol hemiformal), secondary thickeners (cellulose derivatives, acrylic acid derivatives, xanthan gum, modified clays, and finely divided silica), adhesives, gibberellins and processing aids, mineral and vegetable oils, perfumes, waxes, nutrients (including trace nutrients such as iron, manganese, boron, copper, cobalt, molybdenum, and zinc salts), protective colloids, thixotropic substances, penetrants, sequestering agents, and complex formers.

[0221] The choice of auxiliaries is related to the intended mode of Petition 870250039092, dated 05 / 14 / 2025, page 76 / 383 69 / 178 application of the compound of formula (I) and / or physical properties. In addition, auxiliaries may be chosen to impart particular properties (technical, physical and / or biological properties) to the compositions or forms of use prepared from them. The choice of auxiliaries may allow the compositions to be adapted to specific needs.

[0222] The composition may be in any usual form, such as solutions (e.g., aqueous solutions), emulsions, wettable powders, water- and oil-based suspensions, powders, dusts, pastes, soluble powders, soluble granules, dispersion granules, suspoemulsion concentrates, natural or synthetic products impregnated with the compound of the invention, fertilizers, and also microencapsulations in polymeric substances. The compound of formula (I) may be present in a suspended, emulsified, or dissolved form.

[0223] The composition may be supplied to the end user as a ready-to-use formulation, i.e., the compositions may be directly applied to plants or seeds by a suitable device, such as a spraying or dusting device. Alternatively, the composition may be supplied to the end user in the form of concentrates that must be diluted, preferably with water, before use.

[0224] The composition can be prepared in conventional ways, for example by mixing the compound of formula (I) with one or more suitable auxiliaries, as disclosed above.

[0225] The composition generally contains from 0.01 to 99% by weight, from 0.05 to 98% by weight, preferably from 0.1 to 95% by weight, more preferably from 0.5 to 90% by weight, most preferably from 1 to 80% by weight of the compound of formula (I).

[0226] The compound(s) and composition(s) comprising them may be mixed with other active ingredients such as fungicides, bactericides, Petition 870250039092, dated 05 / 14 / 2025, page 77 / 383 70 / 178 acaricides, nematicides, insecticides, herbicides, fertilizers, growth regulators, plant protectants, or semiochemicals. This can broaden the spectrum of activities or prevent the development of resistance. Examples of known fungicides, insecticides, acaricides, nematicides, and bactericides are revealed in the Pesticide Manual, 17th Edition.

[0227] Examples of fungicides that can be mixed with the compound(s) of formula (I) and the composition of the invention are: 1) Inibidores da biossíntese de ergosterol, por exemplo (1.001) ciproconazol, (1.002) difenoconazol, (1.003) epoxiconazol, (1.004) fenexamida, (1.005) fenpropidina, (1.006) fenpropimorfe, (1.007) fenpirazamina, (1.008) fluquinconazol, (1.009) flutriafol, (1.010) imazalila, (1.011) sulfato de imazalila, (1.012) ipconazol, (1.013) metconazol, (1.014) miclobutanila, (1.015) paclobutrazol, (1.016) procloraz, (1.017) propiconazol, (1.018) protioconazol, (1.019) pirisoxazol, (1.020) espiroxamina, (1.021) tebuconazol, (1.022) tetraconazol, (1.023) triadimenol, (1.024) tridemorfe, (1.025) triticonazol, (1.026) (1R,2S,5S)-5-(4-clorobenzil)-2-(clorometil)-2-metil-1-(1H1,2,4-triazol-1 -ilmetil)ciclopentanol, (1.027) (1 S,2R,5R)-5-(4-clorobenzil)-2- (clorometil)-2-metil-1 -(1 H-1,2,4-triazol-1 -ilmetil)ciclopentanol, (1.028) (2R)-2-(1clorociclopropil)-4-[(1 R)-2,2-diclorociclopropil]-1 -(1 H-1,2,4-triazol-1 -il)butan-2-ol, (1.029) (2R)-2-(1-chlorocyclopropyl)-4-[(1 S)-2,2-dichloro-cyclopropyl]-1 -(1 H-1,2,4-triazol-1 yl)butan-2-ol, (1,030) (2R)-2-[4-(4-chlorooxy-fluorophenyl)-2-1]) -(1 H-1,2,4triazol-1 -yl)propan-2-ol, (1.031) (2S)-2-(1-chlorocyclopropyl)-4-[(1 R)-2,2dichlorocyclopropyl]-1 -(1 H-1,2,4-triazol-1 -yl)butan-2-2-2-(2.031) chlorocyclopropyl)-4-[(1S)-2,2-dichlorocyclopropyl]-1 -(1 H-1,2,4-triazol-1 -yl)butan-2-ol, (1.033) (2S)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl -1,14-1-H -yl)propan2-ol, (1.034) (R)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3yl)methanol, (1.035) (S)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4yl](pyridin-3-yl)methanol, (1.036) [3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2 870250039092, of 14 / 05 / 2025, p. 78 / 383. 71 / 178 4-yl](pyridine-3-yl)methanol, (1,037) 1 -({(2R,4S)-2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl1,3-dioxolan-2-yl}methyl)-1 H-1,2,4-triazol, (1,038, (1,038) -({(2S,4S)-2-[2-chloro-4-(4chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole, (1,039) thiocyanate of 1 -{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1 H-1,2,4-triazol-5-yl, (1,040) thiocyanate of 1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1 H1,2,4-triazol-5-yl, (1,041) thiocyanate of 1-{[rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4difluorophenyl)oxiran-2-yl]methyl}-1 H-1,2,4-triazol-5-yl, (1,042) 2-[(2R,4R,5R)-1 -(2,4dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-di-hydro-3H-1,2,4-triazol-3-thione, (1,043) 2-[(2R,4R,5S)-1 -(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,044) 2-[(2R,4S,5R)-1 -(2,4-dichlorophenyl)-5-hydroxy2,6,6-trimethyl-heptane-4-yl]-2,4-di-hydro-3H-1,2,4-triazol-3-thione, (1.045) 2-[(2R,4S,5S)1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptane-4-yl]-2,4-di-hydro-3H-1,2,4-triazol-3thione, (1,046) -[(2,R) 2,1-R -(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]2,4-di-hydro-3H-1,2,4-triazol-3-thione, (1,047) 2-[(2S,4R,5S)-1 -(2,4-dichlorophenyl)-5hydroxy-2,6,6-trimethyl-heptane-4-yl]-2,4-di-hydro-3H-1,2,4-triazol-3-thione, (1,048) 2[(2S,4S,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-di-hydro-3H1,2,4-triazol-3-thione, (1,049) 2-[(2S),4S -(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-di-hydro-3H-1,2,4-triazol-3-thione, (1,050) 2-[1 -(2,4-dichlorophenyl)-5hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-di-hydro-3H-1,2,4-triazol-3-thione, (1,051) 2-[2chloro-4-(2,4-dichlorophenoxy-1,1)phenyl -yl)propan-2-ol, (1,052) 2-[2-chloro4-(4-chlorophenoxy)phenyl]-1 -(1 H-1,2,4-triazol-1 -yl)butan-2-ol, (1,053) 2-[4-(4-chlorophenoxy(trifluoromethyl]-2)(trifluoromethyl) H-1,2,4-triazol-1 -yl)butane-2-ol, (1.054) 2-[4-(4-chlorophenoxy)-2(trifluoromethyl)phenyl]-1 -(1 H-1,2,4-triazol-1 -yl)pentan-2-ol, (1.055) Mefentrifluconazole, (1.056) 2-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-di-hydro-3H-1,2,4triazole-3-thione, (1.057) 2-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2yl]methyl}-2,4-di-hydro-3H-1,2,4-triazole-3-thione, (1.058) 2-{[rel(2R,3S)-3-(2-chlorophenyl)-2(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-di-hydro-3H-1,2,4-triazole-3-thiona, (1.059) 5-(4Petition 8702092,0392 14 / 05 / 2025, p.79 / 383. 72 / 178 chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-l-ylmethyl)cyclopentanol, (1.060) 5(allylsulfanyl)-1-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (1.061) 5-(allylsulfanyl)-1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2yl]methyl}-1H-1,2,4-triazole, (1.062) 5-(allylsulfanyl)-1 -{[rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4difluorophenyl)oxiran-2-yl]methyl}-1 H-1,2,4-triazole, (1.063) N'-(2,5-dimethyl-4-{[3-(1, 1,2,2-tetrafluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (1.064) N'-(2,5dimethyl-4-{[3-(2,2,2-trifluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (1.065) N'-(2,5-dimethyl-4-{[3-(2,2,3,3-tetrafluoropropoxy)phenyl]sulfanyl}phenyl)-N-ethyl-Nmethylimidoformamide, (1.066) N'-(2,5-dimethyl-4-{[3(pentafluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (1.067) N'-(2,5-dimethyl-4-{3-[(1,1,2,2-tetrafluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.068) N'-(2,5-dimethyl-4-{3-[(2,2,2-trifluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-Nmethylimidoformamide, (1.069) N'-(2,5-dimethyl-4-{3-[(2,2,3,3tetrafluoropropyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.070) N'-(2,5dimethyl-4-{3-[(pentafluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.071) N'-(2,5-dimethyl-4-phenoxyphenyl)-N-ethyl-N-methylimidoformamide, (1.072) N'-(4-{[3(difluoromethoxy)phenyl]sulfanyl}-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, (1.073) N'-(4-{3-[(difluoromethyl)sulfanyl]phenoxy}-2,5-dimethylphenyl)-N-ethyl-N-methyl-formamide (1.07). N'-[5-bromo-6-(2,3-di-hydro-1 H-inden-2-yloxy)-2-methylpyridin-3-yl]-N-ethyl-Nmethylimidoformamide, (1.075) N'-{4-[(4,5-dichloro-1,3-thiazol-2-yl)oxy]-2,5-dimethylphenyl}-Nethyl-N-methylimidoformamide, (1.076) N'-{5-bromo-6-[(1 R)-1 -(3,5-difluorophenyl)ethoxy]-2methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (1.077) N'-{5-bromo-6-[(1S)-1 -(3,5difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethylimidoformamide,(1.077)078) N'-{5bromo-6-[(cis-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (1.079) N'-{5-bromo-6-[(trans-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-Nmethylimidoformamide, (1,080) N'-{5-bromo-6-[1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin3-yl}-N-ethyl-N-methylimidoformamide, (1,081) ipfentrifluconazole, (1,082) 2-[4-(4. Petition 870250039092, dated 05 / 14 / 2025, page 80 / 383 73 / 178 chlorophenoxy)-2-(trifluoromethyl)phenyl]-1 -(1 H-1,2,4-triazol-l -yl)propan-2-ol, (1,083) 2-[6-(4bromophenoxy)-2-(trifluoromethyl)-2,3-4pyrydyl(] -yl)propan-2-ol, (1,084) 2-[6(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1 -(1,2,4-triazol-1 -yl)propan-2-ol, (1,085) 3-[2(1-chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile, (1,086) 4-[[6-[rac-(2R)-2-(2,4-difluorophenyl)-1,1 -difluoro-2-hydroxy-3-(5-thioxo-4H-1,2,4triazol-1 -yl)propyl]-3-pyridyl]oxy]benzonitrile and (1,087) 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-(atoxylpropyl,4-3 measure. 2) Respiratory chain inhibitors in complex I or II, for example (2.001) benzovindiflupir, (2.002) bixafen, (2.003) boscalid, (2.004) carboxin, (2.005) fluopiram, (2.006) flutolanil, (2.007) fluxapyroxad, (2.008) furomethpyr, (2.009) isofetamide, (2.010) isopyrazam (anti-epimeric enantiomer 1R,4S,9S), (2.011) isopyrazam (anti-epimeric enantiomer 1S,4R,9R), (2.012) isopyrazam (anti-epimeric racemate 1RS,4SR,9SR), (2.013) isopyrazam (syn-epimeric racemate mixture) 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR), (2.014) isopyrazam (1R,4S,9R syn-epimeric enantiomer), (2.015) isopyrazam (1S,4R,9S syn-epimeric enantiomer), (2.016) isopyrazam (syn-epimeric racemate 1RS,4SR,9RS), (2.017) penflufen, (2.018) penthiopyrad, (2.019) pidiflumetofen, (2.020) Pyraziflumide, (2.021) sedaxane, (2.022) 1,3-dimethyl-N-(1,1,3-trimethyl-2,3-dihydro-1Hinden-4-yl)-1H-pyrazol-4-carboxamide, (2.023) 1,3-dimethyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1 H-inden-4-yl]-1 H-pyrazole-4-carboxamide, (2,024) 1,3-dimethyl-N-[(3C)-1,1,3- trimethyl-2,3-hydro-1 H-inden-4-yl]-1 H-pyrazol-4-carboxamide, (2.025) 1 -methyl-3(trifluoromethyl)-N-[2'-(trifluoromethyl)biphenyl-2-yl]-1 H-pyrazol-4-carboxamide, (2.026) 2fluoro-6-(trifluoromethyl)-N-(1,1,3-trimethyl-2,3-di-hydro-1 H-inden-4-yl)benzamide, (2,027) 3-(difluoromethyl)-1-methyl-N-(1,1,3-trimethyl-2,3-di-hydro-1-inden-4-yl-1) H-pyrazole-4carboxamide, (2.028) inpyrfluxam, (2.029) 3-(difluoromethyl)-1-methyl-N-[(3S)-1,1,3trimethyl-2,3-di-hydro-1 H-inden-4-yl]-1 H-pyrazole-4-carboxamide, (2.031), (2.031) inpyrfluxam. 3-(difluoromethyl)-N-[(3R)-7-fluoro-1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl]-1Petition 870250039092, of 14 / 05 / 2025, p. 81 / 383. 74 / 178 methyl-1H-pyrazole-4-carboxamide, (2.032) 3-(difluoromethyl)-N-[(3S)-7-fluoro-1,1,3trimethyl-2,3-dihydro-1H-inden-4-yl]-1-methyl-1H-pyrazole-4-carboxamide, (2.033) 5,8difluoro-N-[2-(2-fluoro-4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)ethyl]quinazolin-4-amine, (2.034) N-(2-cyclopentyl-5-fluorobenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl1H-pyrazole-4-carboxamide, (2.035) N-(2-tert-butyl-5-methylbenzyl)-N-cyclopropyl-3(difluoromethyl)-5-fluoro-1-methyl-1 H-pyrazole-4-carboxamide, (2.036) N-(2-tert-butylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.037) N-(5-chloro-2-ethylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1 -methyl-1H-pyrazole-4-carboxamide, (2.038) N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (2.039) N-[(1 R,4S)-9(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1 -methyl1H-pyrazole-4-carboxamide, (2.040) N-[(1 S,4R)-9-(diclorometileno)-1,2,3,4-tetra-hidro1,4-metanonaftalen-5-il]-3-(difluorometil)-1 -metil-1 H-pirazol-4-carboxamida, (2.041) N-[1 -(2,4-diclorofenil)-1 -metoxipropan-2-il]-3-(difluorometil)-1 -metil-1 H-pirazol-4carboxamida, (2.042) N-[2-cloro-6-(trifluorometil)benzil]-N-ciclopropil-3-(difluorometil)5-fluoro-1-metil-1 H-pirazol-4-carboxamida, (2.043) N-[3-cloro-2-fluoro-6(trifluorometil)benzil]-N-ciclopropil-3-(difluorometil)-5-fluoro-1-metil-1 H-pirazol-4carboxamida, (2.044) N-[5-cloro-2-(trifluorometil)benzil]-N-ciclopropil-3-(difluorometil)5-fluoro-1-metil-1 H-pirazol-4-carboxamida, (2.045) N-ciclopropil-3-(difluorometil)-5fluoro-1-metil-N-[5-metil-2-(trifluorometil)benzil]-1H-pirazol-4-carboxamida, (2.046) Nciclopropil-3-(difluorometil)-5-fluoro-N-(2-fluoro-6-isopropilbenzil)-1-metil-1 H-pirazol4-carboxamida, (2.047) N-ciclopropil-3-(difluorometil)-5-fluoro-N-(2-isopropil-5metilbenzil)-1 -metil-1 H-pirazol-4-carboxamida, (2.048) N-ciclopropil-3-(difluorometil)5-fluoro-N-(2-isopropilbenzil)-1 -metil-1 H-pirazol-4-carbotioamida, (2.049) Nciclopropil-3-(difluorometil)-5-fluoro-N-(2-isopropilbenzil)-1-metil-1H-pirazol-4carboxamida, (2.050) N-ciclopropil-3-(difluorometil)-5-fluoro-N-(5-fluoro-2isopropilbenzil)-1-metil-1 H-pirazol-4-carboxamida, (2.051) N-ciclopropil-3. Petição 870250039092, de 14 / 05 / 2025, pág. 82 / 383 75 / 178 (difluorometil)-N-(2-etil-4,5-dimetilbenzil)-5-fluoro-1-metil-1 H-pirazol-4-carboxamida, (2.052) N-ciclopropil-3-(difluorometil)-N-(2-etil-5-fluorobenzil)-5-fluoro-1 -metil-1 Hpirazol-4-carboxamida, (2.053) N-ciclopropil-3-(difluorometil)-N-(2-etil-5-metilbenzil)5-fluoro-1-metil-1 H-pirazol-4-carboxamida, (2.054) N-ciclopropil-N-(2-ciclopropil-5fluorobenzil)-3-(difluorometil)-5-fluoro-1 -metil-1 H-pirazol-4-carboxamida, (2.055) Nciclopropil-N-(2-ciclopropil-5-metilbenzil)-3-(difluorometil)-5-fluoro-1-metil-1 H-pirazol4-carboxamida, (2.056) N-ciclopropil-N-(2-ciclopropilbenzil)-3-(difluorometil)-5-fluoro1-metil-1H-pirazol-4-carboxamida, (2.057) pirapropoína. 3) Respiratory chain inhibitors in complex III, for example (3.001) ametoctradine, (3.002) amisulbrom, (3.003) azoxystrobin, (3.004) coumetoxystrobin, (3.005) coumoxystrobin, (3.006) ciazofamide, (3.007) dimoxystrobin, (3.008) enoxastrobin, (3.009) famoxadone, (3.010) fenamidone, (3.011) flufenoxystrobin, (3.012) fluoxastrobin, (3.013) cresoxim-methyl, (3.014) metominostrobin, (3.015) orisastrobin, (3.016) picoxystrobin, (3.017) pyraclostrobin, (3.018) pyramethostrobin, (3.019) pyroxystrobin, (3.020) trifloxystrobin, (3.021) (2E)-2-{2-[({[(1E)-1-(3-{[(E)-1fluoro-2-phenylvinyl]oxy}phenyl)ethylidene]amino}oxy)methyl]phenyl}-2-(methoxy-imino)-Nmethylacetamide, (3.022) (2E,3Z)-5-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy}-2-(methoxy-imino)-N,3-dimethylpent-3-enamide, (3.023) (2R)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2methoxy-N-methylacetamide, (3,024) (2S)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-Nmethylacetamide, (3.025) fenpicoxamide, (3.026) mandestrobin, (3.027) N-(3-ethyl3,5,5-trimethylcyclohexyl)-3-formamido-2-hydroxybenzamide, (3.028) (2E,3Z)-5-{[1 -(4chloro-2-fluorophenyl)-1H-pyrazol-3-yl]oxy}-2-(methoxy-imino)-N,3-dimethylpent-3-enamide, (3.029) Methyl {5-[3-(2,4-dimethylphenyl)-1H-pyrazol-1-yl]-2-methylbenzyl}carbamate, (3,030) methyltetraprol, (3,031) florylpicoxamide. 4) Inhibitors of mitosis and cell division, for example (4.001) carbendazim, (4.002) dietofencarb, (4.003) etaboxam, (4.004) fluopicolide, (4.005) pencicurone, (4.006) thiabendazole, (4.007) thiophanate-methyl, (4.008) zoxamide, (4.009) 3-chloro-4-(2,6- Petition 870250039092, dated 05 / 14 / 2025, page 83 / 383 76 / 178 difluorophenyl)-6-methyl-5-phenylpyridazine, (4.010) 3-chloro-5-(4-chlorophenyl)-4-(2,6 difluorophenyl)-6-methylpyridazine, (4.011) 3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4-(2,4,6trifluorophenyl)pyridazine, (4.012) 4-(2-bromo-4-fluorophenyl)-N-(2,6-difluorophenyl)-1,3dimethyl-1H-pyrazol-5-amine, (4.013) 4-(2-bromo-4-fluorophenyl)-N-(2-bromo-6fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.014) 4-(2-bromo-4-fluorophenyl)-N-(2bromophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.015) 4-(2-bromo-4-fluorophenyl)-N-(2chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.016) 4-(2-bromo-4-fluorophenyl)N-(2-chlorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.017) 4-(2-bromo-4-fluorophenyl)-N-(2 fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.018) 4-(2-chloro-4-fluorophenyl)-N-(2,6 difluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.019) 4-(2-chloro-4-fluorophenyl)-N-(2chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.020) 4-(2-chloro-4-fluorophenyl)-N (2-Chlorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.021) 4-(2-Chloro-4-fluorophenyl)-N-(2fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.022) 4-(4-chlorophenyl)-5-(2,6difluorophenyl)-3,6-dimethylpyridazine, (4.023) N-(2-bromo-6-fluorophenyl)-4-(2-chloro-4fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.024) N-(2-bromophenyl)-4-(2-chloro-4fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.025) N-(4-chloro-2,6-difluorophenyl)-4-(2chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine. 5) Compounds capable of having an action on multiple sites, for example (5.001) Bordeaux mixture, (5.002) captafol, (5.003) captan, (5.004) chlorothalonil, (5.005) copper hydroxide, (5.006) copper naphthenate, (5.007) copper oxide, (5.008) copper oxychloride, (5.009) copper(2+) sulfate, (5.010) dithianone, (5.011) dodine, (5.012) folpet, (5.013) mancozeb, (5.014) maneb, (5.015) metiram, (5.016) zinc metiram, (5.017) copper oxin, (5.018) propineb, (5.019) sulfur and sulfur preparations including calcium polysulfide, (5.020) thiram, (5.021) zineb, (5.022) ziram, (5.023) 6-ethyl-5,7-dioxo-6,7-dihydro-5H-pyrrolo[3',4':5,6][1,4]diti-yne[2,3-c][1,2]thiazol-3 carbonitrile. 6) Compounds capable of inducing a host defense, for example Petition 870250039092, dated 05 / 14 / 2025, page 84 / 383 77 / 178 (6.001) acibenzolar-S-methyl, (6.002) isotinil, (6.003) probenazole, (6.004) thiadinil. 7) Inhibitors of amino acid and / or protein biosynthesis, for example (7.001) cyprodinil, (7.002) kasugamycin, (7.003) kasugamycin hydrochloride hydrate, (7.004) oxytetracycline, (7.005) pyrimethanil, (7.006) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4dihydroisoquinolin-1-yl)quinoline. 8) Inhibitors of ATP production, for example (8.001) silthiofam. 9) Cell wall synthesis inhibitors, for example (9,001) bentiavalicarb, (9,002) dimethomorph, (9,003) flumorph, (9,004) iprovalicarb, (9,005) mandipropamide, (9,006) pyrimorph, (9,007) valifenalate, (9,008) (2E)-3-(4-tertbutylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one, (9.009) (2Z)-3-(4-tertbutylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one. 10) Lipid and membrane synthesis inhibitors, for example (10.001) propamocarb, (10.002) propamocarb hydrochloride, (10.003) tolclofos-methyl. 11) Inhibitors of melanin biosynthesis, for example (11.001) tricyclazole, (11.002) 2,2,2-trifluoroethyl {3-methyl-1-[(4-methylbenzoyl)amino]butan-2-yl}carbamate. 12) Nucleic acid synthesis inhibitors, for example (12.001) benalaxyl, (12.002) benalaxyl-M (ciralaxyl), (12.003) metalaxyl, (12.004) metalaxyl-M (mefenoxam). 13) Signal transduction inhibitors, for example (13.001) fludioxonil, (13.002) iprodione, (13.003) procymidone, (13.004) proquinazide, (13.005) quinoxifene, (13.006) vinclozoline. 14) Compounds capable of acting as an uncoupler, for example (14.001) fluazinam, (14.002) meptildinocap. 15) Other fungicides selected from the group consisting of (15.001) abscisic acid, (15.002) bentiazole, (15.003) betoxazine, (15.004) capsimycin, (15.005) carvone, (15.006) quinomethionate, (15.007) cufraneb, (15.008) cyflufenamide, (15.009) cymoxanil, (15.010) cyprosulfamide, (15.011) flutianil, (15.012) fosetyl-aluminum, (15.013) fosetyl-calcium, (15.014) fosetyl-sodium, (15.015) Petition 870250039092, dated 05 / 14 / 2025, page 85 / 383 78 / 178 methyl isothiocyanate, (15.016) metrafenona, (15.017) mildiomycin, (15.018) natamycin, (15.019) dimethyldithiocarbamate de niquel, (15.020) nitrotal-isopropyl, (15.021) oxamocarbe, (15.022) Oxatiapiproline, (15.023) oxyfenti-ína, (15.024) pentachlorophenol e sais, (15.025) phosphorous acid e sus sais, (15.026) propamocarbefosetilato, (15.027) pyriofenone (clazafenona), (15.028) tebufloquine, (15.029) teclophtalam, (15.030) tolnifanide, (15.031) 1-(4-{4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1 -yl)-2-[5-methyl-3-(trifluoromethyl)-1 H-pyrazol-1-yl]etanone, (15.032) 1-(4-{4-[(5S)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1 -yl)-2-[5-methyl-3-(trifluoromethyl)-1 H-pyrazol-1 yl]etanone, (15.033) 2-(6-benzylpyridin-2-yl)quinazoline, (15.034) dipimethirane, (15.035) 2-[3,5-bis(difluoromethyl)-1 H-pyrazol-1 -yl]-1 -[4-(4-{5-[2-(prop-2-in-1 -yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidine-1-yl]ethanone, (15,036) 2-[3,5bis(difluoromethyl)-1 H-pyrazol-1 -yl]-1 -[4-(4-{5-[2-chloro-6-(prop-2-in-1 -yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (15.037) 2-[diflu-methyl) H-pyrazol-1 -yl]-1 -[4-(4-{5-[2-fluoro-6-(prop-2-in-1 -yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-na.03 -yl15] 2-[6-(3-fluoro-4methoxyphenyl)-5-methylpyridine-2-yl]quinazoline, (15,039) methanosulfonate of 2-{(5R)-3-[2(1-{[3,5-bis(difluoromethyl)-1 H-pyrazol-1 -yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenyl, (15,040) methanosulfonate of 2-{(5S)-3-[2-(1{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidine-4-yl)-1,3-thiazol-4-yl]-4,5-di-hydro1,2-oxazol-5-xyphenyl04,3-1-chloro (15042) 2-{2-fluoro-6-[(8-fluoro2-methylquinolin-3-yl)oxy]phenyl}propane-2-ol, (15,043) fluoxapiproline, (15,044) methanosulfonate of 2-{3-[2-(1-oromethyl-bis{()diflu-3,5- -yl]acetyl}piperidin4-yl)-1,3-thiazol-4-yl]-4,5-di-hydro-1,2-oxazol-5-yl}phenyl, (15,045) 2-phenylphenol and sais, (15,046) 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-di-hydroisoquinolin-1 -yl)quinoline, (15,047) quinofumelin, (15,048) 4-amino-5-fluoropyrimidine-2-ol (tautopyrimidin-H form)-5-flu-2 (15,049)4-oxo-4-[(2-phenylethyl)amino]butanoic acid,. Petition 870250039092, dated 05 / 14 / 2025, p. 86 / 383 79 / 178 (15.050) 5-amino-1,3,4-thiadiazol-2-thiol, (15.051) 5-chloro-N'-phenyl-N'-(prop-2-in-1yl)thiophene-2-sulfono-hydrazide, (15.052) 5-fluoro-2-[(4-fluorobenzyl)óxi]pyrimidin-4-amine, (15.053) 5-fluoro-2-[(4-methylbenzyl)óxi]pyrimidin-4-amine, (15.054) 9-fluoro-2,2dimethyl-5-(quinolin-3-yl)-2,3-di-hydro-1,4-benzoxazepine, (15.055) {6-[({[(Z)-(1-methyl1 H-tetrazol-5-yl)(phenyl)methyleno]amino}óxi)metil]piridin-2-il}carbamato de but-3-in-1-yla, (15.056) (2Z)-3-amino-2-cyano-3-fenilacrilato de ethyla, (15.057) ácido fenazine-1carboxílico, (15.058) 3,4,5-tri-hidroxibenzoato de propila, (15.059) quinolin-8-ol, (15.060) sulfato de quinolin-8-ol (2:1), (15.061) {6-[({[(1-metil-1H-tetrazol-5yl)(phenyl)methyleno]amino}óxi)metil]piridin-2-il}carbamato de terc-butila, (15,062) 5fluoro-4-imino-3-methyl-1-[(4-methylphenyl)sulfonyl]-3,4-di-hidropyrimidin-2(1H)-ona, (15,063) aminopyriphene, (15,064) (N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-Nmethylimidoformamida), (15.065) (N'-(2-chloro-5-methyl-4-phenoxyphenyl)-N-ethyl-N-methylimidoformamide), (15.066) (2-{2-[(7,8-difluoro-2-metilquinolin-3-yl)óxy]-6-fluorofenil}propan2-ol), (15.067) (5-bromo-1-(5,6-dimetilpyridin-3-yl)-3,3-dimetil-3,4-di-hidroisoquinolina), (15.068) (3-(4,4-difluoro-5,5-dimetil-4,5-di-hidrotieno[2,3-c]piridin-7-yl)quinolina), (15.069) (1-(4,5-dimethyl-1H-benzimidazol-1-yl)-4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinoline), (15.070) 8-fluoro-3-(5-fluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1yl)quinolone, (15.071) 8-fluoro-3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1yl)quinolone, (15.072) 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)-8fluoroquinoline, (15.073) (N-methyl-N-phenyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]benzamida), (15.074) ({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}carbamato de methyl), (15.075) (N-{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzyl}-cyclopropanecarboxamida), (15.076) N-metil-4-(5-(trifluorometil)-1,2,4-oxadiazol-3-il]-benzamida, (15.077) N-[(E)-metóxi-iminometil]-4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzamida, (15.078) N-[(Z)-metóxi-iminometil]-4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzamida, (15.079) N-[4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]fenil]-ciclopropano-carboxamida, (15.080) N-(2-fluorofenil)-4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzamida, (15.081). Petição 870250039092, de 14 / 05 / 2025, pág. 87 / 383 80 / 178 2,2-difluoro-N-metil-2-[4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]fenil]-acetamida, (15.082) N-alil-N-[[4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il)fenil]metil]acetamida, (15.083) N-[(E)-N-metóxi-C-metil-carbonimidoil]-4-(5-(trifluorometil)-1,2,4-oxadiazol 3-il]-benzamida, (15.084) N-[(Z)-N-metóxi-C-metil-carbonimidoil]-4-[5-(trifluorometil) 1,2,4-oxadiazol-3-il]benzamida, (15.085) N-alil-N-[[4-[5-(trifluorometil)-1,2,4 oxadiazol-3-il]fenil]-metil]-propanamida, (15.086) 4,4-dimetil-1 -[[4-[5-(trifluorometil) 1,2,4-oxadiazol-3-il]fenil]metil]-pirrolidin-2-ona, (15.087) N-metil-4-[5-(trifluorometil) 1,2,4-oxadiazol-3-il]-benzenocarbotioamida, (15.088) 5-metil-1 -[[4-[5-(trifluorometil)1,2,4-oxadiazol-3-il]fenil]metil]pirrolidin-2-ona, (15.089) N-((2,3-difluoro-4-[5 (trifluorometil)-1,2,4-oxadiazol-3-il]fenil]metil]-3,3,3-trifluoro-propanamida, (15.090) 1 metóxi-1 -metil-3-[[4-[5-(trifluorometil}-1,2,4-oxadiazol-3-il]fenil]-metil]ureia, (15.091) 1, 1 -dietil-3-[[4-[5-(trifluorometil}-1,2,4-oxadiazol-3-il]fenil]metil]ureia, (15.092) N-[[4-[5 (trifluorometil)-1,2,4-oxadiazol-3-il]phen-il]metil]propanamida, (15.093) N-metóxi-N [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, (15.094) 1 -methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.095) N-Methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]-methyl) cyclopropanecarboxamide, (15.096) N,2-Dimethoxy-N-[[4-[5-(trifluoromethyl}-1,2,4 oxadiazol-3-yl]phenyl]-methyl]-propanamide, (15.097) N-Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl)phenyl]methyl]-propanamide, (15.098) 1-Methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]-methyl]-urea, (15.099) 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.100) 3-ethyl-1-methoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.101) 1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]piperidin-2-one, (15.102) 4,4-dimethyl-2-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isooxazolidin-3-one, (15.103) 5,5-dimethyl 2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, (15.104) 3,3 dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]piperidin-2-one, (15.105) 1 -[[3-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]azepane-2-one Petition 870250039092, de 14 / 05 / 2025, p. 88 / 383 81 / 178 ona, (15.106) 4,4-dimethyl-2-[[4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-phenyl]methyl]isoxazolidin-3-one (15.107) 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-phenyl]methyl]isoxazolidin-3-one, (15.108) (1-{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzyl}-1H-pyrazol-4-yl)acetato de ethyla, (15.109) N,N-dimethyl-1-{4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]benzyl}-1H-1,2,4-triazol-3-amine e (15.110) N-{2,3-difluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzyl}butanamide.

[0228] All the mentioned mixing partners of classes (1) to (15) as described above may be present in the form of the free compound and / or, if their functional groups permit, an agriculturally acceptable salt thereof.

[0229] The compounds of formula (I) and compositions comprising them may be combined with one or more biological control agents.

[0230] Examples of biological control agents that can be combined with the compounds of formula (I) and compositions comprising them are: (A) Antibacterial agents selected from the group of: (A1) bacteria, such as (A1.1) Bacillus subtilis, in particular strain QST713 / AQ713 (available as SERENADE OPTI or SERENADE ASO from Bayer CropScience LP, US, having Accession No. NRRL B21661 and described in US Patent No. 6,060,051); (A1.2) Bacillus amyloliquefaciens, in particular strain D747 (available as Double Nickel™ from Certis, US, having accession number FERM BP-8234 and disclosed in US Patent No. 7,094,592); (A1.3) Bacillus pumilus, in particular strain BU F-33 (having Accession No. NRRL 50185); (A1.4) strain FZB24 of Bacillus subtilis var. amyloliquefaciens (available as Taegro® from Novozymes, US); (A1.5) a strain of Paenibacillus sp. having NRRL Accession No. B-50972 or NRRL Accession No. B-67129 and described in International Patent Publication No. WO 2016 / 154297; and (A2) fungi, such as (A2.1) Aureobasidium pullulans, in particular blastospores of the DSM14940 strain; (A2.2) blastospores of Aureobasidium pullulans of Petition 870250039092, dated 05 / 14 / 2025, p. 89 / 383 82 / 178 strain DSM 14941; (A2.3) Aureobasidium pullulans, in particular mixtures of blastospores from strains DSM14940 and DSM14941; (B) Fungicides selected from the group of: (B1) bacteria, for example (B1.1) Bacillus subtilis, in particular strain QST713 / AQ713 (available as SERENADE OPTI or SERENADE ASO from Bayer CropScience LP, US, having Accession No. NRRL B21661 and described in US Patent No. 6,060,051); (B1.2) Bacillus pumilus, in particular strain QST2808 (available as SONATA® from Bayer CropScience LP, US, having Accession No. NRRL B-30087 and described in US Patent No. 6,245,551); (B1.3) Bacillus pumilus, in particular strain GB34 (available as Yield Shield® from Bayer AG, DE); (B1.4) Bacillus pumilus, in particular strain BU F-33 (having Accession No. NRRL 50185); (B1.5) Bacillus amyloliquefaciens, in particular strain D747 (available as Double Nickel™ from Certis, US, having accession number FERM BP-8234 and disclosed in US Patent No. 7,094,592); (B1.6) Bacillus subtilis Y1336 (available as BIOBAC® WP from BionTech, Taiwan, registered as a biological fungicide in Taiwan under Registration Nos. 4764, 5454, 5096 and 5277); (B1.7) strain MBI 600 of Bacillus amyloliquefaciens (available as SUBTILEX from BASF SE); (B1. 8) Bacillus subtilis strain GB03 (available as Kodiak® from Bayer AG, DE); (B1. 9) strain FZB24 of Bacillus subtilis var. amyloliquefaciens (available from Novozymes Biologicals Inc., Salem, Virginia or Singenta Crop Protection, LLC, Greensboro, North Carolina as the fungicide TAEGRO® or TAEGRO® ECO (EPA Registration No. 70127-5); (B1.10) Bacillus mycoides, isolate J (available as BmJ TGAI or WG from Certis USA); (B1.11) Bacillus licheniformis, in particular strain SB3086 (available as EcoGuard™ Biofungicide and Green Releaf from Novozymes); (B1.12) a strain of Paenibacillus sp.

[0231] In some forms, the biological control agent is a strain Petition 870250039092, dated 05 / 14 / 2025, p. 90 / 383 83 / 178 of Bacillus subtilis or Bacillus amyloliquefaciens that produces a fengicin or plipastatin-like compound, an iturin-like compound and / or a surfactin-like compound. For information, see the following review article: Ongena, M., et al., “Bacillus Lipopeptides: Versatile Weapons for Plant Disease Biocontrol,” Trends in Microbiology, Vol 16, No 3, March 2008, pages 115-125. Bacillus strains capable of producing lipopeptides include QST713 of Bacillus subtilis (available as SERENADE OPTI or SERENADE ASO from Bayer CropScience LP, US, with Accession No. NRRL B21661 and described in US Patent No. 6,060,051), and the D747 strain of Bacillus amyloliquefaciens (available as Double Nickel™ from Certis, US, with accession number FERM BP-8234 and disclosed in US Patent No. 7,094,592). MBI600 from Bacillus subtilis (available as SUBTILEX® from Becker Underwood, US EPA Reg.No. 71840-8); Y1336 of Bacillus subtilis (available as BIOBAC® WP from Bion-Tech, Taiwan, registered as a biological fungicide in Taiwan under Registration Nos. 4764, 5454, 5096 and 5277); Bacillus amyloliquefaciens, in particular strain FZB42 (available as RHIZOVITAL® from ABiTEP, DE); and FZB24 of Bacillus subtilis var. amyloliquefaciens (available from Novozymes Biologicals Inc., Salem, Virginia or Singenta Crop Protection, LLC, Greensboro, North Carolina as the fungicide TAEGRO® or TAEGRO® ECO (EPA Registration No. 70127-5); and (B2) fungi, for example: (B2.1) Coniothyrium minitans, in particular strain CON / M / 91-8 (DSM Accession No. 9660; for example, Contans® from Bayer); (B2.2) Metschnikowia fructicola, in particular strain NRRL Y-30752 (for example, Shemer®); (B2.3) Microsphaeropsis ochracea (for example, Microx® from Prophyta); PCT / IT2008 / 000196); (B2.6) Trichoderma harzianum rifai strain KRL-AG2 (also known as strain T-22, / ATCC 208479, for example, PLANTASHIELD T-22G, Rootshield® and TurfShield from BioWorks, US); (B2. 14) Gliocladium roseum, strain 321U from WF Stoneman Company LLC; (B2. 35). Petition 870250039092, dated 05 / 14 / 2025, p. 91 / 383 84 / 178 Talaromyces flavus, cepa V117b; (B2.36) Trichoderma asperellum, cepa ICC 012 da Isagro; (B2.37) Trichoderma asperellum, cepa SKT-1 (por exemplo, ECO-HOPE® da Kumiai Chemical Industry); (B2.38) Trichoderma atroviride, cepa CNCM I-1237 (por exemplo, Esquive® WP da Agrauxine, FR); (B2.39) Trichoderma atroviride, cepa no V08 / 002387; (B2.40) Trichoderma atroviride, cepa NMI no V08 / 002388; (B2.41) Trichoderma atroviride, cepa NMI no V08 / 002389; (B2.42) Trichoderma atroviride, cepa NMI no V08 / 002390; (B2.43) Trichoderma atroviride, cepa LC52 (por exemplo, Tenet da Agrimm Technologies Limited); (B2.44) Trichoderma atroviride, cepa ATCC 20476 (IMI 206040); (B2.45) Trichoderma atroviride, cepa T11 (IMI352941 / CECT20498); (B2.46) Trichoderma harmatum; (B2.47) Trichoderma harzianum·; (B2.48) Trichoderma harzianum rifai T39 (por exemplo, Trichodex® da Makhteshim, US); (B2.49) Trichoderma harzianum, in particular, strain KD (e.g., Trichoplus from Biological Control Products, SA (acquired from Becker Underwood)); (B2. 50) Trichoderma harzianum, strain ITEM 908 (e.g., Trianum-P from Koppert); (B2. 51) Trichoderma harzianum, strain TH35 (e.g., Root-Pro from Mycontrol); (B2. 52) Trichoderma virens (also known as Gliocladium virens), in particular strain GL-21 (e.g., SoilGard 12G from Certis, US); (B2. 53) Trichoderma viride, strain TV1 (e.g., Trianum-P from Koppert); (B2. 54) Ampelomyces quisqualis, in particular strain AQ 10 (e.g., AQ 10® from IntrachemBio Italia); (B2. 56) Aureobasidium pullulans, in particular blastospores of strain DSM14940; (B2. 57) Aureobasidium pullulans, in particular blastospores of strain DSM 14941; (B2. 58) Aureobasidium pullulans, in particular mixtures of blastospores of strains DSM14940 and DSM 14941 (e.g. Botector® from bioferm, CH); (B2.64) Cladosporium cladosporioides, strain H39 (from Stichting Dienst Landbouwkundig Onderzoek); (B2. 69) strain J1446 of Gliocladium catenulatum (Sinonym: Clonostachys rosea f. catenulate) (e.g. Prestop ® from AgBio Inc. and also e.g. Primastop ® from Kemira Agro Oy); (B2. 70) Lecanicillium lecanii. Petition 870250039092, dated 05 / 14 / 2025, p. 92 / 383 85 / 178 (formerly known as Verticillium lecanii) conidia of strain KV01 (e.g., Vertalec® da Koppert / Arysta); (B2.71) Penicillium vermiculatum; (B2.72) Anomalous Pichia, strain WRL-076 (NRRL Y-30842); (B2.75) Trichoderma atroviride , strain SKT-1 (FERM P-16510); (B2.76) Trichoderma atroviride , strain SKT-2 (FERM P16511); (B2.77) Trichoderma atroviride , strain SKT-3 (FERM P-17021); (B2.78) Trichoderma gamsii (formerly T. viride), strain ICC080 (IMI CC 392151 CABI, for example, BioDerma da AGROBIOSOL DE MEXICO, SA DE CV); (B2.79) Trichoderma harzianum, strain DB 103 (e.g., T-Gro 7456 from Dagutat Biolab); (B2.80) Trichoderma polysporum, strain IMI 206039 (e.g., Binab TF WP from BINAB Bio-Innovation AB, Sweden); (B2.81) Trichoderma stromaticum (e.g., Tricovab da Ceplac, Brazil); (B2.83) Ulocladium oudemansii, in particular strain HRU3 (e.g., Botry-Zen® from Botry-Zen Ltd, NZ); (B2.84) Verticillium albo-atrum (formerly V. dahliae), strain WCS850 (CBS 276).92; for example, Dutch Trig from Tree Care Innovations); (B2. 86) Verticillium chlamydosporium; (B2. 87) mixtures of Trichoderma asperellum strain ICC 012 and Trichoderma gamsii strain ICC 080 (product known as, for example, BIO-TAMTM from Bayer CropScience LP, US).

[0232] Other examples of biological control agents that can be combined with the compounds of formula (I) and compositions comprising them are: bacteria selected from the group consisting of Bacillus cereus, in particular B. cereus, strain CNCM I-1562 and Bacillus firmus, strain I-1582 (Accession number CNCM I-1582), Bacillus subtilis, strain OST 30002 (Accession number NRRL B50421), Bacillus thuringiensis, in particular B. thuringiensis subspecies israelensis (serotype H-14), strain AM65-52 (Accession number ATCC 1276), B. thuringiensis subsp. aizawai, in particular strain ABTS-1857 (SD-1372), B. thuringiensis subsp. kurstaki strain HD-1, B. thuringiensis subsp. tenebrionis, strain NB 176 (SD-5428), Pasteuria penetrans, Pasteuria spp. (Rotylenchulus reniformis nematode)-PR3 (Number of Petition 870250039092, dated 05 / 14 / 2025, page 93 / 383 86 / 178 accession ATCC SD-5834), Streptomyces microflavus, strain AQ6121 (= QRD 31,013, NRRL B-50550) and Streptomyces galbus, strain AQ 6047 (NRRL Accession Number 30232); Selected fungi and yeasts from the group consisting of Beauveria bassiana, in particular strain ATCC 74040, Lecanicillium spp., in particular strain HRO LEC 12, Metarhizium anisopliae, in particular strain F52 (DSM3884 or ATCC 90448), Paecilomyces fumosoroseus (currently: Isaria fumosorosea), in particular strain IFPC 200613, or strain Apopka 97 (ATCC Accession No. 20874) and Paecilomyces lilacinus, in particular strain 251 of P. lilacinus (AGAL 89 / 030550); Selected viruses from the group consisting of Adoxophyes orana (summer fruit tortrix) granulosis virus (GV), Cydia pomonella (green apple moth) granulosis virus (GV), Helicoverpa armigera (cotton bollworm) nuclear polyhedrosis virus (NPV), Spodoptera exigua (sugar beet fall armyworm) mNPV, Spodoptera frugiperda (corn armyworm) mNPV and Spodoptera littoralis (African cotton leafworm) NPV. Bacteria and fungi that can be added as 'inoculants' to plants or plant parts or plant organs and which, by virtue of their particular properties, promote plant growth and plant health. Examples are: Agrobacterium spp., Azorhizobium caulinodans, Azospirillum spp., Azotobacter spp., Bradyrhizobium spp., Burkholderia spp., in particular Burkholderia cepacia (formerly known as Pseudomonas cepacia), Gigaspora spp., or Gigaspora monosporum, Glomus spp., Laccaria spp., Lactobacillus buchneri, Paraglomus spp., Pisolithus tinctorus, Pseudomonas spp., Rhizobium spp., in particular Rhizobium trifolii, Rhizopogon spp., Scleroderma spp., Suillus spp. and Streptomyces spp. Plant extracts and products formed by microorganisms, including proteins and secondary metabolites, that can be used as biological control agents. Petition 870250039092, dated 05 / 14 / 2025, page 94 / 383 87 / 178 such as Allium sativum, Artemisia absinthium, azadiraquitina, Biokeeper WP, Cassia nigricans, Celastrus angulatus, Chenopodium anthelminticum, chitin, Armour-Zen, Dryopteris filix-mas, Equisetum arvense, Fortune Aza, Fungastop, Heads Up (Chenopodium quinoa saponin extract), Pyrethrum / Pyrethrins, Quassia amara, Quercus, Quillaja, Regalia, “Requiem™ Insecticide”, rotenone, ryania / ryanodine, Symphytum officinale, Tanacetum vulgare, thymol, Triact 70, TriCon, Tropaeulum majus, Urtica dioica, Veratrin, Viscum album, Brassicaceae extract, in particular rapeseed powder or oilseed mustard powder.

[0233] Examples of insecticides, acaricides and nematicides, respectively, which can be mixed with the compounds given by formula (I) and the compositions comprising them are: (1) Acetylcholinesterase (AChE) inhibitors, such as, for example, carbamates, for example alanicarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, trimetacarb, XMC and xylylcarb;or organophosphates, for example acephate, azamethiphos, azinphos-ethyl, azinphos-methyl, cadusaphos, chlorethoxyphos, chlorfenvinphos, chlormephos, chlorpyriphos-methyl, coumaphos, cyanophos, demeton-S-methyl, diazinone, dichlorvos / DDVP, dicrotophos, dimethoate, dimethylvinphos, dissulfotone, EPN, ethion, ethoprophos, fanfur, fenamiphos, phenitrothion, phenthion, phostiazate, heptenophos, imiciaphos, isofenphos, isopropyl salicylate O-(methoxyaminothiophosphoryl), isoxation, maleation, mecarbam, methamidophos, metidation, mevinphos, monocrotophos, naled, omethoate, oxidemethonemethyl, parathion-methyl, phenthoate, phorate, phosalone, phosmet, phosfamidone, phoxime, pyrimiphos-methyl, profenophos, propetamphos, prothiophos, pIraclophos, pyridaphenthione, quinalphos, sulfotep, tebupyrimphos, temephos, terbuphos, tetrachlorvinphos, thiomethone, triazophos, trichlorfon and vamidothion.; Petition 870250039092, 05 / 14 / 2025, p. 95 / 3 88 / 178 (2) GABA-dependent chloride channel blockers, such as, for example, cyclodiene-organochlorines, for example chlordane and endosulfan or phenylpyrazoles (fiprols), for example etiprol and fipronyl. (3) Sodium channel modulators, such as, for example, pyrethroids, for example, acrinathrin, allethrin, d-cis-trans allethrin, d-trans allethrin, bifenthrin, bioallethrin, s-cyclopentenyl bioallethrin isomer, bioresmethrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyfenothrin [(1R)-trans-isomer], deltamethrin, empentrin [(EZ)-(1R)-isomer], esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucitrinate, flumethrin, tau-fluvalinate, halfenprox, imiprothrin, cadetrin, momfluorothrin, permethrin, phenothrin [(1R)-transisomer], pralethrin, pyrethrins (pyrethrum), resmethrin, silafluofen, tefluthrin, tetramethrin, tetramethrin [(1R)-isomer)], tralomethrin and transfluthrin or DDT or methoxychlor. (4) Competitive modulators for nicotinic acetylcholine receptor (nAChR), such as, for example, neonicotinoids, for example, acetamipride, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid and thiamethoxam or nicotine or sulfoxaflor or flupiradifurone. (5) Allosteric modulators of nicotinic acetylcholine receptor (nAChR), such as, for example, spinosyns, for example, spinetoram and spinosad. (6) Allosteric modulators of the glutamate-dependent chloride channel (GluCl), such as, for example, avermectins / milbemycins, for example abamectin, emamectin benzoate, lepimectin and milbemectin. (7) Juvenile hormone mimics, such as, for example, juvenile hormone analogues, for example, hydroprene, cynoprene and methoprene or fenoxycarb or pyriproxyfen. (8) Miscellaneous non-specific inhibitors (multiple sites), such as, for example Petition 870250039092, dated 05 / 14 / 2025, page 96 / 383 89 / 178 example, alkyl halides, for example, methyl bromide and other alkyl halides; or chloropicrin or sulfuryl fluoride or borax or tartrate emetic or methyl isocyanate generators, for example, diazomet and metam. (9) Chordonal Organ Modulators, such as, for example, pimetrozine or flonicamide. (10) Inhibitors of mite growth, such as, for example, clofentezine, hexthiazine and diflovidazine or ethoxazole. (11) Microbial disruptions of the insect intestinal membrane, such as, for example, Bacillus thuringiensis subspecies israelensis, Bacillus sphaericus, Bacillus thuringiensis subspecies aizawai, Bacillus thuringiensis subspecies kurstaki, Bacillus thuringiensis subspecies tenebrionis and Bt plant proteins: Cry1Ab, Cry1Ac, Cry1Fa, Cry1A,105, Cry2Ab, Vip3A, mCry3A, Cry3Ab, Cry3Bb, Cry34Ab1 / 35Ab1. (12) Mitochondrial ATP synthase inhibitors, such as ATP disruptors such as, for example, diafenthiurone compounds or organotin compounds, for example azocyclotine, cyexatine and fenbutatin oxide or propargite or tetradiphone. (13) Uncouplers of oxidative phosphorylation by disrupting the proton gradient, such as, for example, chlorfenapyr, DNOC and sulfluramide. (14) Nicotinic acetylcholine receptor channel blockers, such as, for example, bensultap, cartap hydrochloride, thiocilam and thioultap-sodium. (15) Type 0 chitin biosynthesis inhibitors, such as, for example, bistriflurone, chlorfluazurone, diflubenzurone, flucicloxurone, flufenoxurone, hexaflumurone, lufenurone, novalurone, noviflumurone, teflubenzurone and triflumurone. (16) Inhibitors of chitin biosynthesis, type 1, for example buprofezin. (17) Molt disruptor (in particular for Diptera, i.e., dipterans), such as, for example, cyromazine. (18) Ecdysone receptor agonists, such as, for example, chromafenozide, halofenozide, methoxyfenozide and tebufenozide. Petition 870250039092, dated 05 / 14 / 2025, page 97 / 383 90 / 178 (19) Octopamine receptor agonists, such as, for example, amitraz. (20) Electron transport inhibitors of mitochondrial complex III, such as, for example, hydramethylnon or acequinoline or fluacripyrim. (21) Electron transport inhibitors of mitochondrial complex I, such as, for example, those of the METI acaricide group, for example, phenazaquin, fenpyroximate, pirimidifen, pyridaben, tebufenpyrad and tolfenpyrad or rotenone (Derris). (22) Voltage-dependent sodium channel blockers, such as, for example, indoxacarb or metaflumizone. (23) Acetyl CoA carboxylase inhibitors, such as, for example, tetronic and tetramic acid derivatives, for example, spirodiclofen, spiromesifen and spirotetramate. (24) Inhibitors of electron transport of mitochondrial complex IV, such as, for example, phosphines, for example, aluminum phosphide, calcium phosphide, phosphine and zinc phosphide or cyanides, for example, calcium cyanide, potassium cyanide and sodium cyanide. (25) Electron transport inhibitors of mitochondrial complex II, such as, for example, beta-ketonitrile derivatives, for example, cyenopyrafene and cyflumethophene and carboxanilides, such as, for example, piflubumide. (28) Ryanodine receptor modulators, such as, for example, diamides, for example, chlorantraniliprole, cyantraniliprole and flubendiamide, other active compounds such as, for example, afidopyropene, afoxolaner, azadirachtin, benclothiaz, benzoximate, bifenazate, broflanilide, bromopropylate, chinomethionate, chlorprolethrin, cryolite, cyclaniliprol, cycloxapride, cylalodiamide, dichlormomethiothiaz, dicofol, epsilon-methofluthrin, epsilon-momfluthrin, flomethoquine, fluazaindolizine, fluensulfone, flufenerim, flufenoxystrobin, flufiprol, fluhexaphane, fluopiram, fluralaner, fluxamethamide, fufenozide, guadipir, heptafluthrin, Petition 870250039092, dated 05 / 14 / 2025, page 98 / 383 91 / 178 Imidaclotiz, Iprodione, capa-Bifentrin, capa-Tefluthrin, Lotilaner, Meperfluthrin, Paichongding, Pyridalila, Pyrifluquinazone, Pyriminostrobin, Spirobudiclofen, Tetramethylfluthrin, Tetraniliprol, Tetrachlorantraniliprol, Tigolaner, Thioxazaphene, Thiofluoximate, Triflumezopyrim and iodomethane; In addition, preparations based on Bacillus firmus (I-1582, BioNeem, Votivo) and also the following compounds: 1-{2fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulfinyl]phenyl}-3-(trifluoromethyl)-1H-1,2,4-triazol-5amine (known from document WO2006 / 043635) (CAS 885026-50-6), {1'-[(2E)-3(4-chlorophenyl)prop-2-en-1-yl]-5-fluorospiro[indol-3,4'-piperidin]-1(2H)-yl}(2-chloropyridin-4yl)methanone (known from document WO2003 / 106457) (CAS 637360-23-7), 2-chloroN-[2-{1-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]piperidin-4-yl}-4(trifluoromethyl)phenyl]isonicotinamide (known from WO2006 / 003494) (CAS 872999-66-1), 3-(4-chloro-2,6-dimethylphenyl)-4-hydroxy-8-methoxy-1,8-diazaspiro[4,5]dec-3en-2-one (known from document WO 2010052161) (CAS 1225292-17-0), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-2-oxo-1,8-diazaspiro[4,5]dec-3en-4-yl ethylcarbonate (known from EP2647626) (CAS 1440516-42-6), 4-(but-2-yn-1-yloxy)-6-(3,5-dimethylpiperidin-1-yl)-5-fluoropyrimidine (known from document WO2004 / 099160) (CAS 792914-58-0), PF1364 (known from JP2010 / 018586) (CAS 1204776-60-2), N[(2E)-1-[(6-chloropyridin-3-yl)methyl]pyridin-2(1H)-ylidene]-2,2,2-trifluoroacetamide (known from document WO2012 / 029672) (CAS 1363400-41-2), (3E)-3-[1-[(6-chloro-3-pyridyl)methyl]-2-pyridilidene]-1,1,1-trifluoro-propan-2-one (known from document WO2013 / 144213) (CAS 1461743-15-6), , N-[3-(benzylcarbamoyl)-4-chlorophenyl]-1-methyl-3-(pentafluoroethyl)-4-(trifluoromethyl)-1H-pyrazol-5-carboxamide (known from document WO2010 / 051926) (CAS 1226889-14-0), 5-bromo-4-chloro-N-[4-chloro-2-methyl-6-(methylcarbamoyl)phenyl]-2-(3-chloro-2-pyridyl)pyrazol-3-carboxamide (known from CN103232431) (CAS 1449220-44-3),4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5(trifluoromethyl)-3-isoxazolyl]-2-methyl-N-(cis-1-oxide-3-thiethanyl)-benzamide, 4-[5-(3,5dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-2-methyl-N-(trans-1-oxide-3, Petition 870250039092, dated 05 / 14 / 2025, page 99 / 383 92 / 178 tietanil)-benzamida and 4-[(5S)-5-(3,5-dichlorophenyl)-4,5-di-hidro-5-(trifluoromethyl)-3isoxazolyl]-2-methyl-N-(c / s-1-óxido-3-tietanil)benzamida (conhecido do documento WO 2013 / 050317 A1) (CAS 1332628-83-7), N-[3-chloro-1-(3-pyridinyl)-1H-pyrazol-4-yl]-N-ethyl3-[(3,3,3-trifluoropropyl)sulfinyl]-propanamida, (+)-N-[3-chloro-1-(3-pyridinyl)-1H-pyrazol4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl)sulfinyl]-propanamida and (-)-N-[3-chloro-1-(3-pyridinyl)1 H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl)sulfinyl]-propanamida (according to document WO 2013 / 162715 A2, WO 2013 / 162716 A2, US 2014 / 0213448 A1) (CAS 1477923-37-7), 5-[[(2E)-3-chloro-2-propene-1-yl]amino]-1-[2,6-dichloro-4-(trifluoromethyl) phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazol-3-carbonitrila (conhecido de CN 101337937 A) (CAS 1105672-77-2), 3-bromo-N-[4-chloro-2-methyl-6-[(methylamino)thioxomethyl]phenyl]-1(3-chloro-2-pyridinyl)-1H-pyrazol-5-carboxamida, (Liudaibenjiaxuanan, conhecido de CN 103109816 A) (CAS 1232543-85-9);N-[4-chloro-2-[[(1,1-dimethylethyl)amino]carbonyl]-6-methylphenyl]-1-(3-chloro-2-pyridinyl)-3-(fluoromethoxy)-1H-Pyrazol-5-carboxamide (known from document WO 2012 / 034403 A1) (CAS 1268277-22-0), N-[2-(5-amino-1,3,4-thiadiazol-2-yl)-4-chloro-6-methylphenyl]-3-bromo-1-(3-chloro-2-pyridinyl)-1H-pyrazol-5-carboxamide (known from document WO 2011 / 085575 A1) (CAS 1233882-22-8), 4-[3-[2,6-dichloro-4-[(3,3-dichloro-2-propen-1-yl)oxy]phenoxy]propoxy]-2-methoxy-6(trifluoromethyl)-pyrimidine (known from CN 101337940 A) (CAS 1108184-52-6); (2E)e 2(Z)-2-[2-(4-cyanophenyl)-1-[3-(trifluoromethyl)phenyl]ethyllidene]-N-[4-(difluoromethoxy)phenyl]hydrazinecarboxamide (known from CN 101715774 A) (CAS 1232543-85-9); ester of 3-(2,2-dichloroethenyl)-2,2-dimethyl-4-(1H-benzimidazol-2-yl)phenylcyclopropanecarboxylic acid (known from CN 103524422 A) (CAS 1542271-46-4);(4aS)-7-chloro-2,5-dihydro-2-[[(methoxycarbonyl)[4-[(trifluoromethyl)thio]phenyl]amino]carbonyl]-indeno[1,2-e][1,3,4]oxadiazine-4a(3H)-carboxylic acid methyl ether (known from CN 102391261 A) (CAS 1370358-69-2); 6-deoxy-3-O-ethyl-2,4-di-O-methyl-, 1-[N-[4-[1[4-(1,1,2,2,2-pentafluoroethoxy)phenyl]-1H-1,2,4-triazol-3-yl]phenyl]carbamate]-α-Lmannopyranose (known from US 2014 / 0275503 A1) (CAS 1181213-14-8); 8-(2Petition 870250039092, of 05 / 14 / 2025, p. 100 / 383; 93 / 178 ciclopropilmetóxi-4-trifluorometil-fenóxi)-3-(6-trifluorometil-piridazin-3-yl)-3-azabiciclo[3,2,1]octano (CAS 1253850-56-4), (8-ant / j-8-(2-ciclopropilmetóxi-4trifluorometil-fenóxi)-3-(6-trifluorometil-piridazin-3-yl)-3-aza-biciclo[3,2,1 ]octano (CAS 933798-27-7), (8-s / n)-8-(2-ciclopropilmetóxi-4-trifluorometil-fenóxi)-3-(6-trifluorometilpiridazin-3-yl)-3-aza-biciclo[3,2,1]octano (conhecido do documento WO 2007040280 A1, WO 2007040282 A1) (CAS 934001 -66-8), N-[3-chloro-1 -(3-pyridinyl)-1 H-pyrazol-4-yl]N-ethyl-3-[(3,3,3-trifluoropropyl)thio]-propanamida (confirmed in WO document 2015 / 058021 A1, WO 2015 / 058028 A1) (CAS 1477919-27-9) and N-[4(aminothioxomethyl)-2-methyl-6-[(methylamino)carbonyl]phenyl]-3-bromo-1-(3-chloro-2-pyridinyl)1H-pyrazol-5-carboxamida (CN approval 103265527 A) (CAS 1452877-50-7), 5(1,3-dioxan-2-yl)-4-[[4-(trifluoromethyl)phenyl]methoxy]-pyrimidine (according to document WO 2013 / 115391 A1) (CAS 1449021-97-9), 3-(4-chloro-2,6-dimethylphenyl)-4-hidróxi-8methóxi-1-methyl-1,8-diazaspiro[4,5]dec-3-en-2-one (known from WO 2010 / 066780 A1, WO 2011 / 151146 A1) (CAS 1229023-34-0), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-1-methyl-1,8-diazaspiro[4,5]decane-2,4-dione (known from WO 2014 / 187846 A1) (CAS 1638765-58-8), ethyl ester of 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-1-methyl-2-oxo-1,8-diazaspiro[4,5]dec-3-en-4-ylcarbonic acid (known from WO 2010 / 066780 A1, WO 2011151146 A1) (CAS 1229023-00-0), N-[1-[(6-chloro-3-pyridinyl)methyl]-2(1H)-pyridinilidene]-2,2,2-trifluoroacetamide (known from DE 3639877 A1, WO 2012029672 A1) (CAS 1363400-412), [N(E)]-N-[1-[(6-chloro-3-pyridinyl)methyl]-2(1H)-pyridinilidene]-2,2,2-trifluoroacetamide, (known from document WO 2016005276 A1) (CAS 1689566-03-7), [N(Z)]-N-[1-[(6chloro-3-pyridinyl)methyl]-2(1H)-pyridinylidene]-2,2,2-trifluoro-acetamide, (CAS 170230540-5), 3-endo-3-[2-propoxy-4-(trifluoromethyl)phenoxy]-9-[[5-(trifluoromethyl)-2-pyridinyl]oxy]9-aza-bicyclo[3,3,1]nonane (known from WO 2011 / 105506 A1, WO 2016 / 133011 A1) (CAS 1332838-17-1).,

[0234] Examples of plant protection products that can be mixed with the Petition 870250039092, dated 05 / 14 / 2025, page 101 / 383 94 / 178 compounds of formula (I) and compositions comprising them are, for example, benoxacor, cloquintocet (-mexil), ciometrinil, cyprosulfamide, dichlormide, fenclorazol (-ethyl), fenclorim, flurazol, fluxofenim, furilazol, isoxadifeno (-ethyl), mefenpir (-diethyl), naphthalic anhydride, oxabetrinil, 2-methoxy-N-({4-[(methylcarbamoyl)amino]phenyl}-sulfonyl)benzamide (CAS 129531-12-0), 4-(dichloroacetyl)-1-oxa-4azaspiro[4,5]decane (CAS 71526-07-3), 2,2,5-trimethyl-3-(dichloroacetyl)-1,3-oxazolidine (CAS 52836-31-4).

[0235] Examples of herbicides that can be mixed with the compounds of formula (I) and compositions comprising them are: Acetochlor, acifluorfen, acifluorfen-sodium, aclonifene, alachlor, allidochlor, aloxidim, aloxidim-sodium, ametryn, amicarbazone, amidochlor, amidosulfurone, 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methylphenyl)-5-fluoropyridine-2-carboxylic acid, aminocyclopyrachlor, aminocyclopyrachlor-potassium, aminocyclopyrachlor-methyl, aminopyralid, amitrol, ammoniumsulfamate, anilophos, asulam, atrazine, azaphenidine, azimsulfurone, beflubutamide, benazoline, benazolin-ethyl, benfluralin, benfuresate, bensulfurone, bensulfuron-methyl, bensulide, bentazone, benzobicyclone, benzofenap, bicyclopyrone, bifenox, bilafos, bilanofos-sodium, bispiribac, bispiribacsodium, bromacil, bromobutide, bromofenoxim, bromoxinil, bromoxinyl-butyrate, potassium, -heptanoate and -octanoate, busoxinone, butachlor, butafenacil, butamiphos, butenachlor, butralin, butroxidim, butylate, cafenstrol, carbetamide, carfentrazone, carfentrazone-ethyl, chloramben, chlorbromurone, chlorfenac, chlorfenac-sodium, chlorfenprope,chlorflurenol, chlorflurenol-methyl, chloridazone, chlorimurone, chlorimurone-methyl, chlorophthalim, chlorotolurone, chlorthal-dimethyl, chlorsulfurone, cinidone, cinidone-ethyl, cinmethylin, cinosulfurone, claciphos, clethodim, clodinafop, clodinafop-propargyl, clomazone, clomeprop, clopyralide, chloransulam, chloransulam-methyl, cumylurone, cyanamide, cyanazine, cycloate, cyclopyrimorate, cyclosulfamurone, cycloxidim, cylalope, cylalope-butyl, ciprazine, 2,4-D, 2,4-D-butyl, -butyl, -dimethylammonium, Petition 870250039092, dated 05 / 14 / 2025, page 102 / 383 95 / 178 diolamine, -ethyl, -2-ethylhexyl, -isobutyl, -isooctyl, -isopropylammonium, -potassium, triisopropanolammonium and -trolamine, 2,4-DB, 2,4-DB-butyl, -dimethylammonium, -isooctyl, potassium and -sodium, daimurone (dimrone), dalapone, dazomet, n-decanol, desmedifam, detosylpyrazolate (DTP), dicamba, diclobenyl, 2-(2,4-dichlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one, 2-(2,5-dichlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one, dichlorprop, dichlorprop-P, diclofop, diclofop-methyl, diclofop-P-methyl, diclosulam, difenzoquate, diflufenican, diflufenzopyr, diflufenzopyr-sodium, dimefurone, dimepiperate, dimetachlor, dimetamethrin, dimethenamide, dimethenamide-P, dimethrasulfurone, dinitramine, dinoterb, diphenamide, diquat, diquat-dibromide, dithiopyr, diurone, DNOC, endotal, EPTC, esprocarb, etalfluralin, etametsulfuron, eta-metsulfuron-methyl, ethiozin, etofumesate, ethoxyphene, ethoxyphene-ethyl, ethoxysulfuron, etobenzanide, F-9600, F-5231, i.e.N-{2-chloro-4-fluoro-5-[4-(3fluoropropyl)-5-oxo-4,5-dihydro-1H-tetrazol-1-yl]phenyl}ethanesulfon-amide, F-7967, i.e. 3-[7-chloro-5-fluoro-2-(trifluoro-methyl)-1H-benzimidazol-4-yl]-1-methyl-6(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione, fenoxaprope, fenoxaprope-P, fenoxa-propetyl, fenoxa-prop-P-ethyl, fenoxasulfone, phenquinotrione, fentrazamide, flamprope, flamprope-M-isopropyl, flamprope-M-methyl, flaza-sulfuron, florasulam, fluazifoper, fluazifop-P, fluazifop-butyl, fluazifop-P-butyl, flucarbazone, flucarbazone-sodium, flucetosulfurone, fluchloralin, flufenacet, flufenpyr, flufenpyr-ethyl, flumetsulam, flumiclorac, flumiclorac-pentyl, flumioxazin, fluometurone, flurenol, flurenol-butyl, -dimethylammonium-methyl, fluoroglycophene, fluoroglycophene-ethyl, flupropanate, flupyrsulfurone, flupyrsulfuron-methyl-sodium, fluridone, flurochloridone, fluroxypyr, fluroxypyrmeptyl, flurtamone, flutiacet, flutiacet-methyl, fomesafene, fomesafene-sodium, foramsulfurone, fosamine,glyphosate, glyphosate-ammonium, glyphosate-P-sodium, glyphosate-P-ammonium, glyphosate-P-sodium, glyphosate, glyphosate-ammonium, -isopropylammonium, -diammonium, -dimethylammonium, -potassium, -sodium and -trimesium, H-9201, that is, isopropylphosphoramidothioate O-(2,4-dimethyl-6-nitrophenyl) O-ethyl, halauxifene, Petition 870250039092, dated 05 / 14 / 2025, page 103 / 383 96 / 178 haloauxifene-methyl, halosaphene, halosulfurone, halosulfurone-methyl, haloxyfope, haloxyfope-P, haloxyfope-ethoxyethyl, haloxyfope-P-ethoxyethyl, haloxyfope-methyl, haloxyfope-P-methyl, hexazinone, HW-02, i.e., ethyl-(2,4-dichlorophenoxy)acetate of 1(dimethoxyphosphoryl), imazametabenz, imazametabenz-methyl, imaza-mox, imazamoxammonium, imazapic, imazapic-ammonium, imazapyr, imazapyr-isopropyl-ammonium, imazaquine, imazaquine-ammonium, imazethapyr, imazethapyr-immonium, imazosulfurone, indanophane, indaziflam, iodosulfurone, iodo-sulfuron-methyl-sodium, ioxynyl, ioxynyl octanoate, -potassium and -sodium, ipfencarbazone, iso-proturone, isourone, isoxabene, isoxaflutol, carbutilate, KUH-043, i.e., 3-({[5-(difluoromethyl)-1-methyl-3-(trifluoromethyl)1H-pyrazol-4-yl]methyl}sulfonyl)-5,5-dimethyl-4,5-dihydro-1,2-oxazole, keto-spiradox, lactophene, lenacil, linurone, MCPA, MCPA-butotyl, -dimethylammonium, -2-ethylhexyl, isopropylammonium, -potassium and -sodium, MCPB, MCPB-methyl, -ethyl and -sodium,meco-prope, mecoprope-sodium and -butotil, mecoprope-P, mecoprope-P-butotil, -dimethylammonium, -2-ethylhexyl and -potassium, mefenacete, mefluidide, mesosulfurone, mesosulfuronemethyl, mesotrione, metabenzthiazurone, metam, metamifope, metamitrone, metazachlor, metazosulfurone, methabenzthiazurone, methiopyrsulfurone, methiozoline, methyl isothiocyanate, metobromurone, metolachlor, S-metolachlor, metosulam, methoxurone, metribuzin, metsulfurone, metsulfuron-methyl, molinat, monolinurone, monosulfurone, monosulfuron-ester, MT-5950, that is, N-(3-chloro-4-isopropylphenyl)-2-methylpentanamide, NGGC-011, napropamide, NC-310, i.e., [5-(benzyloxy)-1-methyl-1H-pyrazol-4-yl](2,4-dichlorophenyl)-methanone, neburone, nicosulfurone, nonanoic acid (pelargonic acid), norflurazone, oleic acid (fatty acids), orbencarb, orthosulfamurone, oryzalin, oxadiargile, oxadiazone, oxasulfurone, oxazylmethone, oxyfluorfen, paraquat, paraquat dichloride, pebulate, pendimethalin, penoxsulam,pentachlor-phenol, pentoxazone, petoxamide, petroleum oils, phenmedifam, picloram, picolinaphene, pinoxaden, piperophos, pretyl-chlor, primisulfuron, primisulfuron-methyl, prodiamine, profoxidim, prometone, promethrin, Petition 870250039092, dated 05 / 14 / 2025, page 104 / 383 97 / 178 propachlor, propanil, propaquizafop, propazine, profam, propisochlor, propoxycarbazone, propoxycarbazone-sodium, propyrilsulfurone, propizamide, prosulfocarb, prosulfurone, pyraclonil, piraflufen, piraflufen-ethyl, pyrasulfotol, pyrazolinate (pyrazolate), pyrazosulfurone, pyrazosulfuron-ethyl, pyrazoxifene, piribambenz, piribambenz-isopropyl, piribambenz-propyl, piribenzoxim, piributicarb, pyridafol, pyridate, piririftalide, piriminobac, piriminobac-methyl, pirimisulfan, piritiobac, piritiobacsodium, piroxasulfone, piroxsulam, quinclorac, quinmerac, quinoclamine, quizalofop, quizalofop-ethyl, quizalofop-P, quizalofop-P-ethyl, quizalofop-P-tefuryl, rimsulfuron, saflufenacyl, sethoxydim, siduron, simazine, symethrin, SL-261, sulcotrione, sulfentrazone, sulfo-meturone, sulfometuron-methyl, sulfosulfuron, SIN-523, SYP249, i.e. 1-ethoxy-3-methyl-1oxobut-3-en-2-yl 5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrobenzoate, SYP-300, i.e.1-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H1,4-benzoxazin-6-yl]-3-propyl-2-thioxo-imidazolidine-4,5-dione, 2,3,6-TBA, TCA (trichloroacetic acid), TCA-sodium, tebuthiurone, tefuryl-trione, tembotrione, tepraloxidim, terbacilla, terbucarb, terbumetone, terbuthylazine, terbutrine, tenyl-chlor, thiazopyr, thiencarbazone, thien-carbazone-methyl, thifensulfuron, thifensulfuron-methyl, thiobencarb, thiafenacyl, tolpiralate, topra-mezone, tralkoxidim, triafamone, tri-allate, triasulfuron, triaziflam, tribenurone, tribenuron-methyl, triclopyr, trietazine, trifloxysulfurone, trifloxysulfuron-sodium, trifludimoxazin, trifluralin, triflu-sulfurone, triflusulfuron-methyl, trito-sulfurone, urea sulfate, vernolate, XDE-848, ZJ-0862, that is, 3,4-dichloro-N-{2[(4,6-dimethoxypyrimidin-2-yl)oxy]benzyl}aniline and the following compounds:, Petition 870250039092, dated 05 / 14 / 2025, page 105 / 383 98 / 178

[0236] Examples of plant growth regulators are: Acibenzolar, acibenzolar-S-methyl, 5-aminolevulinic acid, ancimidol, 6-benzylaminopurine, brassinolide, catechin, chlormequat chloride, chlorpe, cyclanilide, 3-(cycloprop-1-enyl)propionic acid, daminozide, dazomet, n-decanol, dicegulac, dicegulac-sodium, endothal, endothal-dipotassium, disodium and mono(N,N-dimethylalkylammonium), ethephone, flumetraline, flurenol, flurenol-butyl, flurprimidol, forchlorfenuron, gibberellic acid, inabenfide, indole-3-acetic acid (IAA), 4-indole-3-ylbutyric acid, isoprothiolane, probenazole, jasmonic acid, maleic hydrazide, mepiquat chloride, 1-methylcyclopropene, methyl jasmonate, 2-(1-naphthyl)acetamide, 1-naphthylacetic acid, 2-naphthyloxyacetic acid, nitrophenolate mixture, paclobutrazol, N-(2-phenylethyl)-beta-alanine, N-phenylphthalamic acid, prohexadione, prohexadione-calcium, prohydrojasmone, salicylic acid, strigolactone, tecnazene, thidiazurone, triacontanol, trinexapac, trinexapac-ethyl, tsitodefe, uniconazole, uniconazole-P. Methods and uses

[0237] The compounds of formula (I) and compositions comprising them have potent microbicidal activity. They can be used to control unwanted microorganisms, such as unwanted fungi and bacteria. They can be particularly useful in protecting crops (they control microorganisms that cause plant diseases) or in protecting materials (e.g., industrial materials, wood, storage products) as described in more detail in the present invention below. More specifically, the compounds of formula (I) and compositions comprising them can be used to protect seeds, germinating seeds, emerged seedlings, plants, plant parts, fruits, Petition 870250039092, dated 05 / 14 / 2025, page 106 / 383 99 / 178 crop products and / or the soil in which the plants grow contain unwanted microorganisms.

[0238] Control or controlling as used in the present invention encompasses the protective, curative, and eradicative treatment of unwanted microorganisms. Unwanted microorganisms may be pathogenic bacteria, pathogenic viruses, pathogenic oomycetes, or pathogenic fungi, more specifically phytopathogenic bacteria, phytopathogenic viruses, phytopathogenic oomycetes, or phytopathogenic fungi. As detailed in the present invention below, these phytopathogenic microorganisms are the causal agents of a wide spectrum of plant diseases.

[0239] More specifically, the compounds of formula (I) and compositions comprising them can be used as fungicides. For the purpose of this descriptive report, the term “fungicide” refers to a compound or composition that can be used in crop protection for the control of unwanted fungi, such as Plasmodiophoromycetes, Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes and Deuteromycetes and / or for the control of Oomycetes, more preferably for the control of Basidiomycetes (which cause rust diseases).

[0240] The present invention also relates to a method for controlling unwanted microorganisms, such as fungi, oomycetes and phytopathogenic bacteria, comprising the step of applying at least one compound of formula (I) or at least a composition comprising the same to the microorganisms and / or their habitat (to plants, plant parts, seeds, fruits or the soil in which the plants grow).

[0241] Typically, when the compound and composition of the invention are used in curative or protective methods to control phytopathogenic fungi and / or phytopathogenic oomycetes, an effective and plant-compatible amount thereof is applied to the plants, plant parts, fruits, seeds, or to the soil or substrates in Petition 870250039092, dated 05 / 14 / 2025, p. 107 / 383 100 / 178 on which plants grow. Suitable substrates that can be used for growing plants include inorganic-based substrates such as mineral wool, in particular rock wool, perlite, sand or gravel; organic substrates such as peat, pine bark or sawdust; and petroleum-based substrates such as polymer foams or plastic beads. Effective and plant-compatible quantity means a quantity that is sufficient to control or destroy fungi present or likely to appear in the growing area and that does not cause any appreciable symptoms of phytotoxicity to said crops. Such a quantity may vary within a wide range depending on the fungus to be controlled, the type of crop, the growth stage of the crop, the climatic conditions and the respective compound or composition of the invention used. This quantity can be determined by systematic field trials that are within the capabilities of a person skilled in the art. Plants and plant parts

[0242] The compounds of formula (I) and compositions comprising them may be applied to any plants or parts of plants.

[0243] Plants means all plants and plant populations, such as wild plants or crop plants (including naturally occurring crop plants), whether desired or undesired. Crop plants may be plants that can be obtained by conventional cultivation and optimization methods or by biotechnological and genetic engineering methods or combinations thereof, including genetically modified plants (GMOs or transgenic plants) and plant cultivars that are protectable and unprotectable by plant growers' rights.

[0244] Plant parts are understood to mean all parts and organs of plants above and below ground, such as shoots, leaves, flowers and roots, examples of which include leaves, needles, stems, stalks, flowers, fruiting bodies, fruits and seeds, and also roots, tubers and rhizomes. Plant parts also Petition 870250039092, dated 05 / 14 / 2025, page 108 / 383 101 / 178 includes harvested material and vegetative and generative propagation material, for example, seedlings, tubers, rhizomes, shoots and seeds.

[0245] Plants that can be treated according to the methods of the invention include the following: cotton, flax, vine, fruits, vegetables, such as Rosaceae sp. (e.g., pome fruits, such as apples and pears, but also stone fruits, such as apricots, cherries, almonds and peaches, and soft fruits, such as strawberries), Ribesioidae sp., Juglandaceae sp., Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp., Actinidaceae sp., Lauraceae sp., Musaceae sp. (e.g., banana trees and plantations), Rubiaceae sp. (e.g., coffee), Theaceae sp., Sterculiceae sp., Rutaceae sp. (e.g., lemons, oranges and grapefruits); Solanaceae sp. (e.g., tomatoes), Liliaceae sp., Asteraceae sp. (e.g., lettuce), Umbelliferae sp., Cruciferae sp., Chenopodiaceae sp., Cucurbitaceae sp. (e.g., cucumber), Alliaceae sp. (e.g., leek, onion), Papilionaceae sp. (e.g., peas); the main crop plants, such as Gramineae sp.(e.g., corn, peat, cereals such as wheat, rye, rice, barley, oats, millet, and triticale), Asteraceae sp. (e.g., sunflower), Brassicaceae sp. (e.g., white cabbage, red cabbage, broccoli, cauliflower, Brussels sprouts, pak choi, kohlrabi, radish and rapeseed, mustard, horseradish, and watercress), Fabaceae sp. (e.g., beans, peanuts), Papilionaceae sp. (e.g., soybeans), Solanaceae sp. (e.g., potatoes), Chenopodiaceae sp. (e.g., sugar beet, fodder beet, Swiss chard, beet); useful plants and ornamental plants for gardens and wooded areas; and genetically modified varieties of each of these plants.

[0246] In some preferred embodiments, wild plant species and plant cultivars, or those obtained by conventional organic cultivation methods, such as protoplast crossing or fusion, and also parts thereof, are treated in accordance with the methods of the invention. Petition 870250039092, dated 05 / 14 / 2025, page 109 / 383 102 / 178

[0247] In some other preferred embodiments, transgenic plants and plant cultivars obtained by genetic engineering methods, if appropriate, in combination with conventional methods (Genetically Modified Organisms) and parts thereof are treated according to the methods of the invention. More preferably, plants of plant cultivars that are commercially available or in use are treated according to the invention. Plant cultivars are understood to mean plants that have new properties (“traits”) and have been obtained by conventional cultivation, by mutagenesis or by recombinant DNA techniques. They may be cultivars, varieties, bio- or genotypes.

[0248] The methods according to the invention can be used in the treatment of genetically modified organisms (GMOs), for example, plants or seeds. Genetically modified plants (or transgenic plants) are plants in which a heterologous gene has been stably integrated into the genome. The expression “heterologous gene” essentially means a gene that is supplied or assembled outside the plant and when introduced into the nuclear, chloroplast or mitochondrial genome provides the transformed plant with new or improved agronomic or other properties by expressing a protein or polypeptide of interest or by downregulating or silencing other gene(s) that are present in the plant (using for example, antisense technology, co-suppression technology, RNA interference technology - RNAi or microRNA miRNA technology). A heterologous gene that is located in the genome is also called a transgene.A transgene that is defined by its particular location in the plant genome is called a transformation event or transgenic event.

[0249] Plants and plant cultivars that can be treated by the methods disclosed above include all plants that have genetic material that communicates useful traits, particularly advantageous to these plants (if obtained by cultivation and / or biotechnological means). Petition 870250039092, dated 05 / 14 / 2025, page 110 / 383 103 / 178

[0250] Plants and plant cultivars that can be treated by the methods disclosed above include plants and plant cultivars that are resistant to one or more biotic stresses, that is, said plants show improved defense against animal and microbial pests, such as nematodes, insects, mites, phytopathogenic fungi, bacteria, viruses and / or viroids.

[0251] Plants and plant cultivars that can be treated by the methods disclosed above include those plants that are resistant to one or more abiotic stresses. Abiotic stress conditions may include, for example, drought, exposure to cold temperature, exposure to heat, osmotic stress, flooding, increased soil salinity, increased exposure to minerals, exposure to ozone, high light exposure, limited availability of nitrogen nutrients, limited availability of phosphorus nutrients, shade avoidance.

[0252] Plants and plant cultivars that can be treated by the methods disclosed above include those plants characterized by increased yield characteristics. The increased yield in said plants may be the result of, for example, improved plant physiology, growth and development, such as water use efficiency, water retention efficiency, enhanced nitrogen use, enhanced carbon assimilation, enhanced photosynthesis, increased germination efficiency and accelerated maturation.Yield can also be affected by improved plant architecture (under stress and non-stress conditions), including, but not limited to, early flowering, flowering control for hybrid seed production, seedling vigor, plant size, number of internodes and spacing, root growth, seed size, fruit size, pod size, number of pods or ears, number of seeds per pod or ear, seed mass, improved seed filling, reduced seed dispersal, reduced pod dehiscence, and lodging resistance. Other yield characteristics include the composition of the... Petition 870250039092, dated 05 / 14 / 2025, page 111 / 383 104 / 178 seed, such as carbohydrate content and composition, for example, cottonseed or starch, protein content, oil content and composition, nutritional value, reduction of antinutritional compounds, improved processability and better storage stability.

[0253] Plants and plant cultivars that can be treated by the methods disclosed above include plants and plant cultivars that are hybrid plants that already express the heterosis or hybrid vigor trait that results in generally higher yield, vigor, health and resistance to biotic and abiotic stresses.

[0254] Plants and plant cultivars (obtained by plant biotechnology methods such as genetic engineering) that can be treated by the methods disclosed above include plants and plant cultivars that are herbicide-tolerant plants, that is, plants made tolerant to one or more given herbicides. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation that confers such herbicide tolerance.

[0255] Plants and plant cultivars (obtained by plant biotechnology methods such as genetic engineering) that can be treated by the methods disclosed above include plants and plant cultivars that are insect-resistant transgenic plants, that is, plants made resistant to attack by certain target insects. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation that confers such insect resistance.

[0256] Plants and plant cultivars (obtained by plant biotechnology methods such as genetic engineering) that can be treated by the methods disclosed above include plants and plant cultivars that are tolerant to abiotic stresses. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation that confers such stress resistance.

[0257] Plants and plant cultivars (obtained by plant biotechnology methods such as genetic engineering) that can be treated by the methods Petition 870250039092, dated 05 / 14 / 2025, page 112 / 383 105 / 178 disclosed above include plants and plant cultivars that show altered quantity, quality and / or storage stability of the harvested product and / or altered properties of specific ingredients of the harvested product.

[0258] Plants and plant cultivars (obtained by plant biotechnology methods such as genetic engineering) that can be treated by the methods disclosed above include plants and plant cultivars, such as cotton plants, with altered fiber characteristics. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation that confers such altered fiber characteristics.

[0259] Plants and plant cultivars (obtained by plant biotechnology methods such as genetic engineering) that can be treated by the methods disclosed above include plants and plant cultivars, such as rapeseed or related Brassica plants, with altered oil profile characteristics. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation that confers such altered oil profile characteristics.

[0260] Plants and plant cultivars (obtained by plant biotechnology methods such as genetic engineering) that can be treated by the methods disclosed above include plants and plant cultivars, such as rapeseed or related Brassica plants, with altered seed fragmentation characteristics. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation that confers such altered seed fragmentation characteristics and include plants such as rapeseed plants with delayed or reduced seed fragmentation.

[0261] Plants and plant cultivars (obtained by plant biotechnology methods such as genetic engineering) that can be treated by the methods disclosed above include plants and plant cultivars, such as tobacco plants, with altered post-translational protein modification patterns. Petition 870250039092, dated 05 / 14 / 2025, page 113 / 383 106 / 178 Pathogens and diseases

[0262] The methods disclosed above can be used to control microorganisms, in particular phytopathogenic microorganisms such as phytopathogenic fungi, which cause diseases such as: Diseases caused by powdery mildew pathogens, such as Blumeria species (e.g., Blumeria graminis), Podosphaera species (e.g., Podosphaera leucotricha), Sphaerotheca species (e.g., Sphaerotheca fuliginea), and Uncinula species (e.g., Uncinula necator); Diseases caused by rust pathogens, such as species of Gymnosporangium (e.g., Gymnosporangium sabinae), species of Hemileia (e.g., Hemileia vastatrix), species of Phakopsora (e.g., Phakopsora pachyrhizi or Phakopsora meibomiae), species of Puccinia (e.g., Puccinia recondita, Puccinia graminis or Puccinia striiformis), species of Uromyces (e.g., Uromyces appendiculatus); Diseases caused by pathogens from the Oomycetes group, such as Albugo species (e.g., Albugo candida), Bremia species (e.g., Bremia lactucae), Peronospora species (e.g., Peronospora pisi or P. brassicae), Phytoftora species (e.g., Phytoftora infestans), Plasmopara species (e.g., Plasmopara viticola), Pseudoperonospora species (e.g., Pseudoperonospora humuli or Pseudoperonospora cubensis), and Pythium species (e.g., Pythium ultimum); Leaf spot and leaf wilt caused, for example, by Alternaria species (e.g., Alternaria solani), Cercospora species (e.g., Cercospora beticola), Cladiosporium species (e.g., Cladiosporium cucumerinum), Cochliobolus species (e.g., Cochliobolus sativus (conidial form: Drechslera, syn: Helminthosporium) or Cochliobolus miyabeanus), Colletotrichum species (e.g., Colletotrichum lindemuthanium), species of Petition 870250039092, dated 05 / 14 / 2025, p. 114 / 383 107 / 178 Cycloconium (e.g., Cycloconium oleaginum), Diaporthe species (e.g., Diaporthe citri), Elsinoe species (e.g., Elsinoe fawcettii), Gloeosporium species (e.g., Gloeosporium laeticolor), Glomerella species (e.g., Glomerella cingulate), Guignardia species (e.g., Guignardia bidwelli), Leptosphaeria species (e.g., Leptosphaeria maculans), Magnaporthe species (e.g., Magnaporthe grisea), Microdochium species (e.g., Microdochium nivale), Mycosphaerella species (e.g., Mycosphaerella graminicola, Mycosphaerella arachidicola, or Mycosphaerella fijiensis), Phaeosphaeria species (e.g., Phaeosphaeria nodorum), Pirenophora species (e.g., Pirenophora teres or Pirenophora tritici). repentis), Ramularia species (e.g., Ramularia collo-cygni or Ramularia areola), Rhinchosporium species (e.g., Rhinchosporium secalis), Septoria species (e.g.,Septoria apii or Septoria lycopersici), Stagonospora species (e.g., Stagonospora nodorum), Typhula species (e.g., Typhula incarnate), Venturia species (e.g., Venturia inaequalis), root or stem diseases caused, for example, by Corticium species (e.g., Corticium graminaarum), Fusarium species (e.g., Fusarium oxisporum), Gaeumannomyces species (e.g., Gaeumannomyces graminis), Plasmodiophora species (e.g., Plasmodiophora brassicae), Rhizoctonia species (e.g., Rhizoctonia solani), Sarocladium species (e.g., Sarocladium oryzae), Sclerotium species (e.g., Sclerotium oryzae), Tapesia species (e.g., Tapesia acuformis), Tielaviopsis species (e.g., Tielaviopsis basicola); Diseases of the ear and panicle (including corn ears) caused, for example, by Alternaria species (e.g., Alternaria spp.), Aspergillus species (e.g., Aspergillus flavus), Cladosporium species (e.g., Petition 870250039092, dated 05 / 14 / 2025, page 115 / 383 108 / 178 Cladosporium cladosporioides, Claviceps species (e.g., Claviceps purpureia), Fusarium species (e.g., Fusarium culmorum), Gibberella species (e.g., Gibberella zeae), Monographella species (e.g., Monographella species), Stagnospora species (e.g., Stagnospora nodorum); Diseases caused by sows, for example species of Sphacelotheca (e.g., Sphacelotheca reiliana), species of Tilletia (e.g., Tilletia caries or Tilletia controversa), species of Urocystis (e.g., Urocystis occulta), species of Ustilago (e.g., Ustilago nuda); Fruit rot caused, for example, by Aspergillus species (e.g., Aspergillus flavus), Botrytis species (e.g., Botrytis cinerea), Penicillium species (e.g., Penicillium expansum or Penicillium purpurogenum), Rhizopus species (e.g., Rhizopus stolonifer), Sclerotinia species (e.g., Sclerotinia sclerotiorum), Verticillium species (e.g., Verticillium alboatrum); Seed and soil-borne rot and wilt, as well as seedling diseases, caused, for example, by Alternaria species (e.g., Alternaria brassicicola), Aphanomyces species (e.g., Aphanomyces euteiches), Ascochyta species (e.g., Ascochyta lentis), Aspergillus species (e.g., Aspergillus flavus), Cladosporium species (e.g., Cladosporium herbarum), Cochliobolus species (e.g., Cochliobolus sativus (conidial form: Drechslera, Bipolaris Syn: Helminthosporium)), Colletotrichum species (e.g., Colletotrichum coccodes), Fusarium species (e.g., Fusarium culmorum), Gibberella species (e.g., Gibberella zeae), Macrophomina species (e.g., Macrophomina phaseolina), Microdochium species (e.g., Microdochium nivale), species of Monographella (e.g. Monographella nivalis), Penicillium species (e.g. Penicillium Petition 870250039092, dated 05 / 14 / 2025, page 116 / 383 109 / 178 expansum), Phoma species (e.g., Phoma lingam), Phomopsis species (e.g., Phomopsis sojae), Phytoftora species (e.g., Phytoftora cactorum), Pirenophora species (e.g., Pirenophora graminaa), Piricularia species (e.g., Piricularia oryzae), Pythium species (e.g., Pythium ultimum), Rhizoctonia species (e.g., Rhizoctonia solani), Rhizopus species (e.g., Rhizopus oryzae), Sclerotium species (e.g., Sclerotium rolfsii), Septoria species (e.g., Septoria nodorum), Typhula species (e.g., Typhula incarnate), Verticillium species (e.g., Verticillium dahlia); Cancers, galls, and witches' brooms caused, for example, by species of Nectria (e.g., Nectria galligena); Wilt diseases caused, for example, by Monilinia species (e.g., Monilinia laxa); Deformations of leaves, flowers and fruits caused, for example, by Exobasidium species (e.g., Exobasidium vexans), Taphrina species (e.g., Taphrina deformans); Degenerative diseases in woody plants, caused, for example, by species of Esca (e.g., Phaeomoniella chlamydospora, Phaeoacremonium aleophilum or Fomitiporia mediterranean) and species of Ganoderma (e.g., Ganoderma boninense); Diseases of flowers and seeds caused, for example, by species of Botrytis (e.g., Botrytis cinerea); Tuber diseases caused, for example, by Rhizoctonia species (e.g., Rhizoctonia solani), Helminthosporium species (e.g., Helminthosporium solani); Diseases caused by bacterial pathogens, for example, Xanthomonas species (e.g., Xanthomonas campestris pv. oryzae), species of Petition 870250039092, dated 05 / 14 / 2025, page 117 / 383 110 / 178 Pseudomonas (e.g., Pseudomonas syringae pv. Lachrymans) and Erwinia species (e.g., Erwinia amylovora).

[0263] In particular, compounds of formula (I) and compositions comprising them are effective in controlling phytopathogenic fungi that cause rust diseases. Seed Treatment

[0264] The method for controlling unwanted microorganisms can be used to protect seeds from phytopathogenic microorganisms, such as fungi.

[0265] The term “seed(s)” as used in the present invention includes dormant seed, prepared seed, pre-germinated seed and seed with emerged roots and leaves.

[0266] Thus, the present invention also relates to a method for protecting seeds and / or crops from unwanted microorganisms, such as bacteria or fungi, comprising the step of treating the seeds with one or more compounds of formula (I) or a composition comprising the same. Treating the seeds with the compound(s) of formula (I) or a composition comprising the same not only protects the seeds from phytopathogenic microorganisms, but also the germinating plants, the emerged seedlings and the plants after emergence.

[0267] Seed treatment can be carried out before sowing, at the time of sowing or immediately after.

[0268] When seed treatment is carried out before sowing (for example, so-called seed applications), the seed treatment may be carried out as follows: the seeds may be placed in a mixer with a desired quantity of compound(s) of formula (I) or a composition comprising the same (as such or after dilution), the seeds and the compound(s) of formula (I) or the composition comprising the Petition 870250039092, dated 05 / 14 / 2025, page 118 / 383 111 / 178 The same are mixed until a homogeneous distribution over the seeds is achieved. If appropriate, the seeds can then be dried.

[0269] The invention also relates to seeds treated with one or more compounds of formula (I) or a composition comprising the same. As stated before, the use of treated seeds allows not only to protect the seeds before and after sowing from unwanted microorganisms, such as phytopathogenic fungi, but also to protect the germinating plants and young seedlings that emerge from said treated seeds. A large part of the damage to crop plants caused by harmful organisms is caused by seed infection before sowing or after plant germination. This phase is particularly critical since the roots and shoots of the cultivated plant are particularly sensitive and even small damage can result in the death of the plant.

[0270] Therefore, the present invention also relates to a method for protecting seeds, germinating plants and emerged seedlings, more generally to a method for protecting the crop from phytopathogenic microorganisms, comprising the step of using seeds treated with one or more compounds of formula (I) or a composition comprising the same.

[0271] Preferably, the seed is treated in a state where it is sufficiently stable so that no damage occurs during the course of treatment. In general, seeds can be treated at any time between harvest and immediately after sowing. It is common to use seeds separated from the plant and freed from the ears, husks, stems, skins, hairs or fruit pulp. For example, it is possible to use harvested, cleaned and dried seeds with a moisture content of less than 15% by weight. Alternatively, it is also possible to use seeds that, after drying, for example, have been treated with water and then dried again, or seeds immediately after preparation, or seeds stored under prepared conditions, or pre-germinated seeds, or seeds sown in a nursery. Petition 870250039092, dated 05 / 14 / 2025, p. 119 / 383 112 / 178 trays, tapes or paper.

[0272] The amount of compound(s) of formula (I) or composition comprising the same applied to the seed is typically such that seed germination is not impaired, or the resulting plant is not damaged. This must be ensured especially in the case where the active ingredients exhibit phytotoxic effects at certain application rates. The intrinsic phenotypes of transgenic plants must also be taken into consideration when determining the amount of compound(s) of formula (I) or composition comprising the same to be applied to the seed in order to achieve optimal seed and germinating plant protection with a minimum amount of compound(s) of formula (I) or composition comprising the same being used.

[0273] As indicated above, the compounds of formula (I) can be applied as such directly to the seeds, i.e., without the use of any other components and without dilution, or a composition comprising the compounds of formula (I) can be applied. Preferably, the compositions are applied to the seed in any suitable form. Examples of suitable formulations include solutions, emulsions, suspensions, powders, foams, fluid pastes or combined with other seed coating compositions, such as film-forming materials, pelleting materials, fine iron or other metallic powders, granules, inactivated seed coating material and also ULV formulations. The formulations may be ready-to-use formulations or may be concentrates that need to be diluted before use.

[0274] These formulations are prepared in a known manner, for example by mixing the active ingredient or a mixture thereof with usual additives, for example extenders and solvents or diluents, colorants, wetting agents, dispersants, emulsifiers, antifoaming agents, preservatives, secondary thickeners, adhesives, gibberellins and also usual water. Petition 870250039092, dated 05 / 14 / 2025, page 120 / 383 113 / 178

[0275] These formulations are prepared in a known manner by mixing the active ingredients or combinations of active ingredients with usual additives, for example extenders and solvents or diluents, colorants, wetting agents, dispersants, emulsifiers, antifoaming agents, preservatives, secondary thickeners, adhesives, gibberellins and also usual water.

[0276] Useful colorants that may be present in seed treatment formulations are all the usual colorants for such purposes. It is possible to use pigments, which are moderately soluble in water, or colorants, which are soluble in water. Examples include the colorants known by the names Rhodamine B, CI Pigment Red 112 and CI Solvent Red 1. Useful wetting agents that may be present in seed treatment formulations are all substances that promote wetting and that are conventionally used for the formulation of agrochemical active ingredients. Alkyl naphthalene sulfonates, such as diisopropyl- or diisobutyl naphthalene sulfonates, are preferably used. Useful dispersants and / or emulsifiers that may be present in seed treatment formulations are all the non-ionic, anionic and cationic dispersants conventionally used for the formulation of agrochemical active ingredients.Nonionic or anionic dispersants, or mixtures of nonionic or anionic dispersants, are preferable. Useful nonionic dispersants include especially ethylene oxide / propylene oxide block polymers, alkylphenol polyglycol ethers and tristerilphenol polyglycol ether and their phosphate or sulfate derivatives. Suitable anionic dispersants are especially lignosulfonates, polyacrylic acid salts and arylsulfonate / formaldehyde condensates. Antifoaming agents that may be present in seed treatment formulations are all foam-inhibiting substances conventionally used for the formulation of agrochemical active ingredients. Silicone and magnesium stearate antifoaming agents may be used. Petition 870250039092, dated 05 / 14 / 2025, page 121 / 383 114 / 178 used preferably. The preservatives that may be present in seed treatment formulations are all substances usable for such purposes in agrochemical compositions. Examples include dichlorophene and hemiformal benzyl alcohol. The secondary thickeners that may be present in seed treatment formulations are all substances usable for such purposes in agrochemical compositions. Preferred examples include cellulose derivatives, acrylic acid derivatives, xanthan gum, modified clays, and finely divided silica. The adhesives that may be present in seed treatment formulations are all the usual binders usable in seed treatment products. Preferred examples include polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol, and tylose.

[0277] The compounds of formula (I) and compositions comprising them are suitable for protecting the seeds of any variety of plant used in agriculture, in greenhouses, in forests or in horticulture. More particularly, the seed is that of cereals (such as wheat, barley, rye, millet, triticale and oats), rapeseed, maize, cotton, soybean, rice, potato, sunflower, beans, coffee, peas, beet (for example sugar beet and fodder beet), peanuts, vegetables (such as tomato, cucumber, onion and lettuce), lawns and ornamental plants. Of particular importance is the treatment of seeds of wheat, soybean, rapeseed, maize and rice.

[0278] The compounds of formula (I) or compositions comprising them can be used to treat transgenic seeds, in particular seeds of plants capable of expressing a protein that acts against pests, herbicide damage or abiotic stress, thereby increasing the protective effect. Synergistic effects may also occur in interaction with the substances formed by expression. Application Petition 870250039092, dated 05 / 14 / 2025, page 122 / 383 115 / 178

[0279] The compound of formula (I) can be applied as such, or for example in the form of ready-to-use solutions, emulsions, water- or oil-based suspensions, powders, wettable powders, pastes, soluble powders, dusts, soluble granules, dispersion granules, suspoemulsion concentrates, natural products impregnated with the compound of formula (I), synthetic substances impregnated with the compound of formula (I), fertilizers or microencapsulations in polymeric substances.

[0280] The application is carried out in a conventional manner, for example by irrigation, spraying, atomizing, dispersing, powdering, foaming, spreading and the like. It is also possible to apply the compound of formula (I) by the ultra-low volume method, by means of a drip irrigation system or application by watering, to apply it in the furrow or inject it into the stem or trunk of the soil. It is also possible to apply the compound of formula (I) by means of a wound dressing, ink or other wound dressing.

[0281] The effective and plant-compatible amount of the compound of formula (I) that is applied to plants, plant parts, fruits, seeds or soil will depend on several factors, such as the compound / composition used, the individual being treated (plant, plant part, fruit, seed or soil), the type of treatment (powdering, spraying, seed treatment), the purpose of the treatment (curative and protective), the type of microorganisms, the stage of development of the microorganisms, the sensitivity of the microorganisms, the stage of growth of the crop and the environmental conditions.

[0282] When the compound of formula (I) is used as a fungicide, application rates can vary within a relatively wide range, depending on the type of application. For the treatment of plant parts, such as leaves, the application rate can vary from 0.1 to 10,000 g / ha, preferably from 10 to 1,000 g / ha, more preferably from 50 to 300 g / ha (in the case of application by irrigation or drip irrigation, it is still possible to reduce the application rate, especially when inert substrates Petition 870250039092, dated 05 / 14 / 2025, p. 123 / 383 116 / 178 such as rock wool or perlite are used). For seed treatment, the application rate can vary from 0.1 to 200 g per 100 kg of seeds, preferably from 1 to 150 g per 100 kg of seeds, more preferably from 2.5 to 25 g per 100 kg of seeds, even more preferably from 2.5 to 12.5 g per 100 kg of seeds. For soil treatment, the application rate can vary from 0.1 to 10,000 g / ha, preferably from 1 to 5,000 g / ha.

[0283] These application rates are merely exemplary and are not intended to limit the scope of the present invention. Materials Protection

[0284] The compound and composition of the invention can also be used in the protection of materials, especially for the protection of industrial materials against attack and destruction by unwanted microorganisms.

[0285] In addition, the compound and composition of the invention can be used as anti-fouling compositions, alone or in combination with other active ingredients.

[0286] Industrial materials in the present context are understood to mean inanimate materials that have been prepared for use in industry. For example, industrial materials that must be protected from microbial alteration or destruction may include adhesives, glues, paper, wallpaper and cardboard / paperboard, textiles, carpets, leather, wood, fibers and fabrics, paints and plastic articles, refrigeration lubricants and other materials that may be infected or destroyed by microorganisms. Parts of production facilities and buildings, for example, cooling water circuits, cooling and heating systems and ventilation and air conditioning units, which may be damaged by the proliferation of microorganisms, may also be mentioned within the scope of the materials to be protected. Industrial materials within the scope of the present invention preferably include adhesives, sizes, paper and cardboard, leather, Petition 870250039092, dated 05 / 14 / 2025, page 124 / 383 117 / 178 wood, paints, cooling lubricants and heat transfer fluids, more preferably wood.

[0287] The compound and composition of the invention can prevent adverse effects such as rotting, decomposition, discoloration or mold formation.

[0288] In the case of wood treatment, the compound and composition of the invention can also be used against fungal diseases likely to grow on or within the wood.

[0289] Wood means all types of wood species and all types of wood products intended for construction, for example, solid wood, high-density wood, laminated wood and plywood. In addition, the compound and composition of the invention can be used to protect objects that come into contact with salt or brackish water, especially hulls, screens, nets, buildings, moorings and signaling systems, from fouling.

[0290] The compound and composition of the invention can also be used to protect storage products. Storage products are understood to mean natural substances of plant or animal origin or processed products thereof that are of natural origin and for which long-term protection is desired. Storage products of plant origin, for example plants or plant parts such as stems, leaves, tubers, seeds, fruits, grains, can be protected freshly harvested or after processing by (pre)drying, wetting, crushing, grinding, pressing or roasting. Storage goods also include unprocessed wood, such as construction timber, poles and electricity barriers, or in the form of finished products such as furniture. Storage products of animal origin are, for example, hides, leather, fur and hair.The compound and composition of the invention can prevent adverse effects such as rotting and decomposition. Petition 870250039092, dated 05 / 14 / 2025, page 125 / 383 118 / 178 discoloration or mold formation.

[0291] Microorganisms capable of degrading or altering industrial materials include, for example, bacteria, fungi, yeasts, algae, and slime molds. The compound and composition of the invention preferably act against fungi, especially molds, wood-decolorizing and wood-destroying fungi (Ascomycetes, Basidiomycetes, Deuteromycetes, and Zygomycetes), and against slime molds and algae. Examples include microorganisms of the following genera: Alternaria, such as Alternaria tenuis; Aspergillus, such as Aspergillus niger; Chaetomium, such as Chaetomium globosum; Coniophora, such as Coniophora puetana; Lentinus, such as Lentinus tigrinus; Penicillium, such as Penicillium glaucum; Polyporus, such as Polyporus versicolor; Aureobasidium, such as Aureobasidium pullulans; Sclerophoma, such as Sclerophoma pityophila; Trichoderma, such as Trichoderma viride; Ophiostoma spp., Ceratocystis spp., Humicola spp., Petriella spp., Trichurus spp., Coriolus spp., Gloeophyllum spp., Pleurotus spp., Poria spp., Serpula spp. and Tyromyces spp., Cladosporium spp., Paecilomyces spp. Mucor spp., Escherichia, such as Escherichia coli; Pseudomonas, such as Pseudomonas aeruginosa; Staphylococcus, such as Staphylococcus aureus, Candida spp. and Saccharomyces spp., such as Saccharomyces cerevisae.

[0292] Aspects of the present teaching can be further understood in the light of the following examples, which should not be interpreted as limiting the scope of the present teaching in any way. EXAMPLES General Measurement of LogP values

[0293] The measurement of LogP values ​​as provided in the present invention was carried out in accordance with EEC Directive 79 / 831 Annex V. A8 by HPLC (High Performance Liquid Chromatography) on reversed-phase columns with the Petition 870250039092, dated 05 / 14 / 2025, p. 126 / 383 119 / 178 following methods: [a]The LogP value is determined by LC-UV measurement, in an acidic range, with 0.1% formic acid in water and acetonitrile as eluent (linear gradient from 10% acetonitrile to 95% acetonitrile). [b]The LogP value is determined by LC-UV measurement, in a neutral range, with a 0.001 molar ammonium acetate solution in water and acetonitrile as eluent (linear gradient from 10% acetonitrile to 95% acetonitrile). [c]The LogP value is determined by LC-UV measurement, in an acidic range, with 0.1% phosphoric acid and acetonitrile as eluent (linear gradient from 10% acetonitrile to 95% acetonitrile).

[0294] If more than one LogP value is available within the same method, all values ​​are provided and separated by “+”.

[0295] Calibration was performed with straight-chain alkanones (with 3 to 16 carbon atoms) with known LogP values ​​(measurement of LogP values ​​using retention times with linear interpolation between successive alkanones). Lambda-max values ​​were determined using UV spectra from 200 nm to 400 nm and the peak values ​​of the chromatographic signals. 1H NMR data

[0296] The 1H NMR data from selected examples as provided in the present invention are written in the form of a 1H NMR peak list. For each signal peak, the δ value in ppm and the signal intensity are listed in parentheses. Semicolons are used as delimiters between pairs of signal intensity and δ values.

[0297] The peak list of an example, therefore, has the form: δ1 (intensity1); δ2 (intensity2);........; δί (intensityi);......; δn (intensity)

[0298] The intensity of sharp signals correlates with the height of the signals in a printed example of an NMR spectrum in cm and shows the actual relationships. Petition 870250039092, dated 05 / 14 / 2025, page 127 / 383 120 / 178 signal intensities. From broad signals, various peaks or mid-signals and their relative intensity compared to the most intense signal in the spectrum can be shown.

[0299] To calibrate the chemical shift for 1H spectra, we use tetramethylsilane and / or the chemical shift of the solvent used, especially in the case of spectra measured in DMSO. Therefore, in the NMR peak lists, the tetramethylsilane peak may occur, but not necessarily.

[0300] 1H NMR peak lists are similar to classic 1H NMR printouts and therefore usually contain all the peaks that are listed in the classic NMR interpretation.

[0301] Additionally, they may show signs of classic 1H NMR fingerprints of solvents, stereoisomers of the target compounds, which are also the subject of the invention, and / or impurity peaks.

[0302] To show the compound signals in the delta range of solvents and / or water the usual solvent peaks, for example DMSO peaks in DMSO-D6 and the water peak are shown in our 1H NMR peak list and usually have on average a high intensity.

[0303] The stereoisomer peaks of the target compounds and / or impurity peaks usually have on average a lower intensity than the peaks of the target compounds (e.g. with a purity >90%).

[0304] Such stereoisomers and / or impurities may be typical for the specific preparation process. Therefore, their peaks can help to recognize the reproduction of our preparation process through “byproduct fingerprints”.

[0305] An expert, who calculates the peaks of the target compounds using known methods (MasterC, ACD simulation, but also with empirically evaluated expectation values) can isolate the peaks of the target compounds. Petition 870250039092, dated 05 / 14 / 2025, page 128 / 383 121 / 178 as needed, optionally using additional intensity filters. This isolation would be similar to the relevant peak in the classical 1H NMR interpretation.

[0306] Further details on the description of NMR data with peak lists can be found in the publication “Citation of NMR Peaklist Data in Patent Applications” from the Research Disclosure Database Number 564025.

[0307] The following examples illustrate, in a non-limiting manner, the preparation and biological activity of the compounds of formula (I) according to the invention. Synthesis of compounds of formula (I) and intermediates

[0308] Table 1 illustrates, in a non-limiting manner, examples of compounds of formula (I) according to the invention: (I)

[0309] The compounds of formula (I) mentioned in Table 1 below were prepared in accordance with the procedures detailed below in relation to specific examples and with the general description of the processes in the present invention disclosed.

[0310] In Table 1, the values ​​of logP were determined according to method[a]. Petition 870250039092, dated 05 / 14 / 2025, page 129 / 383 Table 1: Example i XY (F)m R1 R2 (L)n A Mass (M+H) logP 1.001 FH - HH - 1 H-imidazole-1 -yl 312 0.90 I.002 FH - HH - 1 H-pyrazol-1 -yl 312 2.16 I.003 FH - H- H 312 2.00 I.004 FH - HH - 1,2-oxazol-4-yl 313 2.41 I.005 FH - HH - cyclopentyl 4.40 I.006 FH - HH - phenyl 322 4.15 I.007 FH - HH - pyride - HH - 1,25 I. - pyrimidine-2-yl 2.03 I.009 FH - HH - pyrazine-2-yl 2.11 1.010 FH - HH - pyrimidine-5-yl 324 1.92 1.011 FH - HH - 1 -methyl-1 H-pyrrol-2-yl 325 3.1016 FH - H - 12 -methyl-1 H-pyrazol-5-yl 326 2.19 122 / 178 Petition 870250039092, of 14 / 05 / 2025, p. 130 / 383 Example XY (F)m R1 R2 (L)n A Mass (M+H) logP 1.013 FH - HH - 4-methyl-1 H-pyrazol-1 -yl 326 2.41 1.014 FH - HH - 3-m ethyl 1-1,2-oxazol-5-yl 325 125 FH HH - 2-thienyl 328 3.42 1.016 FH - HH - cyclohexyl 328 5.34 1.017 FH - HH - 1,3-thiazol-5-yl 329 2..39 1.018 FH - OH H - cyclopentyl 3.83 CH = 1.29 FH= - phenyl 334 3.94 I.020 FH - C= =0 - phenyl 3.02 1.021 FH - HH - 4-methylphenyl 336 4.53 I.022 FH - Me H - phenyl 336 3.83 I.023 FH - OH H - phenyl 338 I - 24 I. 2-OXO-1,2-d ih hydropyride in-3-i I 339 1.90 I.025 FH - HH - 4-fluorophenyl 340 4.17 123 / 178 Petition 870250039092, of 14 / 05 / 2025, p. 131 / 383 Example XY (F)m R1 R2 (L)n A Mass (M+H) logP I.026 FH - HH - 1 -ethyl-1 H-pyrazol-5-yl 340 2.46 I.027 FH - HH - 3-fluoropyridin-4-yl 341 2.46 I. FH - HH - 028 2-fluoropyridin-3-yl 341 2.70 I.029 FH - HH - 2-fluoropyridin-4-yl 341 2.71 I.030 FH - HH - 6-fluoropyridin-3-yl 341 2.75 1.031 FH - HH - 3-1-4-ylzol 341 2.68 I.032 FH - OH H - cyclohexyl 344 3.22 I.033 FH - OH H - tetra-hydro-2H-pyran-4-yl 344(D 1.92 I.034 FH - HH - 2-chloro-1H-imidazol-15 I. 5-cyanopyridin-3-yl 348 2.45 I.036 FH - C=NOH - phenyl 2.69 I.037 FH - HH - 2-methoxyphenyl 352 3.70 I.038 FH - OH H - 2-methylphenyl 352 2.83 124 / 178 Petition 870250039092, of 14 / 05 / 2025, p. 132 / 383 Example XY (F)m R1 R2 (L)n A Mass (M+H) logP I.039 FH - HH - 5-cyclopropyl-1 H-pyrazol-1-yl 352 2.70 I.040 FH - HH - 3-cyclopropyl-1 H-pyrazol-1-yl 2.045 FH - 345 FH - 1 -cyclopropyl-1 H-pyrazol-5-yl 352 2.57 I.042 FH - HH - 4-methoxypyridin-3-yl 353 1.37 I.043 FH - HH - 6-methoxypyridin-2-yl 353 3.19 I. 04 FH - HH -4 2-methoxypyridine-3-yl 353 3.12 I.045 FH - HH - 2-methoxypyridine~4-yl 353 2.75 I.046 FH - HH - 3-methoxypyridine~4-yl 353 1.54 I.047 FH - H-H-3-35-yl 2.87 I.048 FH - HH - 2-(methylamino)pyrimidin-5-yl 353 1.87 I.049 FH - HH - 5-cyano-2-thienyl 353 3.11 I.050 FH - C=O - 4-fluorophenyl nonhum ionization 3.25 125 / 178 Petition 870250039092, of 14 / 05 / 2025, p. 133 / 383 Example XY (F)m R1 R2 (L)n A Mass (M+H) logP 1.051 FH - HH - 1 -propyl-1 H-pyrazol-5-yl 354 2.72 I.052 FH - HH - 4-carboxy-1 H-pyrazol-1 -yl 356 I. 4-fluorophenyl 356 2.70 I.054 FH - HH - 5-form yl-2-thienyl 356 2.80 I.055 FH - HH - 4-chlorophenyl 356 4.53 I.056 FH - HH - 2,4-dimethyl-1,3-3-35-yl I.057 FH - HH - 2,4-difluorophenyl 358 4.29 I.058 FH - HH - 2,3-difluoropyridin-4-yl 359 3.01 I.059 FH - HH - 2,6-difluoropyridin-3-yl 359 3.2 I.02 FH - HH - 2,6-difluoropyridin-4-yl 359 3.17 1.061 FH - HH - 2-chloro-1 -methyl-1 H-imidazole-5-yl 360 2.07 I.062 FH - HH - 4-isopropyl pyrimidine-5-yl 366 I, 2061 FH - HH - 2.07 4,5,6,7-tetra-hydropyrazolo[1,5-a]pyridin-3-yl 366 2.56 126 / 178 Petition 870250039092, of 14 / 05 / 2025, p. 134 / 383 Example XY (F)m R1 R2 (L)n A Mass (M+H) logP I.064 FH - HH - 1 -isobut i 1-1 H-pyrazol-5-yl 368 3.03 I.065 FH - HH - 5-acetyl-2-thienyl 370 2.89 I. FH - = C = 60 4-chlorophenyl nonhum ionization 0 3.64 I.067 FH - C= =0 - 3,5-difluorophenyl nonhum ionization 0 3..44 I.068 FH - OH H - 4-chlorophenyl 372 3.03 I.069 FH - OH - difluorophenyl -374 2.86 I.070 FH - HH - 1 -methyl-1 H-indol-3-yl 375 3.91 1.071 FH - HH - 1 -cyclopente 1-1 H-pyrazol-4-i I 380 3.21 I.072 FH - HH - 4-(eto-yl-carbon-1) 384 2.64 I.073 FH - HH - 1 -phenyl-1 H-pyrazol-5-yl 388 3.00 I.074 FH - HH - 2,6-dichlorophenyl 390 4.82 I.075 FH - HH - 2,3-dichloropyridine-4-31,391 127 / 178 Petition 870250039092, of 14 / 05 / 2025, p. 135 / 383 Example XY (F)m R1 R2 (L)n A Mass (M+H) logP I.076 FH - HH - 2,5-dichloropyridin-4-yl 391 3.48 I.077 FH - HH - 2-(trifluoromethyl)pinm idin-5-yl 392 I. -(2,2,2-trifluoroethyl)- 1 H-pyrazol-5-yl 394 2.80 I.079 FH - HH - 4-(cyclopropylcarbamoyl)1 H-pyrazol-1-yl 395 1.89 I.080 FH - HH - 2,3-di-hydro-1-4-H-benzoyl 394 1.495 3.94 1.081 F Ac - OH H - 4-fluorophenyl 380(2) 3,.37 I.082 FH - HH - 1 -(2-ethoxy-2-oxoethyl)- 1 H-pyrazol-4-yl 398 2.59 I.083 FH - H - 1 H-pyrl - 1 H-pyrl-3 401 4.15 I.084 FH - HH - 1 -benzyl-1 H-pyrazol-5-i I 402 3.13 I.085 FH - HH - 5-m ethyl l-3-phenyl-1,2-oxazol-4-yl 403 3.45 I.086 FH - HH - 3.5-Hdiclophenyl 3.53 I.087 FH - HH - 1 -(2-thiene Im ethyl l)-1 H-pyrazol-4-yl 408 3.01 I.088 FH - HH - 1,2,3,4-tetra-h i dro-9 H -carbazo I9-yl 415 4.69 128 / 178 Petition 870250039092, of 14 / 05 / 2025, p. 136 / 383 Example XY (F)m R1 R2 (L)n A Mass (M+H) logP I.089 FH - HH - 1 -(2-fluorobenzyl)-1 H-pyrazol-3yl 420 3.34 I.090 F Ac - OAc H - phenyl 362(3) 3.98 FH - H - 1.091 4-(4-chlorophenyl)-1 H-pyrazol-1 -yl 422 3.56 I.092 FH - HH - 4-(phenylcarbamoyl)-1 H-pyrazol-1 yl 431 2.54 I.093 F SiMe2tBu - HH - pyrazine-2-yl 5.3 I. 10H-phenothiazin-10-yl 443 4..55 I.095 F SiMe2tBu - HH - 2-chloro-1 H-imidazol-1-yl 5.26 I.096 FH - HH - 2-chloro-5.5-dioxide- 10H-phenothiazin-10-yl 3.59.59. FH - C= =0 CH2 phenyl 3.13 I.098 FH - OH H ch2 phenyl 2.68 I.099 FH - HH s phenyl 3.63 1.100 FH - HH NH 4-fluorophenyl 355 3.11 1.101 FH - C=NOH 2.27 phenyl isomer (8 129 / 178 Petition 870250039092, of 14 / 05 / 2025, p. 137 / 383 Example XY (F)m R1 R2 (L)n A Mass (M+H) logP ) 1.102 FH - C=NOH ch2 phenyl 2.65 isomer2(5 ) 1.103 FH - HH so phenyl 2.29 1.104 FH - HH NH 4-chlorophenyl - 1.67 113 FH. HH NH 3-chlorophenyl 371 3.67 1.106 FH - HH NH 2-chlorophenyl 371 3.77 1.107 FH - HHS(=O)(=NH) phenyl 2.04 1.108 FH - C=O ch2 2,4-difluorophenyl -H so2 phenyl 2.52 1.110 FH - OH H ch2 2,4-difluorophenyl 2.87 1.111 FH - C=NOH ch2 2,4-difluorophenyl 2.94 isomer1(4 ) 1.112 FH - C=NOH ch2 2,4-difluorophenyl isomer 2.28<5 130 / 178 Petition 870250039092, of 14 / 05 / 2025, p. 138 / 383 Example XY (F)m R1 R2 (L)n A Mass (M+H) logP ) 1.113 F SiMe2tBu - HHS phenyl 6.79 1.114 F SiMe2tBu - HH SO phenyl 5.24 1.115 F SiMe2tBu - HHS(=O)(=NH)178 F.16. SiMe2tBu - HH CO2 phenyl 5.38 1.117 F SiMe2tBu - HHS(=N-CN) phenyl 4.83 131 / 178 Note: Me: methyl; tBu: terc-butyl; Ac: acetyl Note(1): MH ion; Note(2): M+H-H2O ion; Note(3): M+H-AcOH ion; Note (4): first elution isomer by normal phase chromatography on silica gel; Note (5): second elution isomer by normal phase chromatography on silica gel Petition 870250039092, dated 05 / 14 / 2025, page 139 / 383 132 / 178 Table 2 provides the 1H NMR data for a selected number of compounds from Table 1. Table 2: NMR peak list 1.001: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.6827 (0.8); 7.7876 (3.2); 7.7386 (3.6); 7.7109 (4.2); 7.3680 (3.8); 7.3403 (3.2); 7.2178 (2.2); 7.2141 (3.5); 7.2103 (2.0); 6.9387 (3.4); 5.2757 (7.1); 3.9630 (1.5); 3.9010 (2.0); 3.5827 (1.3); 3.5204 (1.0); 3.3505 (16.0); 2.9105 (1.4); 2.7517 (1.1); 2.5339 (2.8); 2.5280 (5.7); 2.5220 (7.7); 2.5159 (5.6); 2.5100 (2.6); 0.0310 (0.4); 0.0201 (10.5); 0.0092 (0.4) 1,002: de1H NMR (300.2 MHz, d6-DMSO): δ= 7.8772 (0.4); 7.8697 (0.4); 7.7141 (0.6); 7.6866 (0.6); 7.5047 (0.4); 7.4987 (0.4); 7.3104 (0.6); 7.2832 (0.5); 6.3110 (0.5); 5.4161 (1.2); 3.3474 (16.0); 2.5340 (1.7); 2.5281 (3.7); 2.5221 (5.0); 2.5160 (3.6); 2.5103 (1.7); 0.0204 (6.7) 1,003: de1H NMR (300.2 MHz, d6-DMSO): δ= 12.6380 (0.9); 8.6375 (1.4); 7.6625 (9.3); 7.6348 (11.3); 7.5566 (0.9); 7.3491 (10.6); 7.3213 (8.7); 3.9487 (4.0); 3.8869 (5.6); 3.8513 (16.0); 3.5666 (3.3); 3.5079 (2.4); 3.5045 (2.5); 3.3532 (12.1); 2.9107 (2.3); 2.7521 (1.9); 2.7503 (1.8); 2.5619 (0.9); 2.5346 (5.6); 2.5286 (12.0); 2.5225 (16.7); 2.5164 (12.0); 2.5104 (5.6); 0.0313 (0.5); 0.0205 (15.2); 0.0096 (0.5) I.004: de1H NMR (300.2 MHz, CDCla): δ= 8.2352 (8.8); 8.1605 (11.2); 7.6531 (8.2); 7.6257 (9.4); 7.2974 (10.1); 7.2694 (7.3); 3.8917 (16.0); 3.7706 (3.5); 3.7111 (6.3); 3.5748 (4.2); 3.5153 (2.3); 0.0346 _(220)___________________________________________________________________________________________ Petition 870250039092, dated 05 / 14 / 2025, p. 140 / 383 133 / 178 1.005: 1H NMR (400.2 MHz, d6-DMSO): δ= 8.5965 (6.1); 7.6324 (13.8); 7.6119 (16.0); 7.3077 (14.1); 7.2872 (12.6); 3.9359 (6.2); 3.8897 (7.8); 3.5484 (5.0); 3.5029 (4.1); 3.3334 (20.6); 2.9908 (0.6); 2.7024 (0.4); 2.6757 (0.8); 2.6715 (1.0); 2.6669 (0.9); 2.6291 (12.8); 2.6103 (13.5); 2.5112 (38.7); 2.5068 (76.6); 2.5023 (100.9); 2.4978 (71.1); 2.4934 (32.4); 2.3844 (0.5); 2.3291 (0.8); 2.3245 (1.2); 2.3073 (1.4); 2.2892 (1.1); 2.1159 (0.9); 2.0978 (2.0); 2.0784 (2.8); 2.0594 (2.2); 2.0404 (1.1); 1.6381 (3.8); 1.6125 (8.9); 1.6076 (9.8); 1,6005 (7,6); 1,5858 (5,0); 1,5693 (2,0); 1,5605 (1,5); 1,5237 (1,4); 1,4979 (3,0); 1,4876 (4,4); 1,4803 (5,2); 1,4693 (3,8); 1,4251 (0,6); 1,3535 (0,6); 1,3455 (0,5); 1,3342 (0,8); 1,3164 (0,8); 1,3000 (0,6); 1,2856 (0,7); 1,2676 (0,9); 1,2497 (0,8); 1,2328 (0,7); 1,2026 (1,5); 1,1867 (2,8); 1,1679 (4,0); 1,1587 (3,9); 1,1387 (2,5); 1,1185 (0,9); 0,8817 (2,0); 0,8637 (3,8); 0,8458 (1,4); 0,0080 (0,9); 0,0000 (20,3); 0,0083 (0,6) 1.006: RMN de1H (400,1 MHz, d6-DMSO): δ= 8,5862 (8,2); 7,6560 (7,7); 7,6366 (8,7); 7,3565 (8,7); 7,3368 (7,7); 7,3211 (2,8); 7,3019 (7,4); 7,2831 (6,6); 7,2521 (9,7); 7,2332 (5,2); 7,2216 (2,8); 7,2027 (3,4); 7,1856 (1,2); 4,0023 (16,0); 3,9206 (3,9); 3,8743 (4,9); 3,5455 (3,7); 3,4989 (2,9); 3,3167 (15,1); 2,5102 (11,1); 2,5079 (11,0) I.007: RMN de1H(300,1 MHz, CDCI3): δ= 8.6052 (3.9); 8.5897 (3.7); 7.8455 (1.8); 7.8202 (3.3); 7.7954 (1.9); 7.6067 (2.4); 7.5512 (10.1); 7.5240 (12.5); 7.3635 (3.5); 7.3416 (14.4); 7.3145 (10.5); 7.2854 (8.9); 7.2609 (366.3); 6.9097 (1.8); 6.4659 (0.9); 4.3203 (16.0); 3.6850 (4.1); 3.6256 (8.4); 3.5130 (5.3); 3.4563 (2.6); 2.6644 (0.3); 2.5287 (0.4); 2.5103 (0.4); 2.4913 (0.4); 2.3806 (0.4); 2.2744 (0.4); 2.2278 (0.5); 2.1808 (0.6); 2.1759 (0.6); 2.1569 (0.6); 2.0996 (1.2); 2.0086 (0.6); 1.9814 (0.4); 1.8820 (0.3); 1.2542 (0.4); 0.1946 (0.7); 0.0100 (5.6); -0.0008 (204.3); -0.0113 (13.3); -0.1543 (0.4); -0.1990 (1.1) Petition 870250039092, dated 05 / 14 / 2025, pp. 141 / 383 134 / 178 1.008: 1H NMR (400.2 MHz, d6-DMSO): δ= 8.7494 (9.2); 8.7382 (9.2); 8.6122 (8.8); 7.6546 (7.9); 7.6356 (8.7); 7.5737 (0.3); 7.4087 (9.0); 7.3893 (8.0); 7.3659 (5.2); 7.3556 (2.9); 6.5402 (0.4); 4.2684 (16.0); 3.9265 (3.7); 3.8810 (4.6); 3.5425 (3.8); 3.4958 (3.2); 3.3310 (58.7); 3.2210 (0.4); 2.6747 (1.1); 2.5022 (130.3); 2.3307 (1.1); 0.0003 (9.9) 1.009: RMN de1H (400.2 MHz, d6-DMSO): δ= 8.6681 (6.8); 8.6645 (7.6); 8.5652 (3.8); 8.5589 (5.6); 8.5551 (5.1); 8.5047 (7.1); 8.4984 (6.1); 7.9152 (0.4); 7.6637 (8.4); 7.6430 (10.4); 7.4161 (9.0); 7.3954 (8.0); 6.0792 (0.5); 4.2597 (0.3); 4.2041 (16.0); 4.1053 (0.4); 4.0419 (0.4); 3.9702 (0.4); 3.9220 (4.2); 3.8977 (0.6); 3.8756 (5.2); 3.8129 (0.6); 3.7141 (0.5); 3.6519 (0.6); 3.6069 (0.6); 3.5400 (3.7); 3.4936 (3.2); 3.3354 (6.1); 3.1845 (0.5); 3.1211 (0.3); 2.7516 (0.3); 2.6716 (1.4); 2.6668 (1.3); 2.5110 (63.6); 2.5067 (123.3); 2.5022 (166.8); 2.4977 (130.1); 2.4934 (73.9); 2.3291 (1.8); 2.3248 (1.6); 2.3021 (0.8); 2.2853 (0.8); 2.2443 (0.6); 2.2143 (0.5); 2.1808 (0.5); 2.1648 (0.5); 2.1334 (0.4); 2.0974 (0.4); 2.0781 (0.4); 1.9844 (0.3); 0.0000 (20.9) I. 010: 1H NMR (400.2 MHz, d6-DMSO): δ= 9.0517 (8.4); 8.7467 (16.0); 8.6389 (0.4); 7.6813 (7.1); 7.6607 (8.5); 7.4224 (7.7); 7.4018 (6.7); 4.0566 (13.5); 3.9236 (3.4); 3.8772 (4.3); 3.5489 (3.0); 3.5021 (2.4); 3.3456 (18.2); 2.8924 (1.6); 2.7332 (1.4); 2.5097 (31.5); 2.5053 (40.2); 2.5010 (30.9); -0.0002 (4.6) Petition 870250039092, dated 05 / 14 / 2025, p. 142 / 383 135 / 178 1.011: 1H NMR (400.2 MHz, d6-DMSO): δ= 8.6002 (2.9); 7.9522 (2.0); 7.6875 (0.4); 7.6608 (9.0); 7.6402 (10.3); 7.4218 (0.5); 7.4009 (0.4); 7.2717 (8.6); 7.2511 (8.0); 7.2164 (0.5); 6.6377 (3.8); 6.6318 (5.6); 6.6265 (4.3); 5.8950 (3.9); 5.8870 (6.1); 5.8796 (4.5); 5.7548 (3.5); 5.7503 (4.0); 5.7466 (3.8); 5.7420 (3.4); 3.9673 (16.0); 3.9268 (4.6); 3.8805 (5.6); 3.5767 (0.3); 3.5481 (3.6); 3.5016 (2.8); 3.4281 (0.3); 3.4063 (43.4); 3.3513 (1.0); 3.3343 (39.8); 3.1309 (0.8); 2.9929 (1.6); 2.8902 (13.3); 2.8095 (0.7); 2.7313 (11.7); 2.6708 (0.4); 2.6666 (0.4); 2.5569 (0.4); 2.5242 (1.5); 2.5108 (24.9); 2.5065 (50.4); 2.5020 (67.0); 2.4975 (51.1); 2.4932 (27.2); 2.3288 (0.4); 0.0080 (0.3); -0.0002 (10.0); -0.0083 (0.5) 1.012: RMN de1H (300.2 MHz, d6-DMSO): δ = 8.6474 (1.5); 7.7116 (2.7); 7.6841 (3.2); 7.3424 (2.9); 7.3281 (2.5); 7.3221 (3.0); 7.3150 (2.6); 6.0119 (2.0); 6.0063 (2.0); 4.1098 (4.8); 3.9679 (1.2); 3.9061 (1.6); 3.6987 (15.1); 3.5833 (1.0); 3.5212 (0.8); 3.3523 (16.0); 2.5342 (1.9); 2.5283 (3.7); 2.5223 (4.9); 2.5162 (3.5); 2.5103 (1.7); 2.0956 (0.3); 0.0202 (6.1) 1.013: RMN de1H (400.1 MHz, d6-DMSO): δ= 8.6258 (1.0); 7.6895 (4.8); 7.6708 (5.2); 7.5811 (4.9); 7.2818 (7.1); 7.2664 (4.9); 5.3060 (10.0); 3.9253 (2.2); 3.8788 (2.8); 3.5507 (2.4); 3.5042 (2.0); 3.3274 (189.5); 2.5107 (14.2); 2.0153 (16.0) I. 014: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.6610 (2.1); 7.9731 (1.2); 7.7229 (3.3); 7.6955 (4.1); 7.6742 (0.3); 7.4557 (0.4); 7.4177 (3.7); 7.3902 (3.1); 7.2968 (0.3); 6.1188 (4.0); 5.7793 (0.3); 4.1782 (6.4); 3.9697 (1.6); 3.9078 (2.1); 3.8408 (0.4); 3.5861 (1.4); 3.5217 (1.0); 3.3492 (6.2); 2.9104 (7.3); 2.7512 (6.3); 2.5279 (6.4); 2.5220 (8.5); 2.5162 (6.3); 2.1962 (16.0); 2.0978 (0.9); 0.0199 (4.7) Petition 870250039092, dated 05 / 14 / 2025, pp. 143 / 383 136 / 178 1.015: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.6366 (3.9); 7.6999 (4.5); 7.6723 (5.5); 7.4030 (5.0); 7.3822 (3.8); 7.3777 (5.3); 7.3655 (3.1); 7.3611 (2.8); 6.9926 (1.8); 6.9813 (2.9); 6.9758 (1.7); 6.9644 (3.0); 6.9469 (2.5); 6.9431 (2.5); 6.9357 (1.6); 6.9319 (1.4); 5.7796 (1.0); 4.2263 (8.1); 3.9659 (2.0); 3.9041 (2.7); 3.5774 (1.6); 3.5151 (1.2); 3.3517 (16.0); 2.5340 (2.9); 2.5281 (6.0); 2.5220 (8.2); 2.5160 (6.0); 2.5101 (2.9); 0.0201 (6.5) 1.016: RMN de1H (400.1 MHz, d6-DMSO): δ= 8.5679 (16.0); 7.6367 (12.3); 7.6171 (13.5); 7.2754 (13.3); 7.2555 (11.8); 3.9332 (6.0); 3.8869 (7.6); 3.5530 (5.7); 3.5066 (4.5); 3.3137 (30.0); 2.5250 (14.0); 2.5082 (39.5); 1.6615 (4.5); 1.6386 (6.4); 1.6137 (9.4); 1.5828 (7.5); 1.5584 (1.4); 1.5491 (1.7); 1.5412 (1.7); 1.5309 (2.1); 1.5231 (2.4); 1.5041 (1.7); 1.2447 (0.5); 1.2151 (1.1); 1.1830 (3.4); 1.1530 (8.5); 1.1322 (6.3); 1.1018 (1.3); 1.0711 (0.4); 0.9730 (2.4); 0.9445 (5.0); 0.9167 (4.1); 0.8931 (1.2) I.017: RMN de1H (300.2 MHz, d6-DMSO): δ= 8.9748 (2.8); 8.6380 (4.2); 7.7779 (2.5); 7.7093 (2.9); 7.6818 (3.5); 7.4127 (3.1); 7.3851 (2.6); 4.2958 (5.0); 3.9681 (1.3); 3.9063 (1.8); 3.5785 (1.1); 3.5160 (0.8); 3.3517 (16.0); 2.5342 (2.3); 2.5284 (4.7); 2.5223 (6.3); 2.5163 (4.6); 2.5104 (2.2); 0.0200 (3.1) Petition 870250039092, dated 05 / 14 / 2025, p. 144 / 383 137 / 178 1.018: 1H NMR (300.2 MHz, CDCI3): δ= 7.8592 (0.4); 7.8319 (0.5); 7.6461 (11.0); 7.6412 (12.7); 7.6185 (16.0); 7.6136 (14.6); 7.5428 (0.5); 7.5145 (0.4); 7.4385 (17.7); 7.4117 (13.8); 7.2988 (16.4); 7.0450 (0.4); 4.8166 (0.6); 4.5228 (8.3); 4.4957 (8.4); 4.2930 (1.5); 4.1899 (0.8); 4.1660 (1.8); 4.1423 (1.8); 4.1187 (0.8); 4.0977 (0.5); 3.7697 (8.3); 3.7498 (0.5); 3.7103 (14.3); 3.5588 (6.6); 3.5555 (6.5); 3.4993 (3.8); 3.4959 (3.8); 2.2992 (0.9); 2.2718 (2.8); 2.2446 (5.1); 2.2164 (5.9); 2.1899 (4.2); 2.1642 (1.7); 2.0808 (8.9); 1.9228 (2.0); 1.9074 (2.9); 1.8965 (2.6); 1.8853 (2.6); 1.8699 (2.8); 1.8450 (1.7); 1.7477 (4.8); 1.7353 (5.2); 1.7099 (3.8); 1.6992 (3.7); 1.6849 (5.5); 1.6713 (5.3); 1.6632 (5.8); 1.6459 (6.7); 1.6238 (5.4); 1.6164 (6.6); 1.6017 (3.8); 1.5917 (5.6); 1.5830 (4.5); 1.5777 (4.9); 1.5584 (5.5); 1.5501 (5.1); 1.5334 (4.9); 1.5229 (5.0); 1.4911 (3.2); 1.4651 (2.4); 1.4450 (2.4); 1.4287 (3.0); 1.4197 (2.4); 1.4033 (3.8); 1.3922 (2.5); 1.3778 (2.5); 1.3667 (2.3); 1.3446 (2.8); 1.3153 (7.7);1.3043 (15.4); 1.2923 (13.8); 1.2680 (3.5); 1.2588 (2.1); 1.2316 (3.2); 1.2187 (2.0); 1.2041 (2.8); 1.1919 (2.4); 1.1629 (1.8); 1.1360 (0.8); 0.9943 (0.5); 0.9697 (0.9); 0.9412 (5.3); 0.9194 (15.9); 0.8962 (6.6); 0.1084 (0.8); 0.0480 (0.8); 0.0373 (20.7); 0.0265 (0.9); I.019: RMN de1H (400.2 MHz, d6-DMSO): δ= 8.6573 (3.0); 8.6388 (0.4); 7.9534 (2.3); 7.7430 (3.4); 7.7225 (4.7); 7.6485 (0.4); 7.6300 (0.5); 7.5120 (0.3); 7.4326 (0.5); 7.4265 (0.8); 7.4186 (1.4); 7.4117 (4.6); 7.4053 (3.2); 7.3908 (5.6); 7.3864 (5.8); 7.3818 (2.4); 7.3724 (1.1); 7.3570 (0.4); 7.3528 (0.4); 7.3341 (0.6); 7.3107 (2.9); 7.3054 (2.4); 7.2911 (2.4); 7.2871 (2.0); 5.6068 (3.2); 5.5641 (3.2); 3.9717 (1.6); 3.9254 (2.0); 3.5870 (1.2); 3.5408 (1.0); 3.3306 (29.1); 2.8911 (16.0); 2.7324 (13.9); 2.5250 (0.8); 2.5117 (15.4); 2.5073 (30.1); 2.5028 (38.5); 2.4983 (27.2); 2.4938 (13.0); 1.2399 (0.7); -0.0002 (3.0) Petition 870250039092, dated 05 / 14 / 2025, p. 145 / 383 138 / 178 1.020: 1H NMR (400.2 MHz, d6-DMSO): δ= 8.7779 (13.0); 7.9215 (9.4); 7.9172 (3.9); 7.9048 (5.0); 7.9003 (15.7); 7.8352 (16.0); 7.8307 (4.9); 7.8182 (4.1); 7.8140 (9.6); 7.7690 (8.8); 7.7564 (3.1); 7.7516 (11.0); 7.7481 (9.6); 7.7357 (1.6); 7.7325 (2.3); 7.7293 (1.4); 7.7186 (2.0); 7.7139 (5.6); 7.6986 (2.7); 7.6954 (3.9); 7.6922 (2.0); 7.6098 (7.8); 7.5905 (10.8); 7.5757 (2.1); 7.5718 (4.6); 4.0462 (5.1); 3.9997 (6.4); 3.6449 (3.8); 3.5981 (3.0); 3.3300 (32.0); 2.6717 (0.3); 2.5249 (1.3); 2.5116 (21.9); 2.5072 (44.3); 2.5027 (59.1); 2.4982 (42.1); 2.4938 (19.8); 2.3295 (0.4); 2.0762 (1.1); 0.0081 (0.4); -0.0001 (9.1); -0.0083 (0.4) 1.021: 1H NMR (400.1 MHz, d6-DMSO): δ= 8.5822 (5.3); 7.8288 (0.4); 7.8219 (0.4); 7.8011 (0.4); 7.7893 (0.4); 7.6445 (4.5); 7.6250 (5.0); 7.4847 (0.5); 7.4712 (0.8); 7.3896 (0.4); 7.3480 (0.5); 7.3289 (4.9); 7.3091 (4.3); 7.1328 (1.3); 7.1110 (15.7); 7.0887 (0.9); 3.9480 (9.0); 3.9179 (2.2); 3.8715 (2.8); 3.5420 (2.1); 3.4955 (1.7); 3.3166 (10.3); 2.5099 (6.8); 2.2595 (16.0); 2.0808 (2.9) I. 022: 1H NMR (300.2 MHz, CDCI3): δ= 7.6283 (7.1); 7.6005 (8.6); 7.3633 (2.1); 7.3575 (1.5); 7.3397 (11.6); 7.3268 (2.4); 7.3130 (11.8); 7.2986 (8.0); 7.2876 (0.6); 7.2636 (3.4); 7.2497 (7.9); 7.2420 (5.0); 7.2252 (4.6); 4.2637 (0.8); 4.2398 (2.5); 4.2158 (2.5); 4.1917 (0.8); 3.7579 (3.0); 3.6987 (5.4); 3.5605 (3.3); 3.5572 (3.3); 3.5012 (1.9); 3.4977 (1.9); 3.0472 (0.6); 2.7747 (0.4); 2.7487 (0.4); 1.7042 (16.0); 1.6801 (15.8); 0.0540 (0.3); 0.0432 (8.3); 0.0324 (0.4) Petition 870250039092, dated 05 / 14 / 2025, pp. 146 / 383 139 / 178 1.023: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.6247 (1.0); 7.6863 (2.1); 7.6586 (2.8); 7.5084 (2.6); 7.4809 (2.0); 7.4099 (1.0); 7.4052 (1.4); 7.3815 (2.6); 7.3464 (1.4); 7.3398 (0.6); 7.3226 (2.4); 7.3177 (1.1); 7.2975 (1.1); 7.2558 (0.5); 7.2511 (0.9); 7.2461 (0.5); 7.2350 (0.5); 7.2276 (1.0); 7.2037 (0.4); 6.0491 (1.3); 6.0358 (1.4); 5.7763 (1.2); 5.7638 (1.1); 3.9457 (0.8); 3.8833 (1.0); 3.5632 (0.8); 3.5007 (0.6); 3.3521 (16.0); 2.5337 (1.6); 2.5280 (3.2); 2.5220 (4.2); 2.5161 (3.1); 2.0950 (0.8); 0.0208 (2.4) 1.024: de1H NMR (499.9 MHz, d6-DMSO): δ= 11.5742 (2.4); 8.5982 (5.1); 7.6327 (8.6); 7.6166 (10.2); 7.3572 (9.3); 7.3411 (8.8); 7.2608 (9.5); 7.2476 (10.0); 6.1335 (2.9); 6.1204 (5.6); 6.1073 (3.0); 3.9115 (4.4); 3.8745 (5.4); 3.7492 (16.0); 3.5421 (3.8); 3.5050 (3.2); 3.3404 (8.6); 2.5043 (4.9); 1.9895 (0.6); 1.3030 (0.4); 1.2595 (0.5); 1.2351 (0.8); 1.1755 (0.3); -0.0002 Í2Z)______________________________________________________________________________ 1.025: 1H NMR (400.1 MHz, d6-DMSO): δ= 8.5885 (4.3); 7.6583 (8.1); 7.6384 (9.2); 7.3521 (9.0); 7.3323 (8.0); 7.2963 (3.9); 7.2817 (5.1); 7.2760 (5.9); 7.2617 (4.8); 7.1429 (4.8); 7.1211 (8.1); 7.0995 (3.7); 3.9962 (16.0); 3.9205 (4.0); 3.8741 (5.1); 3.5444 (3.8); 3.4977 (3.0); 3.3136 (32.4); 2.5095 (24.2) I. 026: 1H NMR (300.2 MHz, CDCI3): δ= 7.6332 (6.6); 7.6057 (7.7); 7.4727 (5.0); 7.4668 (5.3); 7.2990 (8.3); 7.2478 (6.7); 7.2204 (5.9); 5.9997 (4.7); 5.9941 (5.0); 5.7585 (0.8); 5.3372 (2.2); 4.0900 (2.2); 4.0657 (7.4); 4.0537 (13.5); 4.0418 (7.8); 4.0176 (2.3); 3.7649 (3.0); 3.7055 (5.1); 3.5422 (3.2); 3.4824 (1.9); 1.6968 (0.8); 1.3417 (7.7); 1.3176 (16.0); 1.2933 (9.3); 0.9170 (0.3); 0.8956 (0.4); 0.0370 (4.3) Petition 870250039092, dated 05 / 14 / 2025, p. 147 / 383 140 / 178 1.027: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.6420 (6.4); 8.5339 (6.2); 8.5283 (6.2); 8.3931 (3.8); 8.3896 (3.8); 8.3770 (3.9); 8.3735 (3.9); 7.7077 (8.0); 7.6801 (9.8); 7.4101 (2.9); 7.3927 (10.7); 7.3708 (5.1); 7.3654 (7.0); 5.7798 (1.4); 4.1172 (12.8); 3.9583 (3.6); 3.8965 (5.0); 3.5715 (2.9); 3.5091 (2.2); 3.3501 (16.0); 2.5343 (5.4); 2.5284 (11.6); 2.5223 (16.0); 2.5163 (11.6); 2.5104 (5.5); 0.0305 (0.5); 0.0196 (13.7); 0.0086 (0.5) 1.028: de1H NMR (300.2 MHz, d6-DMSO): δ= 8.6335 (6.4); 8.1440 (1.4); 8.1284 (1.4); 7.9395 (0.8); 7.9331 (0.8); 7.9149 (0.9); 7.9079 (1.2); 7.8993 (0.8); 7.8812 (0.9); 7.8749 (0.8); 7.6999 (4.2); 7.6724 (5.0); 7.3724 (4.8); 7.3463 (5.1); 7.3300 (1.0); 7.3232 (0.9); 4.0616 (7.3); 3.9566 (1.9); 3.8947 (2.6); 3.5712 (1.6); 3.5080 (1.2); 3.3509 (16.0); 2.9107 (0.4); 2.7518 (0.4); 2.5619 (1.8); 2.5344 (2.8); 2.5285 (5.8); 2.5225 (7.8); 2.5165 (5.7); 2.5108 (2.7); 0.0196 (5.6) 1.029: 1H NMR (300.2 MHz, CDCI3): δ= 8.1711 (4.7); 8.1539 (4.8); 8.0264 (0.8); 7.6842 (8.0); 7.6567 (9.1); 7.2986 (22.6); 7.2704 (7.1); 7.0360 (2.9); 7.0190 (2.9); 6.7467 (5.5); 4.0747 (16.0); 3.7719 (3.2); 3.7125 (5.9); 3.5760 (3.5); 3.5159 (2.0); 2.9916 (5.3); 2.9059 (4.7); 2.6601 (6.9); 1.6796 (0.8); 0.0463 (0.7); 0.0355 (19.4); 0.0247 (0.9) I. 030: 1H NMR (300.2 MHz, CDCI3): δ= 8.1204 (4.8); 8.1133 (4.9); 7.6436 (8.4); 7.6161 (10.4); 7.5932 (3.0); 7.5858 (2.9); 7.5670 (1.8); 7.5587 (1.8); 7.2987 (6.7); 7.2704 (9.0); 7.2431 (7.7); 6.9190 (3.3); 6.9100 (3.4); 6.8911 (3.1); 6.8820 (3.0); 4.0346 (16.0); 3.7624 (3.4); 3.7030 (6.1); 3.5706 (3.6); 3.5113 (2.0); 2.9832 (0.4); 2.8841 (0.4); 2.6576 (1.9); 1.2889 (0.5); 0.0354 (8.2); 0.0245 (0.4) Petition 870250039092, dated 05 / 14 / 2025, pp. 148 / 383 141 / 178 1.031: NMR de1H (300.2 MHz, CDCI3): δ= 8.0274 (0.6); 7.6327 (3.2); 7.6052 (3.6); 7.2990 (5.8); 7.2083 (3.1); 7.1808 (2.7); 3.7603 (1.6); 3.7457 (6.4); 3.7012 (2.4); 3.5637 (1.4); 3.5067 (0.8); 2.9924 (4.0); 2.9070 (3.5); 2.6593 (1.6); 2.3296 (13.9); 2.1121 (16.0); 1.6821 (0.4); 0.0355 (7.4); 0.0246 (0.3) I.032: NMR de1H (300.2 MHz, CDCI3): δ= 7.6680 (12.8); 7.6404 (16.0); 7.4140 (15.2); 7.3866 (12.3); 7.2988 (22.6); 5.3377 (13.2); 4.4958 (4.0); 4.4737 (4.0); 3.8822 (3.9); 3.7804 (6.2); 3.7521 (0.6); 3.7211 (10.4); 3.5739 (5.7); 3.5144 (3.3); 2.0834 (1.7); 2.0290 (3.8); 1.9586 (2.2); 1.9162 (2.3); 1.8194 (2.0); 1.8082 (1.6); 1.7831 (2.5); 1.7351 (2.0); 1.6981 (5.8); 1.6868 (4.8); 1.6700 (15.8); 1.6487 (3.9); 1.6369 (3.0); 1.6215 (2.0); 1.6095 (1.5); 1.5986 (1.4); 1.5876 (0.8); 1.4618 (2.2); 1.4207 (2.5); 1.3174 (1.0); 1.3043 (2.1); 1.2935 (1.9); 1.2809 (4.2); 1.2575 (2.2); 1.2417 (2.8); 1.2324 (3.7); 1.1914 (6.9); 1.1615 (3.9); 1.1265 (2.4); 1.0964 (2.2); 1.0861 (3.0); 1.0566 (2.6); 1.0464 (3.3); 1.0157 (2.4); 1.0050 (3.0); 0.9748 (1.8); 0.9638 (1.9); 0.9351 (0.6); 0.9232 (0.7); 0.1078 (0.4); 0.0479 (1.1); 0.0372 (28.7); 0.0264 (1.0) Petition 870250039092, dated 05 / 14 / 2025, p. 149 / 383 142 / 178 1.033: 1H NMR (499.9 MHz, d6-DMSO): δ= 8.5851 (14.5); 7.6753 (13.1); 7.6590 (16.0); 7.3974 (14.2); 7.3810 (13.7); 5.3237 (9.2); 5.3145 (9.8); 4.3356 (3.5); 4.3234 (5.1); 4.3135 (3.9); 4.0506 (0.3); 4.0363 (1.0); 4.0221 (1.0); 4.0079 (0.4); 3.9342 (6.7); 3.8972 (8.1); 3.8555 (2.6); 3.8490 (2.9); 3.8332 (3.1); 3.8266 (3.1); 3.7883 (2.7); 3.7818 (2.8); 3.7661 (3.1); 3.7595 (3.1); 3.5519 (5.6); 3.5148 (4.8); 3.3151 (44.7); 3.2206 (2.5); 3.1975 (4.5); 3.1777 (3.4); 3.1584 (4.6); 3.1348 (2.4); 2.5037 (16.4); 2.5005 (23.4); 2.4972 (19.8); 1.9879 (4.1); 1.7194 (0.8); 1.7041 (1.5); 1.6964 (2.2); 1.6897 (2.1); 1.6829 (2.3); 1.6750 (2.0); 1.6602 (1.3); 1.6387 (2.9); 1.6119 (3.3); 1.3355 (0.4); 1.3117 (1.5); 1.3029 (1.8); 1.2866 (4.2); 1.2781 (4.5); 1.2614 (4.6); 1.2533 (4.5); 1.2370 (2.4); 1.2291 (1.9); 1.1889 (1.2); 1.1747 (2.2); 1.1605 (1.2); 1.1250 (3.4); 1.0998 (2.6); -0.0002 (9.4) 1,034: RMN de1H (400.2 MHz, d6-DMSO): δ= 7.6824 (6.9); 7.6618 (7.7); 7.4524 (9.2); 7.4487 (9.1); 7.2607 (7.8); 7.2399 (7.1); 6.9496 (8.7); 6.9461 (8.4); 6.8249 (1.3); 5.2516 (16.0); 5.1766 (0.4); 4.9658 (0.4); 3.7677 (1.2); 3.7221 (1.6); 3.4974 (2.9); 3.4511 (2.3); 3.3599 (0.7); 3.2352 (0.4); 3.2256 (0.4); 3.2040 (0.3); 3.1812 (0.4); 2.6758 (0.4); 2.6711 (0.5); 2.6666 (0.4); 2.5112 (26.6); 2.5069 (52.9); 2.5024 (70.0); 2.4979 (49.6); 2.4935 (23.1); 2.3338 (0.3); 2.3292 (0.4); 2.3247 (0.3); 2.0766 (1.0); 0.9537 (0.3); 0.9355 (0.7); 0.0082 (0.5); 0.0001 (11.3); -0.0083 (0.4) I. 035: 1H NMR (300.2 MHz, CDCI3): δ= 8.7874 (4.5); 8.7821 (4.6); 8.7306 (4.1); 8.7247 (4.2); 8.0287 (2.1); 7.7567 (5.1); 7.6952 (7.1); 7.6678 (8.2); 7.2989 (18.0); 7.2911 (8.1); 7.2636 (6.7); 4.1181 (14.3); 3.7691 (2.8); 3.7099 (4.8); 3.5657 (2.9); 3.5068 (1.6); 2.9931 (16.0); 2.9082 (13.7); 2.6601 (2.8); 1.7024 (0.8); 0.0458 (0.7); 0.0349 (21.6); 0.0241 (0.8) Petition 870250039092, dated 05 / 14 / 2025, p. 150 / 383 143 / 178 1,036: RMN de1H (400.2 MHz, d6-DMSO): δ= 11.5624 (1.4); 11.4971 (2.0); 7.8223 (3.4); 7.8016 (3.7); 7.7268 (2.6); 7.7057 (3.0); 7.5065 (0.6); 7.5015 (0.8); 7.4972 (0.6); 7.4849 (2.6); 7.4769 (3.7); 7.4712 (2.0); 7.4667 (2.7); 7.4557 (3.5); 7.4412 (1.2); 7.4132 (4.2); 7.3921 (5.4); 7.3832 (16.0); 7.3062 (2.1); 7.3020 (2.2); 7.2860 (2.0); 4.0143 (1.4); 3.9681 (1.8); 3.9485 (1.1); 3.9021 (1.4); 3.6181 (1.2); 3.5689 (1.5); 3.5185 (0.8); 3.3300 (5.6); 2.5105 (17.5); 2.5064 (31.9); 2.5020 (40.4); 2.4976 (28.5); 2.0750 (5.2); -0.0001 (6.0) 1,037: RMN de1H (300.2 MHz, CDCI3): δ = 7.8134 (0.3); 7.7601 (0.4); 7.6697 (0.4); 7.6569 (0.4); 7.6493 (0.5); 7.6098 (1.2); 7.5832 (1.4); 7.4709 (0.6); 7.4636 (0.4); 7.4580 (0.7); 7.4489 (0.7); 7.3146 (2.4); 7.2985 (8.7); 7.2869 (2.5); 7.2650 (1.1); 7.2598 (1.2); 7.2394 (0.7); 7.2336 (0.8); 7.1576 (0.6); 7.1277 (0.9); 7.1235 (0.9); 7.1044 (1.6); 7.0987 (1.2); 6.9573 (0.8); 6.9541 (1.0); 6.9289 (2.6); 6.9042 (1.0); 6.8994 (1.5); 4.0338 (5.2); 3.8391 (16.0); 3.7500 (0.7); 3.6908 (1.2); 3.5608 (1.1); 3.5014 (0.6); 1.3707 (0.4); 1.3398 (0.7); 1.3241 (0.5); 1.2980 (1.1); 0.8912 (0.4); 0.8719 (0.4); 0.0511 (0.4); 0.0404 (8.8); 0.0295 (0.4) I.038: de1H NMR (300.2 MHz, CDCl3): δ= 7.6384 (3.8); 7.6328 (1.4); 7.6164 (1.5); 7.6104 (5.1); 7.4418 (4.8); 7.4286 (1.2); 7.4144 (4.5); 7.2990 (3.3); 7.2782 (2.9); 7.2685 (1.7); 7.2649 (1.7); 7.2573 (2.3); 7.2477 (3.8); 7.2331 (0.6); 7.2229 (0.5); 7.2119 (1.6); 7.2049 (0.7); 7.1970 (1.0); 7.1928 (0.9); 7.1815 (0.6); 6.0789 (2.4); 4.2760 (0.4); 4.1875 (0.4); 4.1637 (1.1); 4.1399 (1.1); 4.1162 (0.4); 3.7467 (1.4); 3.6873 (2.4); 3.5339 (1.7); 3.5307 (1.8); 3.4744 (1.0); 3.4710 (1.0); 2.4578 (0.7); 2.3149 (16.0); 2.0804 (5.1); 1.7658 (1.3); 1.3149 (1.5); 1.2912 (2.8); 1.2721 (0.5); 1.2673 (1.3); 0.9226 (0.4); 0.0408 (4.0) Petition 870250039092, dated 05 / 14 / 2025, pp. 151 / 383 144 / 178 1.039: 1H NMR (499.9 MHz, d6-DMSO): δ= 8.6333 (4.0); 7.9542 (2.5); 7.6877 (7.0); 7.6711 (11.8); 7.6668 (6.0); 7.3528 (1.3); 7.3495 (1.4); 7.2687 (5.5); 7.2523 (5.2); 7.2116 (1.7); 7.1952 (1.6); 5.9587 (4.5); 5.9543 (4.6); 5.9315 (1.4); 5.9285 (1.4); 5.4627 (3.5); 5.2674 (11.3); 3.9181 (2.9); 3.8811 (3.6); 3.5448 (2.9); 3.5076 (2.4); 3.3184 (15.8); 2.8917 (16.0); 2.7327 (14.2); 2.5059 (6.9); 2.5027 (9.4); 2.4994 (7.3); 1.8665 (0.4); 1.8565 (0.9); 1.8495 (1.1); 1.8397 (1.9); 1.8298 (1.4); 1.8228 (1.2); 1.8128 (0.7); 0.8847 (0.4); 0.8763 (1.0); 0.8718 (1.2); 0.8637 (0.6); 0.8596 (1.1); 0.8552 (1.1); 0.8471 (0.5); 0.8414 (1.1); 0.8333 (3.3); 0.8286 (3.7); 0.8250 (1.8); 0.8211 (1.8); 0.8165 (3.4); 0.8118 (3.5); 0.8043 (1.3); 0.6065 (1.3); 0.5988 (3.7); 0.5944 (4.0); 0.5889 (3.8); 0.5844 (3.9); 0.5762 (1.2); 0.5556 (0.4); 0.5472 (1.2); 0.5433 (1.3); 0.5374 (1.2); 0.5333 (1.3); 0.5247 (0.4) I.040: NMR de1H (300.2 MHz, CDCl3): δ= 7.5734 (6.8); 7.5461 (7.7); 7.2993 (17.5); 7.2931 (7.1); 7.2852 (6.3); 7.2585 (0.3); 7.2020 (7.4); 7.1750 (6.3); 5.9478 (6.2); 5.9403 (6.0); 5.5507 (0.5); 5.5313 (0.4); 5.4977 (0.4); 5.3210 (16.0); 3.6950 (3.1); 3.6357 (5.4); 3.4820 (3.6); 3.4209 (2.0); 2.6538 (2.9); 2.2907 (0.6); 2.2774 (0.4); 2.0553 (0.7); 2.0387 (1.4); 2.0268 (1.5); 2.0104 (2.6); 1.9937 (1.6); 1.9821 (1.4); 1.9657 (0.7); 1.6484 (1.2); 1.2944 (3.3); 1.2596 (1.2); 1.2391 (1.0); 1.0019 (1.5); 0.9872 (4.5); 0.9798 (5.0); 0.9660 (2.7); 0.9588 (4.8); 0.9518 (4.6); 0.9381 (2.3); 0.9172 (1.0); 0.8896 (1.0); 0.8087 (0.4); 0.7959 (0.3); 0.7634 (2.0); 0.7493 (5.4); 0.7428 (5.2); 0.7330 (5.0); 0.7266 (5.5); 0.7108 (1.6); 0.1079 (4.4); 0.0382 (22.2) Petition 870250039092, dated 05 / 14 / 2025, pp. 152 / 383 145 / 178 1.041: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.6352 (3.3); 7.7122 (2.8); 7.6846 (3.4); 7.3739 (2.9); 7.3461 (2.5); 7.2967 (2.4); 7.2909 (2.4); 6.0053 (2.3); 5.9996 (2.2); 4.1988 (4.9); 3.9715 (1.3); 3.9098 (1.7); 3.5849 (1.0); 3.5204 (0.8); 3.4343 (0.6); 3.4238 (0.7); 3.4170 (0.6); 3.4109 (1.1); 3.3985 (0.8); 3.3873 (0.7); 3.3741 (0.4); 3.3503 (16.0); 2.5345 (1.6); 2.5285 (3.3); 2.5225 (4.5); 2.5164 (3.2); 2.5104 (1.4); 1.0897 (1.3); 1.0187 (0.5); 1.0097 (1.0); 1.0004 (1.7); 0.9928 (2.3); 0.9786 (1.4); 0.9618 (1.1); 0.9593 (1.1); 0.9517 (1.4); 0.9491 (1.2); 0.9446 (1.2); 0.9398 (1.7); 0.9278 (1.3); 0.9250 (1.2); 0.9209 (1.3); 0.8992 (0.5); 0.0205 (5.2) 1,042: RMN de1H (300.2 MHz, d6-DMSO): δ = 8.6910 (0.5); 8.3831 (2.1); 8.3643 (2.2); 8.3087 (3.5); 7.6519 (3.0); 7.6244 (3.6); 7.3325 (3.2); 7.3049 (2.6); 7.0544 (2.1); 7.0355 (2.1); 3.9551 (5.2); 3.9373 (1.5); 3.8754 (1.9); 3.8464 (16.0); 3.5643 (1.1); 3.5022 (0.8); 3.3528 (5.0); 2.9108 (1.5); 2.7520 (1.3); 2.7504 (1.3); 2.5346 (2.9); 2.5287 (6.1); 2.5226 (8.4); 2.5165 (6.1); 2.5106 (2.9); 0.0202 (5.1) 1,043: RMN de1H (400.2 MHz, d6-DMSO): δ = 8.6072 (1.5); 7.9537 (0.3); 7.6599 (2.8); 7.6392 (3.5); 7.6307 (1.5); 7.6124 (1.7); 7.6102 (1.7); 7.5920 (1.5); 7.4221 (3.1); 7.4014 (2.6); 6.8561 (1.9); 6.8381 (1.8); 6.6460 (1.9); 6.6256 (1.8); 4.0396 (5.4); 3.9215 (1.4); 3.8753 (1.8); 3.8166 (16.0); 3.5445 (1.1); 3.4981 (0.8); 3.3367 (14.9); 2.8908 (2.3); 2.7320 (2.0); 2.5256 (0.4); 2.5121 (7.0); 2.5078 (13.6); 2.5033 (17.8); 2.4988 (13.1); 2.4944 (6.6); -0.0002 (1.9) I.044: 1H NMR (300.2 MHz, CDCI3): δ= 8.1103 (1.0); 8.1044 (1.1); 8.0935 (1.1); 8.0875 (1.1); 7.6150 (2.4); 7.5876 (2.8); 7.3496 (1.0); 7.3436 (1.1); 7.3256 (1.2); 7.3197 (1.2); 7.2986 (4.3); 7.2711 (2.3); 6.8779 (1.2); 6.8609 (1.2); 6.8539 (1.2); 6.8370 (1.0); 3.9820 (16.0); 3.9695 (5.4); 3.7554 (1.0); 3.6962 (1.7); 3.5641 (1.0); 3.5046 (0.6); 2.6534 (0.6); 0.0383 (2.0) Petition 870250039092, dated 05 / 14 / 2025, pp. 153 / 383 146 / 178 1.045: 1H NMR (300.2 MHz, CDCI3): δ= 8.1093 (2.4); 8.0917 (2.4); 7.6371 (3.7); 7.6103 (4.2); 7.4948 (0.4); 7.4673 (0.4); 7.4558 (0.4); 7.3636 (0.3); 7.3463 (0.4); 7.2983 (2.9); 7.2796 (4.3); 7.2530 (3.7); 6.7322 (2.0); 6.7149 (1.9); 6.5663 (3.6); 3.9701 (7.9); 3.9407 (16.0); 3.7501 (1.4); 3.6908 (2.7); 3.5664 (2.0); 3.5066 (1.1); 2.4267 (0.4); 1.2906 (0.4); 0.0361 (3.2) 1.046: de1H NMR (300.2 MHz, d6-DMSO): δ= 8.6414 (2.0); 8.3363 (2.9); 8.1604 (1.6); 8.1449 (1.7); 7.6732 (3.0); 7.6457 (3.6); 7.3489 (3.2); 7.3213 (2.6); 7.1652 (1.6); 7.1497 (1.5); 3.9900 (5.2); 3.9498 (1.4); 3.9117 (16.0); 3.8880 (1.9); 3.5671 (1.1); 3.5048 (0.8); 3.3526 (10.7); 2.9105 (0.8); 2.7517 (0.6); 2.5343 (2.3); 2.5284 (4.7); 2.5224 (6.4); 2.5164 (4.7); 2.5105 (2.2); 0.0199 (4.7) 1.047: de1H NMR (300.2 MHz, d6-DMSO): δ= 8.6237 (4.2); 8.1203 (2.0); 8.1134 (2.1); 7.6762 (3.2); 7.6490 (3.8); 7.5800 (1.5); 7.5720 (1.4); 7.5517 (1.5); 7.5437 (1.5); 7.3738 (3.5); 7.3466 (2.9); 6.7823 (2.2); 6.7542 (2.0); 3.9561 (6.2); 3.8884 (2.0); 3.8298 (16.0); 3.5665 (1.3); 3.5047 (1.0); 3.3501 (8.2); 2.9107 (0.8); 2.7516 (0.7); 2.5282 (6.5); 2.5225 (8.4); 2.5168 (6.3); 0.0200 (5.7) I. 048: 1H NMR (300.2 MHz, acetone): δ= 8.2211 (6.8); 7.7391 (5.6); 7.7331 (2.0); 7.7175 (2.1); 7.7113 (6.6); 7.4124 (5.6); 7.3842 (5.0); 7.3692 (1.9); 6.1457 (0.6); 3.9934 (2.7); 3.9323 (4.0); 3.9007 (10.9); 3.6709 (2.4); 3.6665 (2.4); 3.6097 (1.6); 3.6053 (1.7); 3.6008 (0.7); 2.9363 (15.7); 2.9198 (16.0); 2.8779 (2.2); 2.0960 (1.9); 2.0887 (3.8); 2.0814 (5.6); 2.0740 (3.8); 2.0667 (1.9); 1.9948 (1.2); 1.2509 (0.3); 1.2271 (0.7); 1.2033 (0.3) Petition 870250039092, dated 05 / 14 / 2025, p. 154 / 383 147 / 178 1.049: 1H NMR (300.2 MHz, CDCI3): δ= 7.6950 (8.1); 7.6673 (9.7); 7.6448 (0.3); 7.5200 (7.1); 7.5074 (7.3); 7.3525 (8.7); 7.3247 (7.4); 7.2989 (23.0); 6.8673 (5.2); 6.8547 (5.0); 4.2461 (16.0); 3.7777 (4.1); 3.7183 (6.5); 3.5790 (3.8); 3.5757 (3.8); 3.5196 (2.1); 3.5163 (2.2); 1.6647 (2.8); 1.5964 (1.3); 1.4689 (0.5); 1.3662 (0.5); 1.3283 (0.5); 1.2905 (2.1); 1.2516 (0.5); 1.2291 (0.5); 0.8981 (2.0); 0.8767 (2.1); 0.0473 (0.8); 0.0365 (24.0); 0.0256 (1.0) 1.050: de1H NMR (400.1 MHz, d6-DMSO): δ= 8.7620 (8.3); 7.9244 (8.0); 7.9042 (12.1); 7.8725 (5.1); 7.8583 (6.4); 7.8521 (6.8); 7.8359 (16.0); 7.8148 (7.7); 7.4454 (5.2); 7.4239 (9.5); 7.4022 (4.6); 4.0433 (4.6); 4.0306 (0.6); 3.9966 (5.6); 3.6485 (4.2); 3.6018 (3.3); 3.3131 (31.3); 2.5094 (14.7); 1.9958 (1.6); 1.2437 (0.7); 1.2002 (0.5); 1.1828 (0.9); 1.1650 (0.4) 1.051: de1H NMR (300.2 MHz, d6-DMSO): δ= 8.6324 (7.8); 7.7076 (5.3); 7.6800 (6.3); 7.3646 (5.5); 7.3583 (8.5); 7.3289 (4.7); 6.0025 (4.4); 5.9968 (4.3); 4.1121 (9.2); 3.9766 (3.8); 3.9695 (3.0); 3.9531 (5.0); 3.9289 (3.6); 3.9074 (3.3); 3.5811 (2.0); 3.5167 (1.5); 3.3523 (16.0); 2.5342 (2.9); 2.5284 (6.0); 2.5224 (8.1); 2.5163 (5.9); 2.5105 (2.8); 1.6993 (0.4); 1.6747 (1.8); 1.6502 (3.4); 1.6262 (3.4); 1.6020 (2.0); 1.5776 (0.5); 1.2556 (0.6); 1.0898 (0.4); 0.8047 (6.4); 0.7801 (13.3); 0.7554 (5.7); 0.0204 (7.4); 0.0094 (0.3) I. 052: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.4273 (2.1); 7.8490 (2.0); 7.7369 (1.6); 7.7093 (2.0); 7.3823 (1.8); 7.3545 (1.5); 5.4407 (2.9); 3.9653 (0.8); 3.9037 (1.0); 3.5806 (0.7); 3.5173 (0.6); 3.3459 (16.0); 3.1906 (0.5); 2.5280 (13.8); 2.5221 (18.5); 2.5161 (13.7); 0.0312 (0.9); 0.0205 (19.6) Petition 870250039092, dated 05 / 14 / 2025, pp. 155 / 383 148 / 178 1.053: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.6255 (2.8); 7.6930 (3.8); 7.6652 (5.1); 7.5010 (4.6); 7.4735 (3.5); 7.4418 (2.0); 7.4348 (1.0); 7.4228 (2.4); 7.4130 (2.7); 7.4012 (1.1); 7.3942 (2.4); 7.1865 (0.4); 7.1767 (2.7); 7.1697 (0.9); 7.1540 (1.1); 7.1469 (4.7); 7.1395 (1.1); 7.1239 (0.8); 7.1172 (2.2); 6.0995 (2.6); 6.0860 (2.8); 5.7951 (2.0); 5.7780 (6.0); 4.0614 (0.7); 4.0377 (0.7); 4.0093 (0.4); 3.9500 (1.4); 3.8878 (1.8); 3.5658 (1.4); 3.5042 (1.1); 3.3517 (16.0); 2.5340 (2.0); 2.5280 (4.1); 2.5220 (5.5); 2.5160 (4.0); 2.5101 (1.8); 2.0139 (1.4); 2.0093 (3.1); 1.2186 (0.8); 1.1949 (1.6); 1.1711 (0.8); 1.0999 (0.7); 1.0766 (1.4); 1.0533 (0.7); 0.9046 (0.5); 0.0202 (3.2) 1,054: RMN de1H (400.2 MHz, d6-DMSO): δ= 9.8198 (16.0); 8.6666 (2.9); 8.6250 (12.8); 7.9533 (1.4); 7.8926 (7.3); 7.8833 (7.7); 7.7464 (2.0); 7.7258 (2.6); 7.7021 (8.6); 7.6816 (10.4); 7.5581 (2.3); 7.5374 (1.9); 7.4277 (9.4); 7.4071 (8.4); 7.1584 (5.7); 7.1491 (5.8); 4.8151 (5.0); 4.3114 (16.0); 3.9658 (1.1); 3.9417 (4.3); 3.9193 (1.4); 3.8954 (5.4); 3.5790 (0.9); 3.5601 (3.6); 3.5329 (0.8); 3.5136 (2.9); 3.3370 (67.2); 2.8911 (8.0); 2.7320 (7.3); 2.6725 (0.4); 2.6680 (0.4); 2.5078 (54.3); 2.5034 (71.2); 2.4991 (57.9); 2.3301 (0.4); 2.3263 (0.4); -0.0002 (3.0) I.055: de1H NMR (400.1 MHz, d6-DMSO): δ= 8.5854 (3.5); 7.6611 (8.0); 7.6416 (8.8); 7.3681 (7.1); 7.3494 (14.0); 7.3345 (8.0); 7.2795 (10.0); 7.2592 (6.3); 4.0467 (0.5); 4.0286 (0.6); 4.0028 (16.0); 3.9227 (3.9); 3.8763 (4.9); 3.6113 (0.8); 3.5454 (3.8); 3.4989 (3.0); 3.3138 (34.6); 2.5099 (28.4); 2.0931 (0.4); 2.0809 (3.6); 1.9972 (1.4); 1.7839 (0.4); 1.7693 (0.8); 1.2690 (0.4); 1.2444 (1.3); 1.2026 (0.6); 1.1844 (1.0); 1.1669 (0.5) Petition 870250039092, dated 05 / 14 / 2025, pp. 156 / 383 149 / 178 1.056: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.6361 (8.0); 7.6897 (8.2); 7.6621 (9.7); 7.3393 (8.6); 7.3117 (7.3); 5.7793 (2.0); 4.1180 (13.4); 4.0844 (0.4); 4.0605 (0.8); 4.0369 (0.8); 3.9605 (3.7); 3.8988 (5.0); 3.5735 (3.0); 3.5116 (2.2); 3.3539 (16.0); 2.9098 (0.5); 2.7499 (0.5); 2.5333 (38.2); 2.5220 (9.8); 2.5160 (6.8); 2.5101 (3.3); 2.2960 (33.8); 2.0091 (3.1); 1.2180 (0.8); 1.1942 (1.7); 1.1705 (0.8); 0.0194 (3.8) 1.057: 1H NMR (400.1 MHz, d6-DMSO): δ= 8.5984 (4.5); 7.6640 (9.1); 7.6443 (10.2); 7.4244 (1.5); 7.4034 (3.3); 7.3851 (3.4); 7.3640 (1.6); 7.3255 (9.7); 7.3056 (8.6); 7.2407 (1.7); 7.2360 (1.8); 7.2113 (3.2); 7.1866 (1.7); 7.0777 (1.9); 7.0590 (3.3); 7.0378 (1.6); 4.0157 (16.0); 3.9194 (4.4); 3.8730 (5.6); 3.5437 (4.4); 3.4973 (3.4); 3.3141 (31.2); 2.5101 (23.7) 1.058: 1H NMR (300.2 MHz, CDCI3): δ= 8.0262 (0.9); 7.9128 (4.4); 7.8968 (4.5); 7.6794 (7.8); 7.6525 (8.9); 7.5985 (0.3); 7.5427 (0.4); 7.5227 (0.6); 7.5072 (0.6); 7.4806 (0.7); 7.4632 (0.4); 7.3297 (9.0); 7.2992 (18.7); 6.9933 (3.0); 6.9774 (5.3); 6.9617 (3.0); 4.6915 (0.5); 4.2265 (0.4); 4.1311 (16.0); 3.7586 (2.9); 3.6995 (5.4); 3.5708 (3.7); 3.5109 (2.1); 2.9911 (4.7); 2.9050 (4.5); 2.6590 (7.4); 1.8357 (0.5); 1.7992 (0.6); 1.7619 (0.8); 1.6606 (0.9); 1.5161 (0.4); 0.0359 (17.1) I. 059: 1H NMR (300.2 MHz, CDCI3): δ= 7.7072 (1.5); 7.6806 (3.2); 7.6595 (10.0); 7.6537 (5.8); 7.6378 (4.0); 7.6318 (11.7); 7.6253 (3.2); 7.3100 (9.5); 7.2990 (6.0); 7.2828 (8.0); 6.8298 (3.3); 6.8204 (3.3); 6.8031 (3.2); 6.7937 (3.1); 4.8255 (0.4); 4.0363 (16.0); 3.8202 (0.3); 3.7833 (0.4); 3.7667 (4.4); 3.7073 (7.7); 3.5706 (4.7); 3.5668 (4.7); 3.5111 (2.5); 3.5072 (2.5); 1.3020 (0.4); 1.2907 (0.8); 1.2788 (0.4); 0.0469 (0.3); 0.0362 (6.0) Petition 870250039092, dated 05 / 14 / 2025, pp. 157 / 383 150 / 178 1,060: RMN de1H (300.2 MHz, CDCI3): δ= 7.6888 (5.4); 7.6617 (6.2); 7.5057 (0.4); 7.4782 (0.6); 7.4655 (0.4); 7.4409 (0.5); 7.3731 (0.4); 7.3633 (0.4); 7.3492 (0.4); 7.3403 (0.4); 7.2984 (7.5); 7.2966 (7.3); 7.2688 (5.5); 6.6442 (16.0); 4.6700 (0.4); 4.6643 (0.4); 4.1958 (0.4); 4.1897 (0.4); 4.0911 (13.2); 3.7692 (2.1); 3.7098 (3.9); 3.5914 (2.4); 3.5319 (1.3); 2.9889 (0.8); 2.8808 (0.7); 2.6681 (1.7); 1.2877 (0.3); 0.0351 (3.7) 1,061: RMN de1H (300.2 MHz, d6-DMSO): δ = 8.6425 (3.0); 7.7147 (2.7); 7.6871 (3.2); 7.3499 (2.8); 7.3222 (2.4); 6.6649 (3.3); 5.7793 (1.7); 4.0422 (4.4); 3.9688 (1.2); 3.9070 (1.6); 3.5796 (1.0); 3.5171 (0.7); 3.4023 (16.0); 3.3506 (12.4); 2.5341 (1.8); 2.5281 (3.8); 2.5220 (5.2); 2.5160 (3.7); 2.5100 (1.7); 0.0196 (4.8) 1,062: RMN de1H (499.9 MHz, d6-DMSO): δ= 9.0245 (4.9); 8.6155 (5.3); 7.6703 (4.0); 7.6538 (4.6); 7.2896 (3.9); 7.2731 (3.8); 4.1234 (6.9); 3.9199 (2.0); 3.8829 (2.4); 3.5384 (1.6); 3.5012 (1.4); 3.3267 (19.7); 3.2421 (0.5); 3.2283 (0.7); 3.2150 (1.2); 3.2016 (1.6); 3.1882 (1.2); 3.1700 (1.4); 2.8910 (0.9); 2.7316 (0.8); 2.5058 (6.4); 2.5023 (8.9); 2.4988 (7.0); 2.3528 (0.5); 2.0734 (3.2); 1.8784 (0.5); 1.0517 (15.7); 1.0384 (16.0); -0.0002 (5.1); -0.0065 (0.4) I.063: de1H NMR (300.2 MHz, d6-DMSO): δ= 8.6333 (1.9); 7.6515 (4.0); 7.6240 (4.8); 7.3081 (4.2); 7.2805 (3.6); 7.2290 (5.4); 5.7796 (2.2); 4.0328 (1.9); 4.0131 (3.6); 3.9928 (2.0); 3.9450 (1.8); 3.8833 (2.4); 3.7442 (7.1); 3.5710 (1.5); 3.5089 (1.1); 3.3554 (16.0); 2.5990 (1.8); 2.5778 (3.7); 2.5570 (2.0); 2.5341 (2.4); 2.5281 (4.9); 2.5221 (6.7); 2.5160 (4.8); 2.5101 (2.2); 1.9629 (0.4); 1.9437 (1.0); 1.9327 (1.2); 1.9244 (1.8); 1.9050 (1.4); 1.8928 (0.6); 1.8853 (0.6); 1.7972 (0.7); 1.7910 (0.6); 1.7769 (1.7); 1.7703 (1.3); 1.7568 (1.6); 1.7389 (1.2); 1.7177 (0.4); 0.0197 (5.7) Petition 870250039092, dated 05 / 14 / 2025, pp. 158 / 383 151 / 178 1.064: 1H NMR (400.1 MHz, d6-DMSO): δ= 8.5979 (4.8); 7.6886 (4.5); 7.6696 (5.0); 7.6138 (0.4); 7.3540 (5.0); 7.3400 (5.1); 7.3205 (4.4); 6.4940 (0.3); 5.9728 (4.7); 4.0913 (9.0); 3.9411 (2.1); 3.8949 (2.7); 3.8060 (5.4); 3.7879 (5.0); 3.5590 (2.3); 3.5123 (1.8); 3.3145 (52.7); 2.5105 (13.8); 2.0819 (0.9); 2.0688 (1.1); 2.0519 (1.4); 2.0349 (1.1); 2.0184 (0.6); 0.7978 (16.0); 0.7814 (15.5); 0.7538 (1.3); 0.7362 (1.2) 1.065: 1H NMR (400.2 MHz, d6-DMSO): δ = 8.6655 (0.5); 8.6206 (11.2); 7.9542 (0.7); 7.7860 (7.5); 7.7766 (7.7); 7.7466 (0.5); 7.7258 (0.7); 7.6942 (9.2); 7.6737 (10.8); 7.5581 (0.6); 7.5375 (0.5); 7.4093 (9.8); 7.3888 (8.6); 7.0522 (5.8); 7.0428 (5.7); 4.8151 (1.3); 4.2605 (16.0); 3.9400 (4.4); 3.9196 (0.4); 3.8936 (5.6); 3.5582 (3.5); 3.5115 (2.8); 3.3361 (56.1); 2.8912 (3.7); 2.7323 (3.3); 2.6721 (0.4); 2.6347 (0.4); 2.5077 (46.4); 2.5033 (60.4); 2.4988 (45.8); 2.4642 (45.7); 2.3300 (0.4); -0.0002 (4.5) 1,066: RMN de1H (400.1 MHz, d6-DMSO): δ= 8.7664 (7.3); 7.9254 (9.9); 7.9052 (15.9); 7.8440 (16.0); 7.8236 (10.0); 7.7930 (11.1); 7.7724 (15.2); 7.6750 (15.1); 7.6544 (10.8); 4.0648 (1.2); 4.0445 (7.0); 4.0301 (3.3); 4.0121 (1.4); 3.9966 (7.3); 3.6479 (5.4); 3.6011 (4.3); 3.3117 (30.6); 2.5095 (22.7); 1.9963 (12.1); 1.2439 (1.0); 1.2018 (3.4); 1.1839 (6.4); 1.1662 (3.1); 0.8945 (0.4) I.067: RMN de1H(400.1 MHz, d6-DMSO): δ= 8.7798 (5.7); 7.9354 (6.9); 7.9150 (16.0); 7.8873 (15.9); 7.8667 (6.7); 7.6671 (2.0); 7.6443 (3.8); 7.6215 (1.9); 7.4394 (7.6); 7.4242 (7.4); 4.0643 (0.8); 4.0454 (6.4); 4.0299 (2.0); 4.0105 (1.0); 3.9979 (6.3); 3.6489 (4.8); 3.6021 (3.8); 3.3130 (40.6); 2.5098 (18.1); 1.9962 (7.1); 1.2430 (0.8); 1.2017 (2.0); 1.1839 (3.7); 1.1662 Ϊ19_________________________________________________ Petition 870250039092, dated 05 / 14 / 2025, p. 159 / 383 152 / 178 1.068: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.6454 (1.6); 7.6927 (2.3); 7.6649 (3.0); 7.4990 (2.8); 7.4714 (2.1); 7.4316 (0.6); 7.4221 (0.4); 7.4015 (5.9); 7.3935 (6.2); 7.3843 (0.6); 7.3730 (0.4); 7.3660 (0.6); 7.3635 (0.6); 6.1556 (1.5); 6.1420 (1.6); 5.7940 (1.3); 5.7808 (1.2); 3.9462 (0.8); 3.8845 (1.1); 3.5755 (0.8); 3.5133 (0.6); 3.3502 (16.0); 2.5342 (2.3); 2.5282 (4.8); 2.5221 (6.5); 2.5161 (4.7); 2.5102 (2.2); 2.0954 (5.7); 0.0201 (4.6) 1,069: RMN de1H (300.2 MHz, d6-DMSO): δ= 8.6330 (2.2); 7.7076 (2.8); 7.6797 (3.9); 7.5430 (3.5); 7.5154 (2.6); 7.1539 (0.4); 7.1342 (2.1); 7.1258 (1.4); 7.1113 (1.9); 7.1051 (1.6); 7.0942 (1.5); 7.0869 (1.3); 7.0799 (0.5); 7.0646 (0.6); 7.0569 (0.6); 6.3144 (2.3); 6.3007 (2.4); 5.8210 (1.5); 5.8075 (1.5); 3.9539 (1.2); 3.8922 (1.6); 3.5709 (1.1); 3.5088 (0.8); 3.3509 (16.0); 2.5341 (1.5); 2.5281 (3.1); 2.5220 (4.3); 2.5159 (3.2); 2.5099 (1.6); 2.0950 (3.7); 0.0192 (2.3) I.070: RMN de1H (300.2 MHz, d6-DMSO): δ= 8.5987 (4.6); 7.6472 (3.1); 7.6197 (4.0); 7.4486 (1.7); 7.4215 (2.5); 7.4136 (5.4); 7.3861 (4.9); 7.1706 (4.0); 7.1428 (1.3); 7.1395 (1.6); 7.1159 (0.9); 7.1124 (0.9); 7.0063 (1.2); 7.0033 (1.2); 6.9800 (1.8); 6.9567 (0.8); 6.9537 (0.8); 4.0993 (5.5); 3.9351 (1.5); 3.8734 (2.0); 3.7595 (16.0); 3.5554 (1.2); 3.4932 (0.9); 3.3460 (16.0); 2.5341 (3.4); 2.5282 (7.0); 2.5222 (9.5); 2.5161 (6.8); 2.5103 (3.2); 2.0953 (2.6); 0.0211 (6.8) Petition 870250039092, dated 05 / 14 / 2025, pp. 160 / 383 153 / 178 1.071: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.6227 (7.9); 7.6660 (7.1); 7.6386 (8.6); 7.6021 (0.4); 7.5741 (8.6); 7.5403 (0.5); 7.5339 (0.5); 7.5215 (0.4); 7.3540 (7.6); 7.3266 (6.4); 7.2705 (8.1); 5.7793 (3.0); 4.6690 (0.5); 4.6449 (1.5); 4.6229 (2.7); 4.6011 (1.7); 4.5758 (0.7); 3.9501 (3.2); 3.8884 (4.4); 3.8123 (12.4); 3.5690 (2.7); 3.5058 (2.0); 3.3501 (16.0); 2.5337 (5.5); 2.5278 (11.4); 2.5219 (15.4); 2.5159 (11.2); 2.5102 (5.3); 2.0906 (0.5); 2.0676 (1.3); 2.0512 (1.8); 2.0247 (2.5); 2.0088 (2.2); 1.9983 (1.3); 1.9834 (0.8); 1.9255 (0.7); 1.9035 (2.0); 1.8800 (2.5); 1.8637 (1.9); 1.8575 (1.9); 1.8433 (1.4); 1.8365 (1.5); 1.8212 (1.4); 1.8152 (1.7); 1.8010 (1.3); 1.7916 (1.8); 1.7797 (2.1); 1.7664 (2.1); 1.7619 (2.2); 1.7482 (1.6); 1.7433 (1.8); 1.7173 (0.7); 1.7099 (0.8); 1.6946 (0.4); 1.6739 (0.8); 1.6663 (0.6); 1.6540 (1.2); 1.6418 (2.2); 1.6278 (2.2); 1.6190 (2.6); 1.6120 (1.6); 1.6019 (2.0); 1.5930 (1.5); 1.5820 (0.8); 1.5629 (0.3); 0.0306 (0.4); 0.0198 (10.5); 0.0088 (0.4) I.072: RMN de1H (300.2 MHz, d6-DMSO): δ= 8.6717 (0.7); 8.5240(1.0); 7.9079 (0.9); 7.9061 (0.9); 7.7355 (0.8); 7.7078 (0.9); 7.3874 (0.8); 7.3597 (0.7); 5.4505 (1.4); 4.2422 (1.0); 4.2186 (1.0); 3.9653 (0.3); 3.9033 (0.5); 3.3462 (16.0); 2.5340 (1.8); 2.5281 (3.8); 2.5220 (5.1); 2.5160 (3.7); 2.5101 (1.8); 1.3031 (1.1); 1.2795 (2.3); 1.2558 (1.0); 0.0203 (7.5); 0.0093 (0.3) Petition 870250039092, dated 05 / 14 / 2025, pp. 161 / 383 154 / 178 1.073: 1H NMR (300.2 MHz, CDCI3): δ= 7.6770 (6.2); 7.6712 (6.4); 7.5831 (8.3); 7.5555 (9.7); 7.4902 (0.9); 7.4784 (1.2); 7.4722 (1.2); 7.4606 (4.9); 7.4461 (4.7); 7.4367 (11.8); 7.4214 (2.7); 7.4168 (1.9); 7.4000 (0.7); 7.3943 (0.6); 7.3660 (7.4); 7.3582 (5.6); 7.3510 (2.7); 7.3486 (2.7); 7.3450 (2.7); 7.3393 (4.7); 7.3338 (3.9); 7.2991 (15.3); 7.1802 (8.3); 7.1526 (7.3); 6.1982 (5.7); 6.1928 (5.8); 4.7439 (1.0); 4.1699 (0.5); 4.1461 (0.7); 4.1228 (0.5); 4.1009 (0.8); 4.0778 (16.0); 3.7274 (3.8); 3.7029 (0.5); 3.6681 (6.2); 3.4933 (3.8); 3.4901 (3.9); 3.4340 (2.3); 3.4305 (2.4); 2.0845 (4.1); 1.6801 (4.4); 1.6204 (0.8); 1.5983 (0.6); 1.5781 (0.5); 1.5436 (0.3); 1.4488 (0.5); 1.4378 (0.5); 1.4039 (0.5); 1.3367 (1.1); 1.3190 (2.0); 1.2930 (6.5); 1.2756 (1.2); 1.2717 (1.5); 0.9961 (0.6); 0,9716 (1,0); 0,9405 (1,0); 0,9193 (2,4); 0,8960 (1,9); 0,8780 (1,3); 0,1086 (2,0); 0,0483 (0,6); 0,0376 (16,9); 0,0269 (0,8) 1.074: RMN de1H (400,1 MHz, d6-DMSO): δ= 8,5970 (6,0); 7,6577 (7,7); 7,6380 (8,3); 7,5556 (8,4); 7,5356 (10,5); 7,3964 (3,2); 7,3761 (4,7); 7,3563 (2,0); 7,2276 (7,9); 7,2076 (7,2); 4,3384 (15,3); 3,9156 (3,7); 3,8692 (4,6); 3,5380 (3,6); 3,4914 (2,8); 3,3148 (15,3); 2,5099 (13,8); 2,0808 (16,0); 1,2429 (0,4) 1.075: RMN de1H (300,2 MHz, CDCI3): δ= 8,2451 (5,6); 8,2287 (5,7); 8,0272 (1,8); 7,6829 (6,8); 7,6556 (7,8); 7,2987 (21,9); 7,2699 (6,6); 7,0274 (5,1); 7,0110 (5,0); 4,2023 (16,0); 3,7651 (2,6); 3,7058 (4,7); 3,5747 (3,0); 3,5148 (1,6); 2,9918 (12,7); 2,9063 (11,5); 2,6600 (4,6); 1,7126 (0,8); 1,6670 (0,6); 1,2892 (0,4); 0,0462 (0,6); 0,0354 (19,6); 0,0246 (1,1) I.076: RMN de1H (300,2 MHz, CDCI3): δ= 8.3937 (10.6); 7.6898 (7.2); 7.6625 (8.2); 7.2984 (11.6); 7.2708 (6.8); 7.0703 (9.4); 5.3349 (0.6); 4.1873 (0.4); 4.1636 (0.7); 4.1288 (16.0); 3.7763 (3.0); 3.7169 (5.3); 3.5869 (3.4); 3.5275 (1.8); 2.6643 (3.7); 2.0826 (2.2); 1.3123 (0.6); 1.2885 (1.5); 1.2647 (0.6); 0.0352 (4.8) Petition 870250039092, dated 05 / 14 / 2025, pp. 162 / 383 155 / 178 1.077: 1H NMR (400.1 MHz, d6-DMSO): δ= 9.6082 (6.6); 9.0104 (16.0); 8.6035 (5.7); 7.9547 (0.3); 7.6922 (6.5); 7.6718 (7.8); 7.6189 (0.4); 7.5990 (0.5); 7.5791 (0.4); 7.5590 (0.6); 7.5497 (0.5); 7.5314 (0.6); 7.5089 (0.4); 7.5003 (0.5); 7.4897 (0.7); 7.4551 (7.2); 7.4347 (6.2); 7.3037 (0.3); 5.7514 (5.4); 4.4990 (0.4); 4.4952 (0.4); 4.2195 (0.9); 4.1884 (11.4); 3.9243 (3.2); 3.8779 (4.1); 3.5500 (2.8); 3.5033 (2.2); 3.3057 (21.1); 2.8918 (1.8); 2.7326 (1.7); 2.5513 (1.0); 2.5061 (14.0); 2.5021 (18.2); 2.4981 (14.1); 2.3535 (1.1); 1.9886 (0.9); 1.1760 (0.4); -0.0002 (5.2) 1.078: 1H NMR (300.2 MHz, CDCI3): δ= 7.6122 (7.3); 7.5849 (9.0); 7.4633 (5.2); 7.4561 (5.3); 7.3405 (8.4); 7.3130 (7.2); 7.2992 (18.4); 6.1347 (6.2); 6.1269 (6.2); 4.7580 (2.7); 4.7300 (8.0); 4.7020 (8.0); 4.6739 (2.7); 4.0662 (16.0); 3.7519 (3.2); 3.6927 (5.4); 3.5423 (3.6); 3.4829 (2.1); 2.0938 (0.4); 1.3214 (0.4); 1.2930 (0.8); 0.8914 (0.6); 0.8761 (0.7); 0.0480 (1.0); 0.0373 (20.6); 0.0266 (1.0) I. 079: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.6714 (0.4); 8.2535 (0.5); 7.8745 (0.5); 7.7342 (0.4); 7.7065 (0.4); 7.3556 (0.4); 7.3280 (0.3); 5.4148 (0.6); 3.3465 (16.0); 2.5341 (1.6); 2.5281 (3.5); 2.5221 (4.8); 2.5160 (3.4); 2.5102 (1.6); 0.0204 (6.7) Petition 870250039092, dated 05 / 14 / 2025, pp. 163 / 383 156 / 178 1.080: 1H NMR (300.2 MHz, CDCI3): δ= 7.8555 (0.4); 7.8269 (0.6); 7.7447 (0.6); 7.7166 (0.5); 7.6831 (8.1); 7.6555 (9.9); 7.6032 (0.4); 7.3939 (8.3); 7.3661 (6.9); 7.2990 (23.1); 7.1422 (3.6); 7.1371 (3.8); 7.1167 (4.0); 7.1116 (4.2); 6.9795 (1.8); 6.9742 (1.8); 6.9507 (3.5); 6.9276 (2.4); 6.9224 (2.3); 6.7066 (2.4); 6.7032 (2.6); 6.6814 (4.0); 6.6785 (4.2); 6.6569 (1.9); 6.6535 (2.0); 6.5895 (4.5); 6.5621 (3.8); 5.3391 (0.6); 4.6043 (16.0); 3.8298 (0.4); 3.7745 (4.1); 3.7555 (6.2); 3.7441 (4.7); 3.7384 (6.8); 3.7317 (4.6); 3.7206 (8.2); 3.7160 (7.8); 3.6290 (0.4); 3.5724 (4.3); 3.5127 (2.4); 3.1482 (6.8); 3.1375 (4.4); 3.1307 (6.5); 3.1249 (4.4); 3.1136 (5.9); 1.6827 (0.9); 1.3093 (0.6); 1.2932 (0.4); 1.2792 (0.7); 0.0491 (1.1); 0.0385 (23.1); 0.0275 (0.9) 1.081: NMR de1H (300.2 MHz, CDCI3): δ= 7.6912 (2.9); 7.6634 (3.8); 7.4913 (3.4); 7.4637 (2.6); 7.3817 (1.4); 7.3750 (0.7); 7.3637 (1.6); 7.3528 (1.9); 7.3419 (0.8); 7.3349 (1.8); 7.2986 (5.0); 7.0944 (1.9); 7.0876 (0.6); 7.0656 (3.4); 7.0434 (0.6); 7.0366 (1.5); 5.8975 (1.9); 3.9789 (0.7); 3.9761 (0.7); 3.9152 (1.2); 3.7571 (2.4); 3.6964 (1.4); 2.3340 (0.8); 2.2078 (16.0); 2.0438 (1.6); 1.6010 (1.0); 1.2938 (0.7); 0.1084 (0.5); 0.0381 (5.1) 1.082: de1H NMR (400.2 MHz, d6-DMSO): δ= 8.6105 (1.3); 7.6490 (6.3); 7.6290 (7.4); 7.5237 (7.6); 7.3327 (6.9); 7.3168 (10.8); 4.9780 (16.0); 4.1512 (2.2); 4.1336 (6.8); 4.1159 (6.9); 4.0980 (2.4); 3.9189 (3.1); 3.8725 (3.9); 3.8288 (11.8); 3.5444 (2.8); 3.4979 (2.2); 3.3343 (24.9); 2.8892 (0.6); 2.7304 (0.6); 2.5013 (43.0); 1.2103 (7.2); 1.1926 (14.5); 1.1748 (7.1); -0.0002 (1.7) I.083: NMR de1H(400.1 MHz, CDCl3): δ= 7.5728 (7.1); 7.5524 (8.2); 7.3380 (2.2); 7.3207 (6.7); 7.3168 (5.6); 7.3099 (9.2); 7.3030 (8.0); 7.2892 (9.1); 7.2697 (3.1); 7.2555 (10.8); 7.1142 (6.1); 7.0967 (5.3); 6.6184 (3.1); 6.6128 (5.2); 6.6070 (3.2); 6.4291 (4.9); 5.9823 (4.7); 5.2950 (0.5); 4.9881 (16.0); 3.8434 (14.5); 3.7203 (3.4); 3.6759 (5.3); 3.5228 (3.7); 3.4785 (2.4); 3.4124 (6.0); 1.5780 (10.9); -0.0002 (6.8) Petition 870250039092, dated 05 / 14 / 2025, pp. 164 / 383 157 / 178 1.084: 1H NMR (300.2 MHz, d6-DMSO): δ= 8.6364 (2.5); 7.6497 (2.0); 7.6222 (2.4); 7.4344 (1.8); 7.4285 (1.8); 7.3402 (0.3); 7.3315 (0.4); 7.3111 (1.6); 7.3060 (0.8); 7.2871 (2.3); 7.2815 (1.7); 7.2735 (2.4); 7.2613 (0.8); 7.2455 (1.9); 7.0779 (1.3); 7.0719 (1.4); 7.0510 (1.3); 6.0384 (1.6); 6.0326 (1.6); 5.3090 (3.8); 4.0559 (3.4); 3.9508 (0.9); 3.8891 (1.2); 3.5650 (0.7); 3.5018 (0.5); 3.3517 (16.0); 2.5344 (1.2); 2.5284 (2.5); 2.5223 (3.4); 2.5163 (2.4); 2.5103 (1.1); 1.0902 (0.4); 0.0206 (3.4) 1,085: RMN de1H (300.2 MHz, d6-DMSO): δ= 8.6048 (2.2); 7.6189 (2.0); 7.5912 (2.2); 7.5488 (0.8); 7.5416 (1.1); 7.5324 (0.9); 7.5267 (1.1); 7.5160 (1.9); 7.5098 (0.4); 7.4853 (0.4); 7.4802 (0.8); 7.4777 (0.7); 7.4708 (2.8); 7.4645 (2.6); 7.4538 (1.2); 7.4468 (1.1); 7.1817 (1.9); 7.1539 (1.6); 5.7796 (3.4); 3.9881 (2.9); 3.9281 (0.8); 3.8663 (1.1); 3.5345 (0.7); 3.4708 (0.5); 3.3489 (16.0); 2.5340 (2.4); 2.5280 (5.1); 2.5219 (7.0); 2.5159 (5.0); 2.5099 (2.3); 2.4409 (8.6); 0.0199 (5.7) 1,086: RMN de1H (300.2 MHz, d6-DMSO): δ = 7.7140 (0.7); 7.6863 (1.0); 7.5430 (1.0); 7.5154 (0.7); 7.4815 (0.6); 7.4752 (0.5); 7.4473 (1.5); 7.4412 (1.2); 6.3383 (0.3); 6.3257 (0.4); 5.8267 (0.4); 5.8161 (0.4); 3.9534 (0.3); 3.8917 (0.4); 3.3466 (16.0); 2.5336 (1.6); 2.5279 (3.0); 2.5220 (4.0); 2.5160 (2.9); 2.0949 (0.4); 0.0201 (2.5) I. 087: 1H NMR (400.2 MHz, d6-DMSO): δ= 8.6038 (1.3); 7.9518 (0.4); 7.6381 (7.0); 7.6177 (8.2); 7.5768 (8.0); 7.4501 (3.5); 7.4472 (3.9); 7.4374 (3.8); 7.4344 (4.0); 7.3198 (7.4); 7.3062 (9.7); 7.2993 (6.8); 7.0640 (3.1); 7.0556 (3.6); 6.9813 (3.7); 6.9727 (3.2); 6.9686 (3.8); 6.9600 (3.0); 5.4400 (16.0); 3.9151 (3.4); 3.8688 (4.3); 3.8012 (12.2); 3.5380 (2.6); 3.4914 (2.1); 3.3373 (35.1); 2.8892 (2.5); 2.7308 (2.2); 2.5239 (1.0); 2.5104 (18.6); 2.5062 (36.9); 2.5017 (48.3); 2.4972 (36.1); 2.4929 (18.4); -0.0002 (3.0) Petition 870250039092, dated 05 / 14 / 2025, pp. 165 / 383 158 / 178 1.088: 1H NMR (499.9 MHz, d6-DMSO): δ= 8.5961 (4.6); 7.6419 (8.9); 7.6255 (10.0); 7.4138 (4.2); 7.3986 (4.7); 7.3434 (4.6); 7.3274 (5.1); 7.1010 (8.6); 7.0846 (8.5); 7.0407 (1.8); 7.0265 (4.2); 7.0120 (3.0); 6.9948 (3.6); 6.9801 (4.8); 6.9659 (2.0); 5.3826 (16.0); 3.8841 (4.5); 3.8470 (5.5); 3.5090 (3.6); 3.4718 (3.1); 3.3232 (62.4); 2.6778 (3.1); 2.6660 (6.1); 2.6524 (4.8); 2.6376 (6.2); 2.6257 (3.6); 2.5059 (7.6); 2.5027 (10.2); 2.4994 (8.0); 1.8582 (2.4); 1.8489 (3.5); 1.8398 (3.7); 1.7943 (3.8); 1.7851 (3.6); 1.7763 (2.6); 1.2365 (1.7) 1,089: RMN de1H (400.1 MHz, d6-DMSO): δ= 8.5862 (8.7); 7.7001 (5.2); 7.6950 (5.1); 7.6315 (6.8); 7.6112 (7.9); 7.3919 (0.7); 7.3867 (0.7); 7.3730 (1.7); 7.3542 (2.2); 7.3274 (7.4); 7.3070 (6.6); 7.2719 (0.3); 7.2387 (2.2); 7.2151 (2.5); 7.1928 (3.2); 7.1739 (3.9); 7.1559 (3.0); 7.1457 (2.4); 7.1410 (2.3); 7.1267 (2.8); 7.1079 (1.2); 6.0472 (5.5); 6.0420 (5.4); 5.3287 (13.2); 3.9177 (16.0); 3.8711 (4.3); 3.5374 (2.8); 3.4913 (2.3); 3.3173 (11.2); 2.5042 (14.0); 2.5005 (17.9); 2.4966 (13.7); -0.0002 (9.1) I.090: RMN de1H (300.2 MHz, d6-DMSO): δ= 7.7274 (3.0); 7.6998 (4.1); 7.5592 (4.0); 7.5316 (3.0); 7.4449 (0.9); 7.4386 (1.4); 7.4310 (0.7); 7.4162 (3.9); 7.4104 (4.6); 7.4061 (3.2); 7.3987 (1.0); 7.3835 (3.6); 7.3775 (1.2); 7.3636 (1.0); 7.3579 (1.4); 7.3442 (1.0); 7.3380 (1.4); 7.3310 (0.8); 7.3258 (0.6); 7.3152 (1.2); 7.3044 (0.3); 7.2984 (0.3); 7.2931 (0.4); 6.8471 (3.8); 4.3108 (0.4); 4.3010 (0.3); 4.2463 (0.8); 4.2361 (0.9); 4.1669 (1.3); 4.1538 (1.2); 4.1030 (0.5); 4.0897 (0.6); 3.3479 (13.5); 2.5339 (2.6); 2.5280 (5.5); 2.5219 (7.6); 2.5159 (5.6); 2.5100 (2.7); 2.1866 (16.0); 2.1666 (1.2); 2.1555 (13.4); 2.1350 (1.3); 1.2561 (1.1); 0.0203 (3.2) Petition 870250039092, dated 05 / 14 / 2025, pp. 166 / 383 159 / 178 1.091: 1H NMR (400.1 MHz, d6-DMSO): δ= 8.6334 (1.2); 8.3473 (7.1); 7.9652 (9.4); 7.7185 (6.1); 7.6998 (6.8); 7.6243 (5.9); 7.6055 (7.1); 7.4212 (7.0); 7.4020 (6.0); 7.3702 (6.7); 7.3510 (6.0); 5.4154 (12.0); 3.9305 (2.8); 3.8837 (3.6); 3.5571 (3.1); 3.5098 (2.5); 3.3187 (163.5); 2.8999 (16.0); 2.7409 (15.2); 2.5612 (0.4); 2.5106 (25.6) 1,092: RMN de1H (300.2 MHz, d6-DMSO): δ= 9.8578 (0.8); 8.6793 (0.3); 8.4945 (1.4); 8.1006 (1.4); 7.7569 (1.0); 7.7289 (1.5); 7.7221 (1.1); 7.6965 (1.0); 7.4074 (1.1); 7.3795 (1.0); 7.3711 (0.7); 7.3456 (0.9); 7.3181 (0.6); 7.1062 (0.3); 7.0816 (0.5); 5.4827 (1.7); 3.9724 (0.4); 3.9106 (0.6); 3.5889 (0.4); 3.3472 (16.0); 2.5339 (2.0); 2.5280 (4.2); 2.5220 (5.7); 2.5159 (4.1); 2.5101 (2.0); 0.0202 (9.4); 0.0093 (0.4) 1,093: RMN de1H (400.2 MHz, CDCI3): δ= 8.5219 (1.1); 8.5054 (1.5); 8.4474 (1.1); 8.4434 (1.0); 7.6250 (1.5); 7.6051 (1.8); 7.3653 (1.7); 7.3454 (1.5); 7.2642 (1.9); 4.2102 (3.2); 3.7597 (0.8); 3.7146 (1.0); 3.3252 (0.7); 3.2800 (0.6); 0.8759 (16.0); 0.2411 (5.2); 0.0889 (5.7); -0.0005 (1.0) 1,094: RMN de1H (400.1 MHz, d6-DMSO): δ= 8.5805 (4.3); 7.9614 (3.7); 7.6961 (3.8); 7.6774 (4.4); 7.4492 (4.3); 7.4294 (3.7); 7.1794 (4.2); 7.1605 (4.8); 7.1024 (2.0); 7.0833 (4.2); 7.0639 (2.6); 6.9468 (2.9); 6.9283 (4.6); 6.9094 (2.0); 6.8163 (4.7); 6.7959 (4.0); 5.2036 (7.0); 3.9218 (1.8); 3.8748 (2.2); 3.5384 (2.0); 3.4924 (1.6); 3.3190 (121.5); 2.8997 (16.0); 2.7407 (15.2); 2.5107 (16.3) I.095: RMN de1H (400.2 MHz, d6-DMSO): δ= 7.7661 (1.2); 7.7453 (1.4); 7.4648 (1.3); 7.4612 (1.3); 7.3030 (1.2); 7.2821 (1.1); 6.9531 (1.2); 6.9496 (1.2); 5.2704 (2.3); 4.1379 (0.6); 4.0906 (0.7); 3.6798 (0.4); 3.6318 (0.3); 3.3321 (5.6); 2.5111 (4.8); 2.5067 (9.8); 2.5023 (13.0); 2.4978 (9.3); 2.4934 (4.4); 0.8558 (16.0); 0.8416 (0.4); 0.1582 (4.8); 0.0575 (5.4); -0.0002 (1.8) Petition 870250039092, dated 05 / 14 / 2025, page 167 / 383 160 / 178 1.096: 1H NMR (400.1 MHz, d6-DMSO): δ= 8.5906 (4.8); 8.0729 (3.3); 8.0525 (3.8); 7.9613 (3.6); 7.7130 (4.2); 7.6937 (4.9); 7.6642 (1.3); 7.4385 (5.3); 7.4086 (4.2); 7.3791 (2.2); 7.2983 (4.2); 7.2789 (3.8); 5.7150 (6.6); 3.9367 (1.9); 3.8903 (2.3); 3.5455 (2.0); 3.4990 (1.6); 3.3184 (182.8); 3.2646 (0.3); 2.9000 (16.0); 2.7408 (15.2); 2.5106 (22.8) 1.097: 1H NMR (400.2 MHz, d6-DMSO): δ= 8.7492 (10.0); 8.1383 (7.6); 8.1173 (8.6); 7.8784 (8.9); 7.8574 (7.3); 7.3366 (2.3); 7.3183 (6.3); 7.3003 (7.4); 7.2783 (9.2); 7.2611 (4.6); 7.2350 (3.2); 7.2175 (1.1); 6.5318 (1.2); 4.4346 (16.0); 4.0241 (3.3); 3.9775 (4.3); 3.6264 (2.8); 3.5798 (2.2); 3.3243 (91.5); 3.3007 (3.6); 2.6747 (1.6); 2.6705 (2.0); 2.5057 (250.8); 2.5014 (310.5); 2.4971 (217.4); 2.3326 (1.5); 2.3281 (1.9); 0.0000 (37.0); -0.0081 (1.7) I.098: 1H NMR (300.1 MHz, d6-DMSO): δ= 8.5964 (13.8); 7.6458 (10.0); 7.6183 (12.7); 7.3969 (11.7); 7.3696 (9.5); 7.2473 (2.4); 7.2224 (5.7); 7.2008 (9.9); 7.1693 (5.7); 7.1563 (13.0); 7.1477 (6.8); 7.1328 (6.6); 6.5292 (1.0); 5.4242 (8.2); 5.4085 (8.8); 4.8416 (1.3); 4.8218 (2.9); 4.8053 (2.8); 4.7830 (1.4); 4.3658 (0.5); 4.3488 (1.2); 4.3320 (0.5); 3.9443 (3.8); 3.8824 (5.3); 3.5529 (3.8); 3.4919 (2.7); 3.4593 (1.0); 3.4531 (0.3); 3.4425 (0.9); 3.4361 (0.8); 3.4192 (0.9); 3.3242 (136.2); 3.3005 (2.3); 2.9549 (0.5); 2.9305 (0.6); 2.9103 (5.0); 2.9014 (5.2); 2.8850 (6.0); 2.8568 (0.7); 2.8397 (0.4); 2.7272 (1.0); 2.6304 (0.4); 2.5128 (64.9); 2.5069 (127.6); 2.5009 (169.7); 2.4950 (116.4); 2.4891 (53.0); 2.3938 (0.4); 2.2704 (1.0); 2.2651 (0.8); 2.0741 (16.0); 1.2378 (0.4); 1.0779 (1.8); 1.0546 (3.6); 1.0312 (1.7); 0.0105 (0.9); -0.0004 (28.4); -0.0115 (0.8) Petition 870250039092, dated 05 / 14 / 2025, pp. 168 / 383 161 / 178 1.09 9: 1H NMR (400.2 MHz, d6-DMSO): δ= 8.6267 (0.6); 7.6410 (7.2); 7.6205 (9.3); 7.4519 (8.4); 7.4313 (7.2); 7.3444 (2.8); 7.3406 (4.5); 7.3227 (9.0); 7.3208 (9.2); 7.3028 (6.4); 7.2977 (2.3); 7.2844 (8.0); 7.2646 (3.8); 7.1950 (2.7); 7.1915 (1.7); 7.1771 (3.6); 7.1593 (1.5); 4.2906 (16.0); 3.9142 (3.3); 3.8680 (4.2); 3.5329 (3.0); 3.4862 (2.4); 3.3257 (7.8); 2.6704 (0.3); 2.5058 (28.8); 2.5015 (39.8); 2.4972 (31.2); 0.9365 (0.3); 0.0000 (3.0) 1,100: de1H NMR (499.9 MHz, CDCl3): δ= 7.6529 (0.4); 7.6494 (0.3); 7.6362 (0.6); 7.6217 (8.0); 7.6051 (9.2); 7.4233 (7.9); 7.4067 (6.5); 7.2543 (4.5); 6.8894 (0.9); 6.8819 (5.0); 6.8774 (1.9); 6.8724 (1.2); 6.8683 (2.5); 6.8644 (8.5); 6.8608 (2.1); 6.8565 (1.0); 6.8516 (1.8); 6.8470 (5.2); 6.8396 (0.5); 6.5551 (1.0); 6.5477 (5.7); 6.5431 (2.4); 6.5390 (5.7); 6.5344 (3.3); 6.5298 (4.9); 6.5256 (1.9); 6.5210 (4.6); 6.5136 (0.4); 5.2920 (1.2); 4.3469 (16.0); 3.9981 (0.3); 3.7343 (0.5); 3.7201 (0.7); 3.7104 (4.2); 3.6748 (5.8); 3.5100 (3.5); 3.5082 (3.4); 3.4744 (2.4); 3.4725 (2.3); 2.6122 (1.1); 1.2518 (0.4); 1.2377 (0.5); 0.0061 (0.4); -0.0002 (4.4) I. 101: 1H NMR(400.2 MHz, d6-DMSO): δ= 11.6946 (16.0); 8.6395 (12.5); 7.7821 (7.1); 7.7608 (11.4); 7.6904 (11.2); 7.6691 (7.0); 7.2650 (2.1); 7.2461 (7.1); 7.2288 (9.7); 7.2176 (10.8); 7.2012 (3.5); 7.1670 (1.7); 7.1628 (2.3); 7.1579 (1.3); 7.1457 (3.4); 7.1332 (0.9); 7.1285 (1.2); 6.5371 (0.4); 4.1847 (11.8); 3.9317 (3.7); 3.8854 (4.7); 3.5476 (3.0); 3.5006 (2.4); 3.3294 (32.4); 3.3059 (1.1); 2.6754 (0.6); 2.6711 (0.7); 2.5105 (44.5); 2.5063 (85.0); 2.5019 (109.9); 2.4975 (77.2); 2.4934 (35.7); 2.3333 (0.5); 2.3286 (0.6); 2.3242 (0.5); 2.0756 (3.9); 0.0000 (11.4); -0.0085 (0.4) Petition 870250039092, dated 05 / 14 / 2025, pp. 169 / 383 162 / 178 1.102: 1H NMR (400.2 MHz, d6-DMSO): δ= 11.0140 (10.8); 11.0045 (1.2); 10.9266 (0.6); 8.6263 (2.8); 8.4395 (0.6); 7.7817 (0.6); 7.7583 (0.9); 7.7399 (0.7); 7.7179 (0.6); 7.6673 (6.9); 7.6471 (9.0); 7.6023 (0.8); 7.5447 (9.2); 7.5240 (6.7); 7.5045 (0.6); 7.4554 (0.7); 7.4511 (0.6); 7.4098 (0.8); 7.3421 (0.7); 7.3286 (0.6); 7.3218 (0.8); 7.3049 (0.8); 7.2436 (3.1); 7.2248 (7.2); 7.2072 (6.2); 7.1616 (10.1); 7.1428 (6.7); 7.1177 (1.7); 4.1853 (0.6); 4.0922 (0.6); 4.0518 (0.6); 4.0144 (0.6); 3.9319 (3.8); 3.8874 (16.0); 3.8374 (0.6); 3.7904 (0.6); 3.7287 (0.7); 3.6660 (0.6); 3.6395 (0.6); 3.6211 (0.6); 3.5908 (0.7); 3.5796 (0.8); 3.5366 (3.5); 3.4899 (3.1); 3.3968 (1.2); 3.3263 (104.0); 3.2549 (1.2); 3.1384 (0.8); 3.1270 (0.8); 3.0773 (0.7); 3.0567 (0.6); 3.0215 (0.8); 3.0070 (0.8); 2.9875 (0.9); 2.9452 (0.7); 2.9149 (0.9); 2.9049 (0.8); 2.8487 (1.0); 2.8183 (0.9); 2.7886 (1.1); 2.7626 (1.4); 2.7411 (1.3); 2.7157 (1.3); 2.6699 (2.8); 2.6283 (2.1); 2.5015 (212.4); 2.3686 (1.6); 2.3283 (2.4); 2.3082 (1.2); 2.2681 (1.0);2.2165 (0.9); 2.2009 (0.8); 2.1649 (0.6); 2.1456 (0.7); 2.1324 (0.7); 2.0978 (0.8); 2.0260 (1.1); 2.0079 (0.6); 1.7809 (0.7); 1.4882 (0.6); 1.2353 (0.8); 0.9118 (0.6); 0.1463 (0.7); -0.0002 (61.2); -0.0529 (0.7); -3.4584 (0.6); -3.5260 (0.6); I. 103: 1H NMR (400.2 MHz, d6-DMSO): δ= 8.6348 (4.1); 7.6132 (5.4); 7.5924 (5.9); 7.5408 (1.8); 7.5224 (16.0); 7.5188 (14.2); 7.5011 (1.1); 7.4979 (0.8); 7.1512 (4.9); 7.1310 (4.4); 4.3892 (1.7); 4.3580 (2.2); 4.1574 (2.1); 4.1539 (2.0); 4.1256 (1.6); 4.1220 (1.6); 3.9310 (2.0); 3.8845 (2.4); 3.5427 (1.3); 3.4961 (1.0); 3.4929 (1.0); 3.3212 (23.0); 2.6703 (0.4); 2.5103 (25.6); 2.5059 (51.9); 2.5013 (69.4); 2.4967 (49.0); 2.4923 (22.7); 2.3283 (0.4); 0.0081 (0.4); -0.0001 (9.8); -0.0084 (0.3) Petition 870250039092, dated 05 / 14 / 2025, pp. 170 / 383 163 / 178 1.104: 1H NMR (300.2 MHz, CDCI3): δ= 10.0955(1.3); 8.0065 (0.8); 7.9845 (0.4); 7.9781 (1.2); 7.8872 (1.1); 7.8596 (0.7); 7.6813 (8.5); 7.6756 (3.1); 7.6593 (3.7); 7.6535 (10.7); 7.4642 (9.0); 7.4361 (6.7); 7.2984 (9.6); 7.1658 (1.1); 7.1550 (11.5); 7.1478 (3.5); 7.1327 (3.7); 7.1253 (12.2); 7.1146 (1.2); 6.5820 (1.3); 6.5713 (12.5); 6.5640 (3.6); 6.5489 (3.5); 6.5416 (11.0); 6.5308 (1.0); 4.4103 (16.0); 4.1919 (0.6); 4.1682 (1.6); 4.1444 (1.6); 4.1206 (0.7); 3.9797 (0.4); 3.9377 (0.4); 3.8201 (0.6); 3.7761 (4.1); 3.7605 (0.9); 3.7167 (7.0); 3.6225 (0.5); 3.6184 (0.5); 3.5747 (4.3); 3.5708 (4.2); 3.5152 (2.4); 3.5113 (2.4); 2.0858 (6.7); 2.0439 (0.3); 1.7042 (0.6); 1.3465 (0.4); 1.3174 (2.6); 1.3059 (2.4); 1.2937 (5.0); 1.2698 (1.9); 0.9431 (0.8); 0.9213 (2.7); 0.8981 (1.0); 0.0502 (0.4); 0.0394 (11.2); 0.0285 (0.4) I.105: de1H NMR (300.2 MHz, CDCl3): δ= 10.1024 (0.9); 8.0113 (0.5); 7.9827 (0.8); 7.8935 (0.8); 7.8663 (0.5); 7.6931 (6.2); 7.6652 (7.8); 7.4691 (6.6); 7.4410 (5.0); 7.2988 (16.1); 7.1274 (2.5); 7.1006 (5.2); 7.0738 (3.1); 6.7436 (2.0); 6.7407 (2.3); 6.7373 (2.5); 6.7345 (2.2); 6.7173 (1.8); 6.7144 (2.0); 6.7110 (2.2); 6.7082 (1.9); 6.6250 (2.9); 6.6179 (5.0); 6.6110 (3.0); 6.5215 (2.3); 6.5189 (2.3); 6.5139 (2.1); 6.5112 (1.9); 6.4942 (2.1); 6.4916 (2.0); 6.4866 (2.0); 6.4839 (1.7); 5.3383 (1.9); 4.4203 (8.1); 4.2699 (0.6); 4.1936 (1.3); 4.1698 (3.5); 4.1460 (3.6); 4.1222 (1.2); 3.8203 (0.4); 3.7819 (3.0); 3.7608 (0.7); 3.7226 (5.5); 3.6227 (0.4); 3.6188 (0.4); 3.5804 (3.2); 3.5766 (3.2); 3.5210 (1.8); 3.5171 (1.8); 2.0847 (16.0); 1.6455 (15.9); 1.3193 (4.7); 1.3062 (1.6); 1.2955 (9.7); 1.2832 (0.9); 1.2717 (4.3); 1.2597 (0.4); 0.9416 (0.4); 0.9198 (1.4); 0.8967 (0.5); 0.0484 (0.6); 0.0377 (20.0); 0.0285 (0.6); 0.0268 (0.7) Petition 870250039092, dated 05 / 14 / 2025, pp. 171 / 383 164 / 178 1.106: RMN de1H (300.2 MHz, CDCI3): δ=8.4641 (1.2); 8.0719(0.9); 8.0445(1.2); 7.8413(1.2); 7.8137(1.0); 7.6974 (12.1); 7.6700 (16.0); 7.6460 (0.3); 7.5123 (0.7); 7.4832 (13.7); 7.4559 (10.8); 7.3634 (0.4); 7.3365 (5.8); 7.3320 (6.5); 7.3102 (6.8); 7.3054 (8.4); 7.2997 (33.3); 7.2373 (0.4); 7.2118 (0.5); 7.1317 (2.7); 7.1270 (2.9); 7.1045 (5.9); 7.1022 (6.1); 7.0800 (3.8); 7.0752 (3.9); 6.7194 (3.2); 6.7148 (3.8); 6.6898 (6.1); 6.6685 (2.7); 6.6639 (3.0); 6.5790 (6.3); 6.5555 (5.4); 6.5519 (5.7); 5.3395 (1.3); 4.8799 (1.5); 4.5144 (13.2); 3.8347 (0.5); 3.7798 (6.3); 3.7206 (10.6); 3.6325 (1.8); 3.5768 (7.7); 3.5173 (4.0); 2.4157 (0.3); 2.3915 (0.6); 2.3662 (0.4); 2.0861 (0.7); 2.0475 (0.4); 1.6355 (16.0); 1.3664 (0.5); 1.2934 (8.9); 0.9398 (0.4); 0.9190 (1.2); 0.8961 (0.7); 0.0498 (1.4); 0.0390 (33.2); 0.0283 (1.7) 1.107: RMN de1H (400.2 MHz, d6-DMSO): δ= 8.6314 (0.8); 8.5751 (0.4); 7.6915 (8.3); 7.6734 (10.1); 7.6704 (8.7); 7.6523 (2.5); 7.6338 (5.4); 7.6153 (3.8); 7.5834 (10.1); 7.5628 (11.2); 7.5376 (7.3); 7.5182 (9.7); 7.4995 (4.0); 7.1622 (10.4); 7.1416 (9.4); 4.5856 (0.7); 4.5512(16.0); 4.5171 (0.6); 4.3774 (8.7); 3.9198 (3.8); 3.8735 (4.7); 3.5315 (3.7); 3.4852 (3.0); 3.3285 (22.9); 2.6708 (0.6); 2.5060 (60.6); 2.5017 (80.2); 2.4974 (62.5); 2.3496 (0.4); 2.3284 (0.7); 2.0754 (1.9); 0.9538 (0.4); 0.9361 (0.7); 0.9178 (0.3); 0.0001 (5.1) I.108: RMN de1H (400.2 MHz, d6-DMSO): δ= 8.7674 (16.0); 8.1537 (10.5); 8.1324 (12.6); 7.9141 (12.6); 7.8929 (10.6); 7.4309 (1.6); 7.4094 (3.5); 7.3925 (3.5); 7.3712 (1.7); 7.2643 (2.0); 7.2579 (2.1); 7.2398 (3.1); 7.2335 (3.3); 7.2154 (2.0); 7.2088 (2.0); 7.1024 (1.8); 7.0958 (1.8); 7.0802 (3.3); 7.0747 (3.2); 7.0591 (1.6); 7.0538 (1.5); 6.5308 (2.1); 4.5264 (15.5); 4.0445 (4.8); 3.9980 (6.1); 3.6457 (3.6); 3.5983 (2.9); 3.3247 (170.1); 3.3017 (2.4); 2.6752 (1.3); 2.6708 (1.7); 2.6663 (1.3); 2.5240 (6.5); 2.5106 (99.9); 2.5062 (203.6); 2.5017 (273.8); 2.4972 (195.3); 2.4929 (91.7); 2.3377 (0.6); 2.3332 (1.2); 2.3286 (1.6); 2.3240 (1.1); 0.0082 (1.7); 0.0000 (42.8); -0.0082 (1.6) Petition 870250039092, dated 05 / 14 / 2025, pp. 172 / 383 165 / 178 I. 109: 1H NMR (400.2 MHz, d6-DMSO): δ= 8.6473 (5.4); 7.7641 (0.4); 7.7507 (1.7); 7.7371 (7.0); 7.7331 (8.6); 7.7164 (11.4); 7.6466 (8.2); 7.6256 (11.5); 7.6036 (7.2); 7.5840 (3.6); 7.2510 (8.7); 7.2304 (8.1); 6.5364 (0.5); 4.7783 (16.0); 3.9365 (3.8); 3.8901 (4.7); 3.5418 (3.2); 3.4948 (2.6); 3.3277 (84.8); 2.7047 (0.3); 2.6706 (1.2); 2.5059 (102.8); 2.5017 (141.2); 2.4976 (110.3); 2.3290 (1.0); 2.2938 (0.3); 1.3438 (0.7); 1.2729 (0.5); 1.2348 (2.5); 0.8842 (0.5); 0.8651 (1.9); 0.8531 (0.7); 0.0708 (0.4); 0.0000 (12.7); -0.0635 (1.6) Petition 870250039092, dated 05 / 14 / 2025, pp. 173 / 383 166 / 178 I. 110: 1H NMR (400.2 MHz, d6-DMSO): δ= 8.6658 (0.4); 8.6069 (2.8); 8.5559 (0.5); 8.5122 (0.5); 8.4938 (0.4); 8.4686 (0.4); 7.8313 (0.4); 7.7521 (0.4); 7.6510 (13.1); 7.6305 (16.0); 7.5587 (0.4); 7.5174 (0.4); 7.4855 (0.4); 7.4278 (0.6); 7.3716 (13.8); 7.3512 (12.5); 7.2972 (2.2); 7.2762 (4.3); 7.2584 (4.6); 7.2368 (2.4); 7.1348 (2.7); 7.1283 (2.8); 7.1096 (4.2); 7.1041 (4.5); 7.0855 (3.0); 7.0789 (3.0); 7.0453 (0.6); 7.0351 (0.4); 7.0213 (0.4); 6.9914 (2.4); 6,9849 (2,4); 6,9695 (4,3); 6,9641 (4,5); 6,9492 (2,5); 6,9431 (2,4); 6,5361 (1,2); 5,5421 (7,3); 5,5310 (8,0); 4,8321 (1,5); 4,8165 (3,4); 4,8022 (3,8); 4,7873 (2,0); 3,9647 (0,4); 3,9390 (4,4); 3,8908 (5,7); 3,8511 (0,6); 3,8190 (0,3); 3,7918 (0,4); 3,6242 (0,4); 3,5482 (4,9); 3,5019 (4,4); 3,4327 (0,8); 3,4079 (0,8); 3,3836 (1,0); 3,3271 (129,0); 3,3033 (6,2); 3,1796 (0,6); 3,1508 (0,6); 3,1322 (0,5); 3,1170 (0,6); 3,0939 (0,6); 3,0466 (0,6); 3,0189 (0,6); 2,9873 (0,8); 2,9596 (1,7); 2,9379 (1,9); 2,9251 (4,8); 2,9064 (9,1); 2,8916 (5,9); 2,8727 (2,7); 2,8590 (2,4); 2,7999 (1,1); 2,7718 (1,1); 2,7272 (1,4); 2,7159 (1,4); 2,7084 (1,4); 2,6981 (1,5); 2,6754 (2,8); 2.6708 (3.4); 2.6665 (3.0); 2.6134 (2.4); 2.5106 (113.2); 2.5062 (227.2); 2.5018 (308.9); 2.4973 (231.9); 2.4930 (123.1); 2.3719 (1.3); 2.3330 (2.2); 2.3289 (2.6); 2.2892 (0.8); 2.2408 (0.6); 2.2176 (0.6); 2.2022 (0.6); 2.1679 (0.6); 2.1551 (0.6); 2.1259 (0.6); 2.1141 (0.5); 2.0755 (3.1); 2.0470 (0.6); 2.0317 (0.5); 2.0024 (0.4); 1.9312 (0.4); 1.9122 (0.4); 1.8981 (0.4); 1.8931 (0.4); 1.8663 (0.4); 1.8329 (0.4); 1.8042 (0.3); 1.7846 (0.3); 1.7464 (0.3); 1.6628 (0.3); 1.3233 (0.3); 1.2577 (0.3); 1.2347 (0.4); 1.1463 (0.3); 0.8439 (0.4); 0.0082 (1.8); 0.0000 (42.2); -0.0082 (2.8) Petition 870250039092, dated 05 / 14 / 2025, pp. 174 / 383 167 / 178 1.111: 1H NMR (400.2 MHz, d6-DMSO): δ= 11.7861 (13.1); 8.6468 (10.6); 7.7378 (2.5); 7.7157 (16.0); 7.7080 (15.4); 7.6856 (2.4); 7.2132 (1.4); 7.2066 (1.4); 7.1873 (2.1); 7.1830 (2.2); 7.1645 (2.1); 7.1574 (1.6); 7.1449 (2.4); 7.1278 (2.4); 7.1064 (1.2); 6.9958 (1.4); 6.9893 (1.3); 6.9739 (2.3); 6.9678 (2.3); 6.9514 (1.1); 6.9468 (1.1); 6.5358 (0.6); 4.1246 (9.3); 3.9434 (3.3); 3.8970 (4.1); 3.5555 (2.6); 3.5091 (2.1); 3.3741 (0.4); 3.3281 (60.3); 3.3060 (1.8); 2.6709 (1.3); 2.6471 (0.4); 2.5064 (150.6); 2.5020 (195.3); 2.4976 (139.8); 2.3286 (1.2); 0.0081 (1.1); 0.0000 (19.0); -0.0078 (0.8) 1.112: RMN de1H (400.2 MHz, d6-DMSO): δ= 11.7876 (10.3); 11.0540 (5.7); 8.6330 (1.1); 7.7378(2.0); 7.7157 (16.0); 7.7078 (13.1); 7.7008 (2.7); 7.6948 (4.4); 7.6856 (2.1); 7.5681 (3.8); 7.5470 (2.9); 7.3221(0.5); 7.3008(1.0); 7.2840(1.0); 7.2621 (0.5); 7.2137(1.2); 7.2072(1.2); 7.1879(1.7); 7.1836 (1.7); 7.1651 (2.2); 7.1584 (1.7); 7.1440 (2.4); 7.1346 (1.1); 7.1277 (2.0); 7.1230 (1.4); 7.1061 (1.1); 7.0020 (0.6); 6.9959 (1.5); 6.9893 (1.1); 6.9823 (1.1); 6.9751 (2.6); 6.9683 (1.8); 6.9538 (1.2); 6.9467 (0.8); 6.5434 (1.6); 4.1246 (7.3); 3.9589 (1.4); 3.9431 (2.7); 3.9127 (1.9); 3.8959 (7.1); 3.5568 (2.6); 3.5108 (2.1); 3.3287 (110.1); 3.3051 (1.4); 2.6755 (1.2); 2.6711 (1.6); 2.6666 (1.2); 2.5242 (7.6); 2.5109 (83.1); 2.5065 (162.7); 2.5021 (213.4); 2.4976 (150.4); 2.4933 (69.8); 2.3334 (1.2); 2.3290 (1.5); 2.3244 (1.1); 1.2339 (0.4); -0.0001 (5.6) I.113: RMN de1H (400.2 MHz, d6-DMSO): δ= 7.6772 (1.1); 7.6608 (0.4); 7.6564 (1.4); 7.4773 (1.2); 7.4563 (1.0); 7.3546 (0.5); 7.3510 (0.7); 7.3355 (0.7); 7.3332 (1.3); 7.3305 (1.2); 7.3074 (0.9); 7.2890 (1.2); 7.2853 (0.5); 7.2690 (0.5); 7.1957 (0.5); 7.1777 (0.6); 4.3027 (2.2); 4.1140 (0.5); 4.0667 (0.6); 3.6556 (0.4); 3.3228 (4.1); 2.5110 (3.3); 2.5065 (6.8); 2.5019 (9.3); 2.4974 (6.5); 2.4929 (3.0); 0.8632 (1.0); 0.8560 (16.0); 0.8486 (1.0); 0.8425 (0.3); 0.1579 (4.5); 0.0584 (5.2); 0.0002 (1.3) Petition 870250039092, dated 05 / 14 / 2025, pp. 175 / 383 168 / 178 1.114: 1H NMR (400.2 MHz, d6-DMSO): δ= 7.6569 (1.2); 7.6362 (1.3); 7.5328 (6.3); 7.2010 (1.2); 7.1804 (1.1); 4.3974 (0.6); 4.3656 (0.7); 4.1390 ​​(0.6); 4.1289 (0.6); 4.1073 (0.5); 4.0816 (0.6); 3.6619 (0.4); 3.3233 (4.2); 2.5106 (2.8); 2.5062 (5.8); 2.5016 (7.8); 2.4971 (5.6); 2.4926 (2.6); 0.8628 (16.0); 0.1627 (4.5); 0.0651 (4,4); -0.0004 (1,2) I.115: 1H NMR (400.2 MHz, d6-DMSO): δ= 7.7106 (1.0); 7.6928 (1.2); 7.6895 (1.0); 7.6381 (0.7); 7.6229 (1.5); 7.6198 (1.0); 7.6023 (1.4); 7.5381 (0.8); 7.5183 (1.1); 7.4998 (0.5); 7.1979 (1.2); 7.1771 (1.1); 4.5543 (1.9); 4.3843 (0.7); 4.1173 (0.4); 4.0700 (0.5); 3.6527 (0.4); 3.3265 (5.3); 2.5105 (7.8); 2.5060 (15.3); 2.5015 (20.4); 2.4969 (14.5); 2.4925 (6.8); 0.8586 (16.0); 0.1568 (4.8); 0.0573 (4.8); -0.0001 (2.7) PREPARATION EXAMPLES Example of preparation 1: Preparation of 3-(4-benzylphenyl)-5-(trifluoromethyl)4,5-dihydro-1,2-oxazol-5-ol (compound I.006)

[0311] In a 5 mL microwave tube, 100 mg (0.32 mmol) of 3-(4-bromophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol were dissolved under argon in 4 mL of dry tetrahydrofuran [THF]. Subsequently, 14.7 mg (0.016 mmol) of tris(dibenzylideneacetone)dipalladium and 9.6 mg (0.032 mmol) of tri-tert-butylphosphonium tetrafluoroborate were added followed by 0.71 mL (0.35 mmol) of a 0.5 molar solution of benzylzinc bromide in THF. The reaction mixture was heated under microwave at 100 °C for 20 minutes. The reaction mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried in a ChemElut™ cartridge and concentrated under vacuum to leave 130 mg of residue. The crude product was purified by preparative HPLC (acetonitrile / water + 0.1% HCO2H gradient) to yield 50 mg (48%) of 3(4-benzylphenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol. LogP = 4.15. Mass Petition 870250039092, dated 05 / 14 / 2025, pp. 176 / 383 169 / 178 (M+H) = 322. Example of preparation 2: Preparation of 3-{4-[(4-chlorophenyl)(hydroxy)methyl]phenyl}-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-5-ol (compound I.068)

[0312] To a solution of 400 mg (1.54 mmol) of 4-[5-hydroxy-5-(trifluoromethyl)4,5-dihydro-1,2-oxazol-3-yl]-benzaldehyde in 8 mL of THF and cooled to -78 °C...

Claims

CLAIMS 1. Compound CHARACTERIZED in that it is of formula (I): (I) wherein X is fluorine; Y is selected from the group consisting of hydrogen, acetyl and tri-C1-C4 alkylsilane; m is 0; R1 is hydrogen and R2 is hydrogen, hydroxy or C1-C4 alkyl, or R1, R2 can form, together with the carbon atom to which they are attached, a C=CH2, C=O or C=N-OH group; n is 0;A is a phenyl, cyclopentyl, cyclohexyl, imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine or pyrazine, wherein said cyclopentyl, cyclohexyl, phenyl, imidazole, pyrazole, 1,2-oxazole, pyrrole, thiophene, thiazole, pyridine, pyrimidine or pyrazine may be substituted, one or more times, in the same way or differently, with R6, wherein R6 is selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 halogen alkyl, C1-C8 alkoxy, C1-C4 alkylamino, C3-C6 cycloalkyl, halogen-substituted phenyl, halogen-substituted benzyl, thienyl methyl, formyl, C1-C4 alkyl carbonyl, carboxyl, C1-C4-alkoxycarbonyl, C1-C4-alkoxycarbonyl-C1-C4-alkyl, C3-C6-cycloalkylcarbamoyl and phenylcarbamoyl.; 2. Compound of formula (I), according to claim 1, Petition 870260054125, dated 03 / 06 / 2026, page 7 / 15 2 / 2 CHARACTERIZED in that R6 is selected from the group consisting of Cl, F, cyano, methyl, ethyl, n-propyl, isopropyl, isobutyl, trifluoromethyl, difluoromethyl, trifluoroethyl, methoxy, methylamino, cyclopropyl, cyclopentyl, phenyl, 4-chlorophenyl, benzyl, 2-fluorobenzyl, thienylmethyl, formyl, acetyl, carboxyl, ethoxycarbonyl, 2-ethoxy-2-oxoethyl, C3-C6-cyclopropylcarbamoyl and phenylcarbamoyl.

3. Compound of formula (I), according to claim 1 or 2, CHARACTERIZED in that Y is hydrogen, tert-butyl(dimethyl)silane or acetyl.

4. Composition CHARACTERIZED in that it comprises at least one compound of formula (I), as defined in any one of claims 1 to 3, and at least one agriculturally acceptable carrier.

5. Use of a compound of formula (I), as defined in any one of claims 1 to 3, or of a composition, as defined in claim 4, CHARACTERIZED in that it is for controlling phytopathogenic fungi in plants.

6. Method for controlling phytopathogenic fungi CHARACTERIZED in that it comprises the step of applying at least one compound of formula (I), as defined in any of claims 1 to 3, or a composition, as defined in claim 4, to plants, plant parts, seeds, fruits or the soil in which the plants grow.